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In this study, we studied the effect of genetic polymorphism and drug/food 
interaction on members of SLC superfamily, SLC16A family of proton-linked 
membrane transport proteins known as monocarboxylate transporters (MCTs). The 
genetic polymorphism in SLC16A1 and SLC16A3 genes that may be present in the 
ethnic Chinese (n = 95) and Indian (n = 96) groups of Singapore population have 
been examined. The promoter, coding region and exon-intron junctions of the 
SLC16A1 and SLC16A3 genes encoding the MCT1 and MCT4 transporters were 
screened for genetic variations by DNA sequencing. A total of 21 genetic 
variations, including 14 novel ones, were found in SLC16A1 gene. Of the 3 
nonsynonymous variants, the 303T>G (Ile101Met) was predicted by PolyPhen and 
SIFT as having a potentially detrimental effect on MCT1 activity. In contrast, the 
1282 G>A (Val428Ile) and 1470 T>A (Asp490) were speculated to be benign. A 
total of 46 genetic variants were detected in SLC16A3 gene, of which 33 are novel. 
Among the 5 nonsynonymous variants, only 44 C>T (Ala15Val) was predicted by 
both bioinformatics algorithms as having damaging effect on MCT4 protein 
function, whereas 55 G>A (Gly19Ser), 574G>A (Val192Met) and               
916G>A (Gly306Ser) had conflicting results between the SIFT and PolyPhen 
programs. Lastly, the 641C>T (Ser214Phe) was predicted to be a benign variant.  
 
A common MCT1 polymorphism, 1470 T>A (Asp490Glu), has been identified in 
both ethnic Chinese and Indian groups. Given that MCT1 is the only MCT isoform 
found in the human erythrocyte and contributes up to 90% of lactate influx, we 
chose to study human erythrocytes to investigate the effect of this polymorphism in 
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the MCT1-mediated lactate influx. The 10-assay grouped data suggests that human 
MCT1 system exhibited a low affinity but high capacity transport mechanism for 
the transport of lactate into red blood cells. Besides, low interindividual variations 
were observed in the total- and MCT1-mediated lactate influx into human 
erythrocytes in the local Chinese population. In addition, the data shows that T 
allele of 1470 T>A (Asp490Glu) may have a defective effect in transport function 
and appear to have a lower transport activity. However, additional studies 
involving larger samples are required to verify the impact of 1470 T>A 
(Asp490Glu) polymorphism in MCT1 transporter activity.  
 
The diet-interaction via MCT1 inhibition may affect lactate shuttling and drug 
disposition. Therefore, the effects of various dietary and pharmacological agents on 
MCT1 were examined on human erythrocyte lactate influx. Of these, diflunisal, 
diclofenac, mefenamic acid, meclofenamic acid, tolfenamic acid, luteolin, etodalac, 
phloretin and morin exhibited strong inhibition on MCT1-mediated L-lactate 
influx. The inhibitory concentrations of some of these tested NSAIDs are in the 
range of physiologically relevant concentrations that are achievable from the oral 
intake. Therefore, a clinical trial was designed to investigate the effect of one of the 
tested NSIADs, diflunisal, on lactate distribution between plasma and erythrocytes. 
In this study, the subjects were pre-treated with 5 oral doses of placebo or diflunisal 
(500mg) followed by a single dose infusion of sodium lactate at the infusion rate of 
5.6mg/kg/min for 30 min. We observed small differences between placebo- and 
diflunisal-treated groups. These differences, however, were not statistically 
significant. The data suggests that given dose of diflunisal was insufficient to 
inhibit lactate transport in the blood for this study. 
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1.1 ROLES OF MEMBRANE TRANSPORTERS IN THE SAFETY 
PROFILE OF DRUGS 
It has increasingly been recognized that few molecules move across the cell 
membrane without the assistance of transporter proteins. Singer and Nicholson 
(1972) conceptualized the idea of the plasma membrane being a fluid dynamic 
entity [1]. The cell membrane consists primarily of the amphipathic lipid bilayer, 
by which the arrangement of hydrophilic heads and hydrophobic tails of the lipid 
bilayer prevents polar solutes (e.g. monocarboxylates, carbohydrates, proteins, 
ions, nucleic acids and amino acids) from diffusing across the membrane, but 
generally allows for the passive diffusion of hydrophobic molecules. Therefore, the 
movement of polar molecules across the amphipathic lipid bilayer often involves 
interaction with some sort of active transport processes. Transmembrane transport 
is mediated by specific integral membrane proteins called transporters. Although 
non-polar solutes can diffuse across the lipid bilayer, it is now known that the 
transport of some hydrophobic molecules is mediated by transporters. For example, 
the cellular trafficking of cholesterol, phospholipid and other endogenous lipophilic 
substrates is mediated by ABCA1 transporter. Transporters are categorized into 
passive and active transporters. Passive transporters, also known as facilitated 
transporters, allow solutes to flow downhill with their electrochemical gradients. 
Active transporters, in contrast, allow the movement of solutes against their 
concentration gradients. The characterization of these transporters and their roles in 
cellular physiology and drug disposition has been the focus of intensive research 




Crane was the first to formulate the cotransport concept to explain active transport 
in 1961 [2]. He demonstrated that sodium-glucose cotransport as the mechanism 
for intestinal glucose absorption and his findings eventually led to the cloning of 
the glucose transporter [3]. However, it was the discovery of the P-glycoprotein 
(ABCB1) that proved pivotal in our understanding of the vital role drug 
transporters play in drug disposition that largely determines the pharmacodynamics 
and pharmacokinetics of drugs [4]. ABCB1 is an ATP-dependent efflux pump with 
broad substrate specificity and is expressed primarily in certain cell types found in 
the liver, pancreas, kidney, colon, and blood brain barrier [5], and has likely 
evolved as a protective mechanism against harmful xenobiotic compounds. The  
P-glycoprotein transporter was first cloned and characterized by using its ability to 
confer cellular resistance to a wide range of chemotherapeutic drugs [4]. It causes 
decreased drug accumulation in multidrug-resistant cells and developed resistance 
to anticancer drugs. The discovery of P-glycoprotein’s role in cellular resistance 
was the starting point to evaluate the role of transporters as important determinants 
of drug efficacy and toxicity.  
 
The pharmacological compound must reach the target organ at sufficient 
concentrations in order for it to exert an effect. Since the discovery of the ABCB1, 
numerous similar transporters have been identified and gathered into a superfamily 
of ABC (ATP binding cassette) transporters. Meanwhile, another large superfamily 
of transporter called the SLC (solute carrier) transporters have also been identified 
since the discovery of the glucose transporter. These transporters are selectively 
expressed in many tissues and served a fundamental function in regulating the 
movement of endogenous and exogenous chemicals across both cellular and tissue 
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membranes, and play critical roles in determining drug efficacy and toxicity. 
Therefore, the assessment of the protein levels and transport capacity of each ABC 
and SLC transporter in target organs are therefore critical towards determining the 
drug disposition. Nishimura and Naito have done an excellent job in evaluating and 
detailing the levels of tissue-specific mRNA expression profiles of ABC and SLC 
transporters [6, 7]. A summary of the ten most highly expressed ABC and SLC 
transporter mRNAs in human tissues has been presented in Table 1. The studies 
conducted by Nishimura and Naito have comprehensively profiled the gene 
expression level of a large spectrum of transporters across various tissues and 
provided a framework for understanding the fundamental functions of transporters 








Table 1. The ten most highly expressed ABC and SCL transporters mRNAs in 
human tissues (Adapted from Nishimura and Naito, 2005; Nishimura and Naito, 
2008 [6, 7]) 
Tissue Expression of Human ABC 
Transporters in Various Tissues 




ABCA1, ABCC3, ABCB1, ABCD1, 
ABCA8, ABCG1, ABCF2, ABCF1, 
ABCA6, ABCD3 
SLC16A9, SLC40A1, SLC25A3, SLC25A37, 
SLC39A9, SLC24A6, SLC3A2, SLC30A1, 
SLC6A6, SLC25A44 
Bladder  NA SLC25A6, SLC25A23, SLC25A3, SLC40A1, 




ABCB10, ABCF1, ABCD3, ABCF2, 
ABCC4, ABCE1, ABCB2, ABCC1, 
ABCC10, ABCB8 
SLC25A37, SLC4A1, SLC40A1, SLC16A3, 
SLC25A6, SLC25A39, SLC2A3, SLC25A3, 
SLC25A5, SLC30A6 
Brain ABCA2, ABCA5, ABCF2, ABCD2, 
ABCF1, ABCD3, ABCE1, ABCC5, 
ABCB9, ABCB8 
SLC22A17, SLC25A23, SLC39A10, 
SLC25A6, SLC17A7, SLC25A3, SLC1A2, 
SLC25A44, SLC25A5, SLC12A5 
Colon ABCD3, ABCC3, ABCB2, ABCC7, 
ABCA1, ABCF2, ABCA5, ABCE1, 
ABCD1, ABCB10 
SLC25A6, SLC25A5, SLC25A3, SLC39A5, 
SLC25A23, SLC39A9, SLC25A24, 
SLC16A3, SLC25A44, SLC30A6 
Heart ABCA8, ABCF2, ABCC9, ABCD3, 
ABCF1, ABCE1, ABCA9, ABCA5, 
ABCB1, ABCD1 
SLC25A3, SLC8A1, SLC16A7, SLC40A1, 
SLC25A30, SLC25A23, SLC25A11, 
SLC25A6, SLC25A37, SLC25A5 
Kidney ABCD3, ABCC4, ABCF2, ABCF1, 
ABCB1, ABCC2, ABCE1, ABCA2, 
ABCC3, ABCB8 
SLC39A5, SLC25A6, SLC25A5, SLC5A12, 
SLC7A7, SLC12A1, SLC27A5, SLC34A1, 
SLC3A2, SLC25A3 
Liver ABCA6, ABCG8, ABCB11, 
ABCB4, ABCG5, ABCA1, ABCD3, 
ABCC2, ABCC9, ABCF1 
SLC22A1, SLC40A1, SLC2A2, SLC25A5, 
SLC13A5, SLC39A5, SLC38A3, SLC22A7, 
SLC25A3, SLC39A9 
Lung ABCA6, ABCA1, ABCB2, ABCF1, 
ABCC4, ABCA8, ABCF2, ABCD3, 
ABCG1, ABCE1 
SLC40A1, SLC34A2, SLC6A4, SLC25A6, 




 NA SLC25A3, SLC25A37, SLC25A6, SLC40A1, 
SLC25A39, SLC25A44, SLC37A3, 
SLC12A2, SLC20A2, SLC16A3 
Ovary  NA SLC25A6, SLC40A1, SLC30A6, SLC25A37, 
SLC16A9, SLC25A3, SLC25A5, SLC25A23, 
SLC25A24, SLC24A6 
Pancreas ABCC7, ABCF1, ABCA5, ABCD3, 
ABCE1, ABCF2, ABCC3, ABCD1, 
ABCC1, ABCC10 
SLC25A6, SLC25A5, SLC39A5, SLC40A1, 




ABCB2, ABCF1, ABCD1, ABCF2, 
ABCE1, ABCB3, ABCB10, ABCA2, 
ABCC1, ABCA1 
SLC25A37, SLC16A3, SLC25A6, SLC2A3, 
SLC25A3, SLC25A44, SLC25A5, SLC40A1, 
SLC30A6, SLC7A7 
Placenta ABCD1, ABCF1, ABCA1, ABCB8, 
ABCF2, ABCG2, ABCG1, ABCB2, 
ABCD3, ABCC10 
SLC2A1, SLC40A1, SLC25A6, SLC3A2, 
SLC39A9, SLC7A2, SLC30A6, SLC39A6, 
SLC25A5, SLC39A8 
The ten most highly expressed ABC and SCL transporters mRNAs in human tissues. The 
transporter expression level is ranked from highest to lowest. 
NA= The mRNA expression level of transporters has not been analyzed in this target tissue.  
ABC=ATP-binding cassette  
SLC= Solute carrier 
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Table 1. (continue) 
Prostate ABCC4, ABCF1, ABCD3, ABCF2, 
ABCA5, ABCE1, ABCB2, ABCC1, 
ABCA1, ABCB10 
SLC30A4, SLC39A10, SLC39A6, SLC25A6, 
SLC25A37, SLC39A9, SLC40A1, SLC14A1, 
SLC25A3, SLC25A23 
 
Retina  NA SLC16A3, SLC25A6, SLC25A3, SLC23A2, 
SLC25A44, SLC25A5, SLC30A6, 
SLC16A14, SLC40A1, SLC25A23 
Salivary 
gland 
ABCF1, ABCF2, ABCD3, ABCA6, 
ABCE1, ABCC7, ABCD1, ABCB2, 
ABCB10, ABCG1 
SLC25A6, SLC39A9, SLC25A5, SLC13A5, 




ABCF1, ABCF2, ABCA5, ABCD1, 
ABCD3, ABCC1, ABCC9, ABCA6, 
ABCB10, ABCA1 
SLC16A3, SLC25A3, SLC25A11, SLC25A4, 
SLC40A1, SLC25A23, SLC25A30, 
SLC19A2, SLC25A9, SLC25A6 
Small 
intestine 
ABCD1, ABCD3, ABCF1, ABCG5, 
ABCB2, ABCF2, ABCG8, ABCB10, 
ABCC3, ABCG2 
SLC5A1, SLC25A6, SLC40A1, SLC25A5, 




 NA SLC25A6, SLC25A23, SLC25A3, SLC8A1, 
SLC40A1, SLC25A5, SLC30A6, SLC12A2, 
SLC25A24, SLC25A37 
Spinal cord ABCA2, ABCD3, ABCA8, ABCF1, 
ABCA6, ABCA1, ABCE1, ABCA5, 
ABCB2, ABCB8 
SLC22A17, SLC25A6, SLC39A10, 
SLC14A1, SLC16A9, SLC25A23, SLC39A9, 
SLC25A3, SLC39A6, SLC25A44 
Spleen ABCB2, ABCF1, ABCF2, ABCG1, 
ABCA1, ABCD1, ABCE1, ABCC1, 
ABCD3, ABCB10 
SLC25A6, SLC16A9, SLC39A10, SLC25A5, 
SLC16A3, SLC25A3, SLC25A37, SLC30A6, 
SLC39A9, SLC40A1 
Stomach ABCD3, ABCF1, ABCC3, ABCF2, 
ABCE1, ABCB2, ABCA6, ABCA5, 
ABCC1, ABCA8 
SLC25A6, SLC25A5, SLC25A3, SLC40A1, 
SLC25A37, SLC39A9, SLC16A3, SLC30A6, 
SLC25A23, SLC39A7 
Testis ABCF1, ABCF2, ABCD1, ABCB9, 
ABCE1, ABCC1, ABCD3, ABCA5, 
ABCA8, ABCC12 
SLC25A37, SLC30A6, SLC16A3, SLC30A4, 
SLC30A1, SLC25A33, SLC40A1, SLC2A5, 
SLC16A9, SLC25A6 
Thymus  ABCF1, ABCA1, ABCB2, ABCD3, 
ABCF2, ABCC1, ABCG1, ABCD1, 
ABCA7, ABCC10 
SLC25A6, SLC25A5, SLC40A1, SLC25A3, 




ABCF1, ABCA2, ABCF2, ABCA6, 
ABCD3, ABCA5, ABCE1, ABCA8, 
ABCC4, ABCA1 
SLC25A6, SLC5A3, SLC26A7, SLC5A5, 
SLC25A23, SLC26A4, SLC25A3, SLC30A6, 
SLC25A37, SLC40A1 
Trachea ABCF1, ABCD3, ABCB2, ABCC1, 
ABCA1, ABCG1, ABCA5, ABCA8, 
ABCC4, ABCE1 
SLC25A6, SLC12A2, SLC16A3, SLC25A37, 
SLC40A1, SLC25A3, SLC25A5, SLC39A9, 
SLC16A9, SLC25A44 
Uterus ABCF1, ABCF2, ABCA6, ABCD1, 
ABCD3, ABCA1, ABCG2, ABCB2, 
ABCE1, ABCB10 
SLC25A6, SLC40A1, SLC25A3, SLC25A5, 
SLC16A9, SLC39A9, SLC25A37, 
SLC25A23, SLC37A3, SLC30A6 
The ten most highly expressed ABC and SCL transporters mRNAs in human tissues. The 
transporter expression level is ranked from highest to lowest. 
NA= The mRNA expression level of transporters has not been analyzed in this target tissue.  
ABC=ATP-binding cassette  
SLC= Solute carrier  
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1.2 TRANSPORTER SUPERFAMILIES 
1.2.1 The ABC Transporters 
One of the largest and most ancient classes of transporters is the ATP-binding 
cassette (ATP) transporter superfamily [8-10]. This superfamily of transporters is 
identified not just by the presence of nucleotide binding domains but more 
specifically by a very characteristic and specific amino acid (LSGGQ) motif in the 
nucleotide binding domain [10]. It is the ability to bind ATP that allows these 
transporters to harness ATP as a source of energy to mediate active transport for 
molecules across the biological membranes. Members of the ABC transporter 
family are present in organisms from all kingdoms of life, with representatives in 
all extant phyla from prokaryotes to humans [8]. Transporters in this family have 
attracted considerable attention because they are involved in many crucial 
physiological functions, as well as being associated with human diseases including 
tumor resistance, cystic fibrosis and bacterial multidrug resistance [11]. So far there 
are 49 members of the ABC superfamily in humans which have been gathered into 
7 families (Human Genome Organization) [12]. Of these, most studies have been 
done on ABCB1 (MDR1), ABCC1 (multidrug resistance-associated protein, 
MRP1), ABCC2 (MRP2) and ABCG2 (breast cancer resistance protein, BCRP), 
which are considered therapeutically important.  
 
The variety of substrates handled by different ABC transporters is enormous: 
ranging from amino acids, sugars, inorganic ions, polysaccharides, peptides to 
proteins. These substrates are chemically different and vary greatly in size. 
However, each ABC transporter is relatively specific for a given substrate. The 
mechanism by which allows each transporter to retain a high degree of specificity 
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for a particular substrate, while achieving such diversity, is still being debated [8]. 
ABC transporters are divided into three main functional categories. In prokaryotes, 
importers provide an influx mechanism for essential nutrients. The ability of 
bacteria to grow and compete depends on the efficiency with which they can obtain 
and scavenge nutrients. The correlation in bacteria between the number of ABC 
transporters and the size of the bacterial genome suggest that the transporters are 
essential for normal bacterial metabolism and growth [13]. The ABC importers 
involved in uptake have yet been characterized in eukaryotic cells.  The ABC 
exporters or effluxers are found in prokaryotes and eukaryotes [8]. In view of their 
ability to efflux molecules from the cytoplasm to the periplasm, the exporters are 
likely to serve as secretory mechanisms for cellular metabolic products. In bacteria, 
the effluxers are associated with bacterial antibiotic resistance by pumping the 
offending agents from the cell. An example of bacterial drug resistance is the 
erythromycin resistance of Staphylococcus which is mediated by the ABC protein 
MsrA [14]. The presence of these transporters in parasites and microorganisms, 
therefore, present challenges in the development of new anti-infectives, and in 
dealing with the emergence of drug resistant strains [15]. The third subgroup of 
ABC transporters involved in translation and DNA repair mechanisms, but do not 
function as transporters [16].  
 
In humans, the ABC transporters function as part of the cellular defense 
mechanism, protecting the body against amphipathic xenotoxins. The ABC 
transporters have been found in every cell type studied so far. The P-glycoprotein 
is plentiful in the gut, liver and kidney, preventing entry of toxins into the body. In 
the blood-brain barrier, testis, bone marrow and placental trophoblasts,                  
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P-glycoprotein provides protection of vital body parts. The wide xenobiotic 
substrate specificities handled by P-glycoprotein makes it the perfect candidate for 
this task. This broad specificity, however, could interfere with the delivery of drugs 
























1.2.2 The SLC Transporters 
The solute-carrier gene (SLC) superfamily comprises 55 gene families, covering as 
much as 362 putatively functional protein-coding genes [17]. The gene products 
include passive transporters, symporters and antiporters. These transporters are 
found in all cellular and organelle membranes except the nuclear membrane.      
SLC transporters mediate the transport of a wide and diverse range of substrates 
including endogenous substrates (e.g. carboxylates, amino acids, peptides, glucose, 
neurotransmitters, vitamins, fatty acids and lipid), drugs, non-essential metals and 
other environmental xenobiotics. Unlike the ABC transporters, the SLC 
transporters do not have direct access to an energy source to power their activity. 
The passive transporters (also known as uniporters or facilitative transporters) 
transport solutes down a concentration gradient. Secondary active transporters, by 
contrast, allow solutes to move against concentration gradient by coupling to the 
transport of a second solute that flows down its concentration gradient. As such, the 
overall free energy change is still favorable. Although most of the SLC transporters 
function as influx mechanisms, they are not exclusively so and many can function 
as efflux or bidirectional transporters.   
 
Contrary to gene nomenclature commonly assigned on the basis of evolutionary 
divergence, members within SLC superfamily has been named largely on 
functional rather than evolutionary relatedness. The homology between SLC 
families is very low to non-existent [17]. Furthermore, the properties of each 
family are often summarized based on just a few members that have been 
thoroughly characterized. One should bear in mind that some of the other members 
yet to be characterized will not adhere strictly to that specific moniker [17]. 
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1.3 THE ROLE OF TRANSPORTERS IN DRUG ABSORPTION, 
DISTRIBUTION, METABOLISM AND EXCRETION 
1.3.1 Transporters and Drug Absorption 
In the past decades, membrane transporters have long been recognized as important 
determinants in the overall disposition of numerous pharmacological agents. In 
addition to the physicochemical properties (e.g. molecular size, charge distribution 
and hydrophobicity), drug interactions with membrane transporters determine the 
extent and direction of drug movement across organs.  
 
In the small intestine, enterocytes express an array of carriers crucial for absorption 
of dietary compounds and pharmacological compounds. Both ABC and SLC 
transporters show considerable variability in expression along the gastrointestinal 
tract [18, 19]. For example, the expression of BCRP is found throughout the entire 
small intestine and colon, while MDR1 is expressed in greater abundance towards 
the terminal ileum and colon. MRP2, on the other hand, is expressed preferentially 
in the duodenum. It remains unclear that how the various transporters are 
collectively regulated in their spatial distribution along the intestines. Besides, the 
clinical implication of differential expression of transporter on drug absorption is 
not entirely clear. The studies of knockout animals such as mdr1a (-/-) allow us an 
insight into potential tissue pharmacokinetic consequences of compromised 
transporter function (Table 2). MDR1 actively pumps drugs back into the intestinal 
lumen and thus effectively limiting the extent (bioavailability) of drug absorption. 
The oral bioavailability of ivermectin, vinblastine, digoxin, and some human 
immunodeficiency virus (HIV) 1 protease inhibitors is markedly increased in 
mdr1a knockout mice as compared to wildtype mice. Furthermore, studies showed 
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that the interindividual variation in the bioavailability of cyclosporine and digoxin 
could be explained by the extent of intestinal MDR1 expression and activity  
[20, 21]. The expression of transporters also varies considerably between 
individuals. This further supports the role of transporters in determining the 


















Table 2. The ratio of the concentrations in different tissues for various substrates, between mdr knockout (-/-) and wildtype (+/+) mice (Adapted 
from Lee et al., 2009 [15]) 
 
 
Ivermectina  Vinblasatina  Dexamethasone Digoxin  Cyclosporin A   Nelfinavir Nelfinavir Indinavir Saquinavir 
mdr1a(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a/b(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a(-/-):(+/+) 
Brain 87.0 22.4 2.5* 35.5* 17.0* 16.1 36.3* 10.6* 7.4* 
Muscle 5.0 6.7 1.0 1.5* 1.8     
Heart 4.0 3.4 0.8 1.9* 1.6* 1.9 1.2 1.0 2.5* 
Kidney 3.0 2.3 1.2 1.9 1.0 9.3 1.5 0.9 1.3 
Liver 3.8 2.4 1.1 2.0 1.2 3.0 1.1 1.2 0.8 
Gall bladder 9.4 1.4 1.7 1.7 0.6     
Lung 4.0 2.1 0.8 2.2* 1.2  5.4 1.0 1.6 
Stomach 1.7 1.8  1.6* 1.4     
Small 
intestine  3.9 2.9  1.1 1.9*  2.4 2.7* 1.9 
Colon 3.5 2.1 1.3 0.7* 1.6*  1.4 0.8 0.7 
Testis  7.4 2.5 1.2 2.8* 2.6*     
Penis          
Epididymus 2.8 1.0        
Spleen 3.7 1.7 0.9 2.3* 1.5* 4.1 2.1 1.0 1.4 
Thymus 2.8 1.4  2.2* 1.1     
Lymph 
nodes - 1.3   1.4     
Plasma 3.3 2.0 1.0 1.9* 1.4 1.0 1.26* 1.1 1.1 
 
0.2mg/kg, 
1 hr after oral 
administration 
1mg/kg, 
1 hr after oral 
administration 
0.2mg/kg, 
























4 hr after 
intravenous 
injection 
 [22] [22] [23] [23] [23] [24] [25] [25] [25] 
*Significantly different from wild-type mice at P < 0.05.  
a Statistic test has not been performance for the assays.  
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Table 2. (continue) 
 
 
Morphine Grepafloxin Olanzapine FK506 Doxepin Venlafexine Paroxetine Mirtazapine 
mdr1a(-/-):(+/+) mdr1a/b(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a(-/-):(+/+) mdr1a/b(-/-):(+/+) mdr1a/b(-/-):(+/+) mdr1a/b(-/-):(+/+) mdr1a/b(-/-):(+/+) 
Brain 1.7* 2.8* 3.0* 33.0* 1.2* 2.3* 2.1* 1.3 
Muscle 1.3        
Heart 1.1 1.0  3.0*     
Kidney 0.8 1.4 1.8* 2.4* 1.1 1.1 0.9 1.1 
Liver 1.1 1.0 2.6* 5.0* 1.3 1.4* 0.9 1.2 
Gall bladder 2.2*        
Lung 1.1 1.0  4.2*     
Stomach 0.8   2.4*     
Small 
intestine  0.7 0.9       
Colon 0.6        
Testis  0.7 0.6       
Penis   0.9      
Epididymus         
Spleen 1.1  1.0 2.2* 1.0 1.1 1.0 1.0 
Thymus 0.8        
Lymph 
nodes         
Plasma 1.1 1.1 1.1  1.1 1.3* 1.4 1.3 
  

















1 hr after 
subcutaneous 
injection 





1 hr after 
subcutaneous 
injection 




 [23] [26] [27] [28] [29] [29] [29] [29] 
*Significantly different from wild-type mice at P < 0.05.  
a Statistic test has not been performance for the assays.  
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1.3.2 Transporters and Drug Metabolism 
Although a wide variety of biological tissues are able to metabolize drugs, the main 
organ responsible for the drug metabolism is the liver. Classical drug metabolism 
has been divided into Phase I and Phase II [30]. Phase I represents the oxidation, 
reduction and hydrolyses of foreign compounds. Phase II reaction involves 
conjugation (e.g. glucuronidation and glutamylation) of the partially detoxified 
metabolites. Two additional steps, called Phase 0 and Phase III of drug disposition 
have recently been described. These phases modulate the entry and existence of the 
unmodified or metabolized compounds, which mediated by various transporters on 
cell membranes. The hepatocyte is populated by large numbers of both ABC efflux 
and SLC influx transporters. These transporters are differentially expressed on the 
sinusoidal and bile canalicular surfaces of the hepatocytes. The differential 
expression profiles of transporters not only have major influences on the influx and 
efflux of drug molecules across the hepatocyte sinusoidal membrane, but they also 
determine the extent of drug elimination into the bile.  
 
These developing ideas of transporter-mediated drug disposition have mounted 
challenges to the previous concepts based on passive diffusion of unbound drugs. 
Although these processes can be described, it remains unclear how transporter-
mediated movement of drug molecules will eventually affect our concepts of drug 





1.3.3 Transporters and Renal Elimination 
The renal elimination of drug molecules involves three main processes in the 
nephron: glomerular filtration, reabsorption and secretion. Of these processes, 
glomerular filtration is the only process that is truly dependent on the circulating 
unbound fraction of drug. Most drug molecules, however, can only enter and exit 
the renal tubules through influx and efflux transporters. Because drug molecules 
traverse the entire depth of the renal tubular cells during reabsorption and secretion, 
both processes require the actions of influx and efflux transporters acting in concert 
to produce vectorial movements of drug molecules across the tubular epithelium 
[15]. The OAT transporters are important renal carriers for uptake of organic 
anions. OAT mediates the transportation of pharmacologically important drugs 
including β-lactam antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), 
diuretics, nucleoside antiviral drugs, and anticancer agents [31]. The members of 
MRP and OATP families are localized on the apical membrane of proximal tubular 
cells and responsible to the urinary elimination of drug molecules.  
 
1.3.4 Transporters and Tissue Distribution  
The distribution of drug molecules throughout the body largely depends on the 
ability of the molecule to traverse across lipophilic membranes and into the various 
tissue compartments and volumes. The movement may be envisaged to be driven 
by the concentration of unbound molecule in the circulation when a molecule is 
fully permeable. This paradigm influenced our understanding in drug disposition 
and also how drug disposition affects therapeutic efficacy and toxicity [15]. The 
volume of distribution of a drug is thought to be largely determined by a balance 
between plasma protein binding and tissue binding. Notably, it is the unbound 
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fraction which exhibits pharmacologic effects. It is also the fraction that may be 
metabolized and/or excreted. The common plasma proteins that drug molecules 
bind to are human serum albumin, glycoprotein, lipoprotein, α, β‚ and γ globulins. 
However, what tissue binding actually represents has never been entirely clear. The 
pharmacodynamic responses of a drug are thought to be related to central 
compartment concentration of either unbound or total drug. The basic premise for 
this paradigm is assuming that the unbound drug molecules equilibrate freely 
across efficacy and toxicity compartments; thus central compartment 
concentrations of the drug provide a reasonable approximation of drug responses 
throughout the body. This paradigm is a simple and mechanistic model that relates 
central compartment concentration of drug molecules to drug efficacy and toxicity. 
However, there is no compelling evidence that the model is accurate [15].  
 
An increase understanding of how extensively involved transporters are with drug 
disposition has revealed the inadequacies of the previously working paradigm. 
Drug distribution is now being determined by the dynamic interplay between 
uptake and efflux transporters within any given epithelial cells. Grover and Benet 
reviewed the effects of transporters in different compartments [32]. The complexity 
of the situation is reflected in the inability of the review to go beyond looking at 
central compartment measurements of distributional effects. The review concludes 
that the primary location of the transporter interaction, either at liver or kidneys, 
serves as the chief predictor of distributional volume changes [32]. This analysis 
provides a framework for understanding potential pharmacokinetic interactions 
rooted in drug transporters as they modify drug distribution. 
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1.3.5 Food and Drug Interactions 
There is a growing recognition that transporters are not just mediators of an 
isolated physiological process, but rather part of an extended cellular and whole 
body mechanism for protection against unwanted xenobiotic effects. In addition, 
transporters also have roles in the disposition of pharmacologically active 
compounds. The complex actions of transporters during drug-transporter or     
food-transporter interactions may have far-reaching consequences.  
 
Serious drug-drug interactions have contributed to a number of United States 
market withdrawals of approved drugs and also to recent rejections of a few new 
molecular entities [33]. Many of these interactions involved induction or inhibition 
of metabolizing enzymes and transporters, resulting in increased or reduce systemic 
exposure and subsequently altering the efficacies and side effects of 
pharmacological compounds. In addition to drug-transporter interaction, the 
popular use of dietary supplements and herbal medicines has raised awareness of 
the potential dietary-transporter interactions. A recent survey indicated that in 
United States, the use of prescription drugs continue to increase over the past 10 
years [34]. The percentage of Americans who took at least one prescription drug in 
the past month increased from 44% to 48%. The use of two or more drugs 
increased from 25% to 31% and the use of five or more drugs increased from 6%  
to 11% [34]. Besides, it has been reported that over 40% used supplements in 
1988-1994, and over 50% in 2003-2006 [35]. Furthermore, it is very common that 
prescribed drugs are taken together with herbal dietary products. Therefore, 
detailed information about potential transporter interactions between drugs and 
dietary supplements is needed.  
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It is reasonably expected that transporters will naturally have complex and 
multivariate interactions with both xenobiotics found in the diet and 
pharmaceuticals. Several studies have already documented the in vitro and clinical 
potential for such interactions [36, 37]. A summary of drug-transporter interactions 
or toxicities involving drug transporters is presented in Table 3. Transporter-based 
drug interactions may be inhibitory, inductive or both. Such interactions may alter 
the efficacy-toxicity profile of the affected drug. The transporter-based interactions 
will be clinically significant if such interaction alters the concentration of said 
affected drug at the site of action such that it falls outside of the therapeutic 
window [36]. Evidence shows that such transporter based interactions may result in 
changes in tissue concentration of affected drug without significantly affect the 
plasma concentration of the substrate [36]. For example, Cyclosporine (CsA) alters 
verapamil’s distribution to the brain by inhibiting the P-gp transporter without 
affecting the plasma concentration-time profile of the substrate [38]. The 
transporter-based drug interactions may exert beneficial effects. For example, 
inhibition of human organic anion transport (hOAT) by probenecid reduced the 











Table 3. Drug-drug interactions or toxicities involving drug transporters (Adapted from Ho and Kim, 2005 [41]) 
 
Drug Inhibitor/inducer Measured effect/toxicity Putative mechanism References 
Penicillin Probenecid Decreased renal clearance, prolonged half-life Inhibition of OATs [42] 
ACE inhibitors Probenecid Decreased renal clearance, prolonged half-life Inhibition of OATs [42] 
Antiviral drugs Probenecid Decreased renal clearance, prolonged half-life Inhibition of OATs [42] 
Procainamide Cimetidine Decreased renal clearance, increased AUC Inhibition of OCT, OAT, OATP [42] 
Levofloxacin Cimetidine Decreased renal clearance, increased AUC Inhibition of OCT, OAT, OATP [42] 
Dofetilide Cimetidine Decreased renal clearance, increased AUC Inhibition of OCT, OAT, OATP [42] 
Fexofenadine Fruit juices Decreased plasma levels Inhibition of OATPs [43] 
Methotrexate NSAIDs Decreased renal clearance Inhibition of OAT3 [44] 
Methotrexate Probenecid Decreased renal clearance Inhibition of OAT3 [44] 
Loperamide Quinidine Increased CNS adverse effects Inhibition of MDR1 [45] 
Talinolol Verapamil Decreased plasma levels Inhibition of MDR1 [46] 
Fexofenadine Erythromycin Increased plasma levels Inhibition of MDR1 [47] 
Fexofenadine Rifampin Decreased plasma levels Inhibition of MDR1 [48] 
Digoxin Quinidine Increased plasma levels, decreased renal clearance Inhibition of MDR1 [49] 
Digoxin Verapamil Increased plasma levels, decreased renal clearance Inhibition of MDR1 [50] 
Digoxin Talinolol Increased plasma levels, decreased renal clearance Inhibition of MDR1 [51] 
Digoxin Clarithromycin Increased plasma levels, decreased renal clearance Inhibition of MDR1 [52] 
Digoxin Statins Increased plasma levels, decreased renal clearance Inhibition of MDR1 [53] 
Digoxin Rifampin Decreased plasma levels Inhibition of MDR1 [54] 
Digoxin Troglitazone Hepatotoxicity Inhibition of BSEP [55] 
Digoxin Bosentan Cholestasis Inhibition of BSEP [56] 
Digoxin Estrogens Cholestasis Inhibition of BSEP [57] 
Digoxin Cyclosporine Cholestasis Inhibition of BSEP [57] 
Digoxin Cidofovir Nephrotoxicity Inhibition of OAT1 [58] 
Digoxin Adefovir Nephrotoxicity Inhibition of OAT2 [58] 
Digoxin Cephaloridine Nephrotoxicity Inhibition of OAT3 [59] 




1.3.6 Summary of Role of Transporters in Drug Distribution 
There is a growing recognition that transporters are not just mediators of an 
isolated physiological process but rather part of an extended cellular and whole 
body mechanism for protection against unwanted xenobiotic effects. Transporters 
are involved in almost every part of the therapeutic process from absorption, 
distribution and elimination of drug molecule to their efficacy and toxicity sites. 
The complex actions of transporters across various tissue and cell membranes 
during disease [60-62] or various drug-drug [63, 64] or food-drug interactions  
[65, 66] may potentially lead to large shifts in compartment: plasma concentration 
ratios at efficacy and toxicity sites. The studies of knockout animals such as    
mdr1a (-/-) allow us an insight into potential tissue pharmacokinetic consequences 
of compromised transporter function (Table 4). As transporter-mediated drug 
disposition is the dynamic interplay between the uptake and efflux transporters,   
the changes in transporter kinetics (e.g. genetic polymorphism, drug/food 
interaction, disease-altered expression) may shift the efficacy-toxicity relationship 
of a drug. Therefore, it is important to evaluate the transporter activity and potential 
drug/food interaction of individual transporter. As mentioned above, drug 
transporters can be generally separated into 2 superfamilies – ABC and SLC 
transporters. In this project, we focus on members of SLC superfamily, SLC16A 







Table 4. Tissue-to-plasma concentration ratio (Kp) of drug substrates in wild-type (wt) and knockout mice (ko) (Adapted from Lee et al., 2009 [15]) 
Tissue 
Morphine [23] Dexamethasone [23] Digoxin [23] Digoxin [67] 
mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a(+/+) mdr1a(-/-) ko/wt 
Brain 0.49 0.72 1.48 0.28 0.71 2.49 0.08 1.54 18.73       
Muscle 0.59 0.65 1.10 0.65 0.62 0.95 1.11 0.87 0.78 0.80 0.42 0.53 
Heart 0.84 0.85 1.00 1.02 0.79 0.77 0.67 0.67 1.01 1.13 0.63 0.55 
Kidney 4.45 3.03 0.68 2.21 2.66 1.20 0.91 0.92 1.01 1.07 0.80 0.74 
Liver 2.80 2.65 0.95 47.91 52.56 1.10 1.41 1.51 1.07 1.87 2.09 1.12 
Gall bladder 48.35 93.06 1.92 304.13 517.38 1.70 46.99 43.49 0.93      
Lung 1.72 1.66 0.97 1.26 0.97 0.77 0.54 0.62 1.15      
Stomach 1.99 1.48 0.74      0.57 0.47 0.83      
Small intestine  4.52 2.94 0.65      1.90 1.12 0.59 2.59 0.54 0.21 
Colon 7.73 4.25 0.55 4.26 5.74 1.35 1.50 0.54 0.36      
Testis  1.93 1.13 0.59 0.68 0.84 1.23 0.32 0.47 1.48      
Spleen 1.27 1.22 0.96 0.90 0.85 0.94 0.32 0.39 1.21      
Thymus 1.27 0.84 0.66      0.32 0.38 1.18      
Lymph nodes                   
      
Tissue 
Cyclosporin A [23] Vinblastine [22] Ivermectin [22] Saquinavir [25] 
mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a(+/+) mdr1a(-/-) ko/wt 
Brain 0.28 3.30 11.93 1.67 18.67 11.20 0.09 2.52 26.87 0.13 0.88 6.67 
Muscle 2.50 3.13 1.25 7.33 24.67 3.36 0.60 0.92 1.54     
Heart 7.95 8.91 1.12 21.33 36.50 1.71 1.56 1.92 1.23 1.00 2.32 2.32 
Kidney 36.89 26.98 0.73 133.00 155.33 1.17 2.94 2.71 0.92 3.65 4.38 1.20 
Liver 140.00 118.46 0.85 38.33 46.83 1.22 8.13 9.56 1.18 6.00 4.38 0.73 
Gall bladder 172.42 67.06 0.39 114.00 77.67 0.68 9.19 26.46 2.88     
Lung 15.89 13.09 0.82 172.33 176.33 1.02 1.44 1.75 1.22 2.74 3.97 1.45 
Stomach 22.42 22.20 0.99 106.67 93.83 0.88 3.94 2.06 0.52     
Small intestine  28.16 38.00 1.35 65.67 96.17 1.46 1.94 2.33 1.20 7.13 12.15 1.70 
Colon 14.16 16.33 1.15 71.33 74.00 1.04 1.94 2.08 1.07 30.77 20.79 0.68 
Testis  1.50 2.74 1.83 8.67 10.67 1.23 0.59 1.35 2.29     
Penis                    
Epididymus      77.67 39.67 0.51 3.69 3.15 0.86     
Spleen 18.63 19.91 1.07 292.00 240.33 0.82 0.81 0.92 1.14 1.19 1.53 1.28 
Thymus 12.71 10.13 0.80 105.33 71.00 0.67 2.69 2.33 0.87      
Lymph nodes 16.08 15.30 0.95 131.33 82.67 0.63           
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Table 4. (continue) 
Tissue 
Indinavir [25] Nelfinavir [25] Nelfinavir [24] Grepafloxacin [26] 
mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a/1b(+/+) mdr1a/1b(-/-) ko/wt mdr1a/1b(+/+) mdr1a/1b(-/-) ko/wt 
Brain 0.08 0.81 9.61 0.09 2.65 30.88 0.92 14.88 16.19 0.30 0.80 2.67 
Muscle                     
Heart 0.79 0.76 0.97 0.69 0.71 1.03 1.75 3.30 1.89 8.20 7.80 0.95 
Kidney 7.11 6.00 0.84 1.79 2.12 1.19 1.42 13.27 9.31 15.00 18.70 1.25 
Liver 20.89 21.81 1.04 61.00 53.18 0.87 5.40 15.99 2.96 16.1 13.90 0.86 
Gall bladder                     
Lung 3.21 3.00 0.93 7.71 34.24 4.44      16.80 14.80 0.88 
Stomach                     
Small intestine  18.11 44.05 2.43 8.57 31.35 3.66      10.00 8.50 0.85 
Colon 72.74 53.67 0.74 39.64 44.94 1.13           
Testis                 1.40 0.80 0.57 
Epididymus                     
Spleen 1.05 1.00 0.95 3.00 5.24 1.75 5.22 21.22 4.06      
Thymus                     
Lymph nodes                   
      
Tissue 
Olanzapine [27] Ezetimibe [68] L-Carnitine [69]  
mdr1a(+/+) mdr1a(-/-) ko/wt mdr1a/b(+/+) mdr1a/b(-/-) ko/wt octn2(+/+) octn2(-/-) ko/wt    
Brain 0.90 2.00 2.60 0.82 0.55 0.67 0.53 0.48 0.91    
Muscle           1.51 0.35 0.23    
Heart           11.70 1.05 0.09    
Kidney 2.60 4.40 1.70 12.20 10.70 0.88 11.60 6.6 0.58    
Liver 2.50 5.50 2.40 151.00 188.00 1.25 5.47 5.47 1.00    
Gall bladder                   
Lung           17.90 33.50 1.87    
Stomach           6.11 2.92 0.48    
Testis       8.44 4.54 0.54         
Penis 1.00 0.80 0.90              
Epididymus                   
Spleen 5.20 4.70 0.90              
Thymus                   
Lymph nodes                
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1.4 OVERVIEW OF MONOCARBOXYLATE TRANSPORTER FAMILY 
The monocarboxylate transporter (MCT) family currently comprises of 14 
members related to each other by sequence homology. The first 4 members 
(MCT1-MCT4) have been proven experimentally to mediate the transport of 
metabolically important endogenous monocarboxylates such as lactate, pyruvate, 
acetate and ketone bodies [70]. It was originally thought that these 
monocarboxylates would diffuse across the membrane via non-ionic of the free 
acid. However, the uptakes of these monocarboxylates were inhibited by  
-cyano-4-hydroxycinnimate (CHC) [71] and p-chloromercuribenzene sulphonate 
(pCMBS) [72], indicating that their uptakes into human erythrocytes were 
mediated by some sort of transporter systems. The pKa of L-lactate, pyruvate are 
3.86 and 2.39, respectively [73], thus under physiological pH, these acids 
dissociate almost entirely to their anions. These monocarboxylate anions are highly 
charged chemical structures and are transported across the plasma membrane via 
facilitated MCT transporters down their concentration gradients. The contribution 
of passive diffusion on monocarboxylate transportation is thought to be 
insignificant.  
 
MCT1-4 classically transport metabolites across plasma membranes with direction 
controlled by proton and metabolite concentrations. Its transport of 
monocarboxylate anions is coupled by 1:1 stoichiometry to the symport of a 
proton. This transport does not require ATP, and is controlled instead by hydrogen 
ion and substrate gradients, thus facilitating the movement of substrates in (influx) 
or out (efflux) of the cell [73-75]. Before considering each of the members in more 
detail, a number of points are worth making about the MCT family in general. 
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Firstly, the name of MCTs does not correspond to the gene number except for 
MCT1, MCT9 and MCTs11-14. This confusion has been further aggravated by the 
renaming of some of the MCTs in 1998 [76]. For clarification purpose, the original 
name of each MCT is presented in Table 5. Secondly, only the first four members 
of the family (MCT1-MCT4) have been experimentally demonstrated to transport 
aliphatic monocarboxylates, whereas the substrate specificities of MCTs 5-7, 9 and 
11-14 are yet to be elucidated. MCT8 is the thyroid hormone transporter. 
SLC16A10 was named T-type amino acid transporter 1 (TAT1) rather than MCT10 
and it is involved in the transport of system-T aromatic amino acids [70]. Thirdly, 
the regulation of MCTs is at the transcriptional and translational levels. No 
convincing experimental data indicates that the MCTs are regulated by protein 
phosphorylation. Lastly, MCT1 [77], MCT3 [78] and MCT4 [77] require the  
co-expression of the accessory protein CD147 (also known as OX-47, basigin, 
extracellular matrix metalloproteinase inducer (EMM-PRIN) and HT7) for correct 
functional expression in the membrane. MCT2 requires a different accessory 
protein, gp70 (also known as embigin) for its expression in plasma membrane [79].  
 
We focus here on the first four classic members of SLC16A family. This literature 
research will progress through the following sections: (1) The kinetic and 
modulation of MCT1-4; (2) Tissue distribution of MCTs; (3) Intracellular lactate 
shuttle (4) Biochemical and structural aspects; (5) MCT mutation and genetic 




Table 5. Human SLC16 family members (adapted from Meredith and Christian, 2008 [70]) 
 








Substrate Tissue distribution Key references 
MCT1 SLC16A1  NM_003051/1p13.2 
Monocarboxylates  
(lactate, pyruvate, ketone 
bodies) 
Ubiquitous [80, 81] 













RPE, choroid plexus 
 
[84, 85] 
MCT4 SLC16A3 (MCT3) NM_004207/17q25.3 Monocarboxylates 
Skeletal muscle, chondrocytes, 
leukocytes, testis, lung, placenta, 
heart, corneal epithelium, adipocytes 
[76, 83, 86, 87]           
 
MCT5 SLC16A4 (MCT4) NM_004696/1p13.3 Unknown Brain, muscle, liver, kidney, lung, ovary, placenta, heart [86] 
MCT6 SLC16A5 (MCT5) NM_004695/17q25.1 Unknown Kidney, muscle, brain, heart, pancreas, prostate, lung, placenta [86] 
MCT7 SLC16A6 (MCT6) NM_004694/17q24.2 Unknown Brain, pancreas, muscle [86] 
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MCT8 SLC16A2 XPCT    (MCT7) NM_006517/Xq13.2 T3, T4 
Liver, heart, brain, thymus, intestine, 
ovary, prostate, pancreas, placenta [88] 
MCT9 SLC16A9  BN000144/10q21.2 Unknown Endometrium, testis, ovary, breast, brain, kidney, adrenal, retina [73] 
TAT1 SLC16A10 MCT10 NM_018593/6q21-q22 Aromatic amino acids (W, Y, F, L-dopa) 
Kidney, intestine, muscle, placenta, 
heart [89, 90] 
MCT11 SLC16A11  NM_153357/17p13.2 Unknown Skin, lung, ovary, breast, pancreas, RPE, choroid plexus [91] 
MCT12 SLC16A12  NM_213606/10q23.3 Unknown Kidney [91] 
MCT13 SLC16A13  BN000145/17p13.1 Unknown Breast, bone marrow stem cells [91] 
MCT14 SLC16A14  BN000146/2q36.3 Unknown Brain, heart, ovary, breast, lung, pancreas, RPE, choroid plexus [91] 
Notes: *Before publication of Wilson et al. (1998). 





1.4.1 Monocarboxylate Transporter 1-4 
MCT1-4 are the only members to date, which have been shown to mediate the 
transport of monocarboxylates, such as lactate, pyruvate and butyrate. All four 
isoforms mediate the transport of monocarboxylates in a proton-mediated manner, but 
the detailed mechanism of other isoforms has not been studied. The topology of the 
MCT family is shown in Fig. 1 and will be discussed in detail under section 
“Biochemical and structural aspects”.  
 
1.4.1.1 Monocarboxylate Transporter 1 (SLC16A1) 
MCT1 is the most studied and functionally characterized member of the MCT family, 
largely due to the fact that it is the only monocarboxylate transporter expressed in 
human erythrocytes. MCT1 is found in the great majority of tissues of all species 
studied, with no evidence for splice variants. Recently, MCT1 has been found to be 
expressed in human white fat and in human adipocytes (and preadipocytes) [83]. It 
was the first isoform to be identified at the molecular level and from these studies, 
MCT1 substrate and inhibitor specificity has been characterized in various models 
(Table 6). MCT1 mediates the transport of a wide variety of monocarboxylates. 
Characterization of endogenous MCT1 in erythrocytes [72], and MCT1 expressed in 
Xenopus oocytes [92, 93] has revealed that it transports short chain (C-2 to C-5) 
unbranched aliphatic monocarboxylates such as acetate (Km = 3.5 mM) and 
propionate (Km = 1.5 mM). Three and four carbon atom substrates with C-2 
substitutions are preferred, such as L-lactate (Km = 3-5 mM), pyruvate  
(Km = 0.7 mM), acetoacetate (Km = 4-6 mM), and β-hydroxybutyrate (10-12 mM) 
[91]. MCT1 lactate transport is stereoselective. It has a ten-fold preference for          
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L-lactate over D-lactate [94]. However, this stereoselective preference is not observed 
in 2-chloropropionate and β-hydroxybutyrate. A large number of inhibitors of  
MCT1-mediated transport are known, including α-cyana-4-hydroxycinnamate, 
























Figure 1. The proposed topology of the monocarboxylate transporter (MCT) family. MCTs 
have 12 transmembrane domains (TMDs) with intracellular N- and C-termini and a large 
intracellular loop between TMDs 6 and 7. The N- and C- termini and the large loop between 
TMDs 6 and 7 show the greatest variation between family members, whilst the TMDs 
themselves are highly conserved. Critical residues identified in MCT1 and two highly 
conserved motifs characteristic of the MCT family are included. CD147, the ancillary protein 
that associates with MCT1, MCT3 and MCT4, is also shown. (Adapted from Halestrap and 

















Table 6. Substrate and inhibitor affinities for monocarboxylate transporter 1 in various expression systems  
Substrate Km  Transporter Source, Expression System Ki  Transporter Source, Expression System 
Monocarboxylates     
L-lactate 8.3 mM Hamster, Sf-9 cells [82] 2.20 mM Rat, erythrocytes [95] 
 6.0 mM Human, oocyte [96]   
 5.6 mM Rat, oocyte [97]   
 3.5 mM Rat, oocyte [75]   
 1.19 mM Human, RD cells [98]   
 6.4 mM  Mouse, ELT cells [99]    
 1.7 mM Rat, TR-iBRB2 [100]   
 9.1 mM Human, erythrocytes [101]   
 13.4 mM Human, erythrocytes [102]   
D-lactate   51.0 mM Rat, erythrocytes [95] 
Acetate   3.50 mM Rat, erythrocytes [95] 
Pyruvate 3.1 mM Hamster, Sf-9 cells [82] 0.64 mM Rat, erythrocytes [95] 
 2.5 mM Human, oocyte [96]   
 2.1 mM Mouse, ELT cells [99]   
 1.0 mM Rat, oocyte [75]   
 2.0 mM Human, erythrocytes [101]   
Butyrate 2.6 mM Human, Caco2 cells [103]   
Propionate   1.50 mM Rat, erythrocytes [95] 
Glycolate   6.60 mM Rat, erythrocytes [95] 
4-Hydroxybutyrate   7.20 mM Rat, erythrocytes [95] 
D,L--Hydroxybutyrate 12.5 mM Mouse, ELT cells [99]   
Oxamate   17.0 mM Rat, erythrocytes [95] 
Glyoxylate   70.0 mM Rat, erythrocytes [95] 
2-Oxobutyrate   0.19 mM Rat, erythrocytes [95] 
3-Oxobutyrate (Acetoacetate) 5.5 mM Rat, oocyte [75] 3.50 mM Rat, erythrocytes [95] 
L-2-chloropropionate   0.92 mM Rat, erythrocytes [95] 
D-2-chloropropionate   0.98 mM Rat, erythrocytes [95] 
D/L-2-hydroxybutyrate   1.30 mM Rat, erythrocytes [95] 
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Substrate Km  Transporter Source, Expression System Ki  Transporter Source, Expression System 
D/L-3-hydroxybutyrate   8.10 mM Rat, erythrocytes [95] 
Formate   >100 mM Rat, erythrocytes [95] 
Bicarbonate   >100 mM Rat, erythrocytes [95] 
2-Hydroxy-2-methlproprionate   >100 mM Rat, erythrocytes [95] 
     
Pharmaceutical Compounds      
Salicylic acid   4.5 mM Rat, TR-iBRB2 cells [100] 
Valproic acid  Human, BeWo cells [104] 5.4 mM Rat, TR-iBRB2 cells [100] 
Atorvastatin  Human, Caco-2 cells [105]   
γ-Hydroxybutyric acid (GHB) 2.07 mM Human, HK-2 cells [106]   
     
     
Inhibitor  IC50 Transporter Source, Expression System Ki Transporter Source, Expression System 
Cyanocinnamate derivatives     
-Cyano-4-hydroxycinnamate 
(CHC)   50 uM Human erythrocytes [101] 
   425 uM Rat, oocyte [75] 
Cinnamic acid   0.6 mM Human erythrocytes [107] 
-Fluorocinnamate   75 uM Human erythrocytes [101] 
-Cyano--(1-phenylindol-3-
yl) acrylate   12 uM Human erythrocytes [101] 
     
NSAIDs     
Diflunisal  50 uM Human, Caco-2 cells [108]   
Diclofenac 100 uM Human, Caco-2 cells [108]   
Ketoprofenc  440 uM Human, Caco-2 cells [108] 380 uM Human, Caco-2 cells [108] 
Naprofenc  250 uM Human, Caco-2 cells [108] 220 uM Human, Caco-2 cells [108] 



















Inhibitor  IC50 Transporter Source, Expression System Ki Transporter Source, Expression System 
Flavonoids      
Naringeninc 23.4 uM Human, Caco-2 cells [109] 15.3 uM Human, Caco-2 cells [109] 
Silybinc 30.2 uM Human, Caco-2 cells [109] 19.7 uM Human, Caco-2 cells [109] 
Luteolinc 0.41 uM Rat MCT1 gene-transfected MDA-MB231 cells [110]   
Morin 6.21 uM Rat MCT1 gene-transfected MDA-MB231 cells [110]   
Phloretin 2.57 uM Rat MCT1 gene-transfected MDA-MB231 cells [110] 28 uM Rat, oocyte[75] 
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1.4.1.2 Monocarboxylate Transporter 2 (SLC16A7) 
MCT2 was cloned from hamster liver and has 60% homology to MCT1 [82]. 
Northen blot analysis and inspection of human expressed sequence tag (EST) 
database suggests that MCT2 is expressed poorly in major tissues. There is no 
evidence for splice variants of the protein although splicing in the 5’- and 3’- 
untranslated region (UTR) has been reported [96, 111]. Human MCT2 was 
exogenously expressed in Xenopus oocyte. The kinetic studies revealed that MCT2 
catalyzed the proton-coupled transport of monocarboxylates but with a higher 
affinity than MCT1. The Km values of pyruvate and L-lactate are 0.1 mM and    
0.7 mM, respectively [92]. Besides, MCT2 is also more sensitive than MCT1 to 
inhibition by inhibitors such as CHC and DIDS. However, MCT2 is not inhibited 
by pCMBS, an inhibitor that interferes with the accessory protein, CD147. This is 
because MCT2 has a different, pCMBS insensitive accessory protein, namely   
gp70 [79]. Interestingly, MCT2 is expressed in several cancer cell-lines although 
its expression was not found in the respective native tissue. This finding suggests 
that MCT2 plays a specific role in cancer cell metabolism [96].  
 
1.4.1.3 Monocarboxylate Transporter 3 (SLC16A8) 
The expression of MCT3 is restricted to the basal membrane of the retinal pigment 
epithelium [78, 112] and choroid plexus epithelia [84]. While MCT3 has not been 
extensively studied, chicken MCT3 transports L-lactate with a Km value of 6 mM 
when it is expressed in yeast [113]. In contrast to MCT1, MCT3 is insensitive to 
CHC, phloretin and pCMBS [113]. CD147-null mice shown a reduction in MCT3 
expression and the loss of polarized expression [114]. This indicates that CD147 
accessory protein is required for functional expression of MCT3.  
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1.4.1.4 Monocarboxylate Transporter 4 (SLC16A3) 
MCT4 expression is high in glycolytic tissue such as white skeletal muscle fibres, 
astrocytes, white blood cells and chondrocytes [76, 86, 115-119]. As glycolytic 
white tissues are the primary source of lactate formation via anaerobic glycolysis, it 
has been proposed that MCT4 may work as an efflux transporter to mediate the 
transport of lactic acid out into the interstitial fluid [91, 93, 98, 115, 117, 120]. 
Indeed, MCT4 is expressed in the rat neonatal heart, which is more glycolytic in its 
energy metabolism than the adult heart where MCT4 is absent [121]. 
Characterization of MCT4 transport in Xenopus occyte system reveals that MCT4 
has lower affinity for both MCT substrates and inhibitors than MCT1 [93, 117]. 
For example, the Km for L-lactate were 3.5 mM and 28 mM for MCT1 and MCT4, 
respectively [93].  
 
The properties of MCT4 are suitable for its proposed role in lactate efflux from 
muscle. The very low affinity of MCT4 for L-lactate may slow down the transport 
of lactic acid from the muscle and thus results in lactate accumulation during 
exercise. The drop in pH in myocytes inhibits the muscle contractile machinery and 
glycolysis and probably plays an important role in the development of muscle 
fatigue [93]. Although such accumulation of lactate within myocytes and 
consequent impairment of glycolysis may impair exercise performance, it serves as 
a feedback loop to limit the lactic acid production by muscle under extreme 






1.4.2 Tissue Distribution of MCTs  
The MCT expression profile varies among tissues within a single species, as 
examined at both mRNA and protein levels. As mentioned above, only MCT3 has 
a uniquely restricted distribution, while MCT1, MCT2 and MCT4 are expressed in 
many tissues. Fishbein et al. examined the human tissue distribution of MCT1, 
MCT2 and MCT4 at protein level by Western blot analysis [115] (Fig. 2). MCT1 
was detected in all 14 tissues examined, with highest expression in heart. 
Furthermore, MCT1 is the only MCT isoform expressed in human erythrocytes. 
MCT2 was expressed in 13 tissues while MCT4 was detected in 7 tissues. It is 
worth noting that although MCT4 is hypothesized to work as efflux transporter in 
glycolytic cell, its expression has also been found in highly oxidative tissues like 
heart.  
 
Although this data may reveal the tissue distribution of the expressed protein, it is 
more important to determine the cellular and subcellular localization of these 
proteins within the tissue. This can be achieved by using Western blot analysis and 
both immunofluorescence microscopy and immunogold electron microscopy with 
specific antipeptide antibodies [115]. Several studies have examined the 
localization of MCT1, 2 and 4 within the muscle and central nervous system    
[119, 122-124]. However, there is currently no published data for MCT5-MCT14.  
 
In many tissues, more than one MCT isoform is expressed. The co-existence of 
several MCT isoforms may have physiological implication that is related to their 
unique properties and/or to their regulation. The differences in kinetic 
characteristics and tissue distribution of these isoforms allow for fine tuning as well 
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as differential regulation of the transport depending on the specific needs of a 
particular tissue [74]. One well-documented examples is skeletal muscle tissue 
(Fig. 3). MCT1 and MCT4 have been reported to be the major MCT isoforms 
expressed in skeletal muscle [91, 115, 117, 120] and this appears to correlate with 
either the influx or efflux of lactic acid into different muscle fibre types. MCT1 
expression is the most predominant isoform in oxidative red fibres, whereas MCT4 
expression is high in glycolytic white fibres [115, 116]. As glycolytic white fibres 
are the primary source of lactate formation via anaerobic glycolysis, MCT4 may 
work as an efflux transporter to mediate the transport of lactic acid out into the 
interstitial fluid, to be taken up by red oxidative fibres that express primarily MCT1 
[91, 93, 98, 115, 117, 120]. 
 
MCT1 is expressed on the plasma membrane of cerebrovascular endothelial cells. 
It is the only known facilitator of lactic acid transport across the blood brain barrier 
[91, 125-129]. Cerebral lactate is a matter of great interest because lactate is an 
important brain energy substrate [130, 131]. Under pathological states such as 
diabetes, prolonged starvation or hypoglycemia, significant monocarboxylate 
utilization by the brain was reported [132-134]. Besides, systemic lactate is taken 
up by the brain during intensive exercise when circulating lactate level is elevated 
[135-138]. Therefore, MCT1 plays critical role in brain energy metabolism. 
Moreover, monocarboxylate transporters may involve in central nervous system 
disorders such as ischemia and stroke. Cerebral lactate is a key metabolite 
pathways leading to brain damaging during stroke and brain injury [139-141].    
The level of lactic acidosis is thought to be the factor or key indicator of the 
severity of damage [142, 143]. Recently, the role of intracellular pH (pHi) in 
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controlling the transport of MCT1 was studied in cerebrovascular endothelial cells 
[144]. Under normal condition, brain lactate influx into cerebrovascular endothelial 
cell cytoplasm and subsequently release into the blood. During ischemic lactic 
acidosis, reduced oxygen delivery to the brain leads to anaerobic glycolysis 
resulting in lactic acid production in affected cerebrovascular endothelial cells in 
the parenchyma. The fall in endothelial intracellular pH prevents the movement of 
lactate from the brain into endothelial cells, thus blocks the brain-to-blood flux of 
lactic acid [144]. Therefore, the authors of this study concluded that acidic 
intracellular pH inhibits lactate transport by MCT1 in the cerebrovascular 
endothelial cell and MCT1 may contribute to the development of lactic acidosis in 

















Figure 2. Relative distribution of MCT1, MCT2 and MCT4 in 15 frozen human tissues. 
For each MCT, the optical density or absorbance (A) per mg protein was averaged for 
several runs for each tissue, and its mean and standard error were normalized to that of 
the highest mean tissue value, which was set at 100. The tissues are listed here in 
ascending order for MCT 1 levels. Spleen gave smears rather than bands, and was 
therefore counted as zero, although they could represent degraded bands (Adapted from 

















Figure 3. Hypothesized routes of lactate transportation and compartmentalization of 
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1.4.3 Intracellular Lactate Shuttle  
Monocarboxylates such as lactate, pyruvate and ketone bodies are important in 
body energy metabolism. This is particularly true for lactate. For many centuries, 
lactate was largely considered as a dead-end waste product of glycolysis resulting 
from muscle hypoxia [145]. Lactic acid was thought to be the main cause of 
oxygen debt following exercise, an important factor in acidosis-induced tissue 
damage, and a major cause of muscle fatigue during intensive exercise [146]. 
Nonetheless, a new lactate paradigm has evolved since the early 1970s. Lactate is 
no longer considered as a dead-end waste product, but instead a central player in 
cellular, regional and whole body metabolism. 
 
Over the past 40 years, considerable evidence suggests that lactate is an important 
intermediary in numerous metabolic processes and pathways. Lactate has been 
reported to be capable of inducing insulin resistance in muscle [147], of regulating 
energy homeostasis in the central nervous system [124], of inhibiting lipolysis in 
adipocytes [148], and of stimulating inflammatory pathways in L6 cells and in 
macrophages [149, 150]. Besides, lactate has even been shown to induce MCT1 
expression in muscle cells [149]. The introduction of the lactate shuttle  
(cell-to-cell) hypothesis by George Brooks in 1984 has redefined the role of lactate 
in energy metabolism [151]. The cell-to-cell lactate shuttle provides the basic 
framework for interpretation of lactate metabolism. It posits that lactate formation 
and its subsequent distribution throughout the body is a major mechanism whereby 
the coordination of intermediary metabolism in different tissues, and cells within 
those tissues, can be accomplished [152]. Due to its large mass and metabolic 
capacity, the skeletal muscle is probably the major lactate producer as well as 
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consumer. During moderate- to high-intensity exercise, lactate is produced by 
glycolytic muscle fibres. Some of this lactate will be taken up by the neighbouring 
oxidative muscle fibres, and subsequently used as oxidative fuel [26, 153]. Part of 
this lactate escapes into the circulation, and is consumed by heart, and used for 
gluconeogenesis by the liver and kidney [154]. Lactate released into the blood can 
also be taken up by resting muscle and used as oxidative fuel [155, 156]. 
Furthermore, a recent study demonstrated that systemic lactate is an important 
substrate for the brain [138].  
 
Blood is a key component in the lactate shuttle because it is the vehicle that 
distributes lactate to different tissues. It provides the route by which tissues 
throughout the body are linked together in the cell-to-cell lactate shuttle (Fig. 4) 
[157]. During exercise, lactate and protons move out from interstitial fluid of active 
muscles primarily through monocarboxylate transporter MCT1 and MCT4 and 
enter the plasma [73, 120, 158, 159]. From plasma, lactate is further transported 
into red blood cells (RBC) through MCT1 [73, 81, 82]. The cotransport of lactate 
and protons from lactate into RBC establishes a gradient between the plasma and 
interstitial fluid, which provides an additional space for lactate to be exported out 
from working muscles [157, 160]. This redistribution of lactate is crucial as the 
transport of lactate, together with its proton, out of contracting muscles and into 
blood may delay fatigue and hence improve exercise performance [161]. 
Furthermore, it has been calculated by Lindinger et al. that in human subjects 
lacking such transport, the lactate level in plasma would reach 162 mM after four 
30s bouts of high intensity exercise [160]. Therefore, the role of MCT1 in 
transporting lactate into RBC is very important.  
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Three pathways mediate the transport of lactate across erythrocyte membrane:  
1) nonionic diffusion of the undissociated acid; 2) an inorganic anion exchange 
system, often referred to as the band 3 system; and 3) a monocarboxylate-specific 
carrier mechanism [94, 162, 163]. The contribution of each of these systems in 
lactate transport is varying among species [94, 107]. In some mammals, 
monocarboxylate-specific transport system is the predominant pathway for lactate 
transport in the red blood cells, whereas the band 3 system is the preferred pathway 
for lactate transport in erythrocytes of other mammals. Deuticke has quantified the 
contributions of the three pathways in human erythrocytes and a few other species 
such as ox, rabbit, rat and guinea pig [107]. At a L-lactate concentration of 5 mM, 
transport via monocarboxylate system accounts for 90% of lactate flux across 
human erythrocyte membrane, while the band 3 system and nonionic diffusion 
contributed 6% and 4%, respectively. However, the band 3 system is the 
predominant pathway in ox’s erythrocytes, which accounts for 53% of lactate 
transport. The monocarboxylate system and nonionic diffusion contributed 15% 
and 32% of lactate transport, respectively.  
 
The roles of different carriers and the rate of total lactate influx vary among tissues 
and also among animal species. Previously, the RBC lactate transport capacities 
and pathways between athletic and non-athletic species have been studied. The 
study reported that lactate influx into the RBC of the athletic species was 
significantly greater than lactate influx into the RBC of the non-athletic species. 
The lactate influx into the RBC of athletic species (horses and dogs) is 3-65 times 
faster than lactate influx into the RBC of non-athletic species (cattle and goats). 
Differences in the influx of lactate into the RBC of the athletic species compared 
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with the nonathletic species correlate with the predominant pathway of transport. 
The monocarboxylate pathway was the primary pathway in RBC of the athletic 
species (~90% of total lactate influx), whereas the band 3 system was the primary 
pathway in RBC of nonathletic species (56-83% of total lactate influx) [164]. 
 
Human monocarboxylate transporters play important roles in shuttling of lactate 
among neighbouring cells, among tissues, between tissues, and among blood. At 
physiological pH, lactic acid is dissociated almost entirely to lactate anion [73]. 
Therefore, being highly charged, the contribution of passive diffusion on 
monocarboxylate transportation is thought to be insignificant. Previously, the 
inhibition of lactate transport mediated by MCTs has been suggested to be one of 
the factors that leads to apoptosis in skeletal muscle [165]. Given the current 
understanding of the roles of lactate as a central player in cellular, regional and 
whole body metabolism, any impairment in MCT activities may have greater 






















Figure 4. Schematic diagram of cell-to-cell lactate shuttle. Glucolytic muscle fibres 
produce lactate during exercise. Some of the lactate will be taken up by oxidative muscle 
fibres and be used as respiratory fuels. Part of the lactate enters blood circulation, and is 
consumed by heart, and used for gluconeogenesis by the liver. Systemic lactate can also be 

















































1.4.4 Biochemical and structural aspects 
The MCTs are generally predicted to have 12 α-helical transmembrane domains 
(TMDs), with the N- and C-termini located at the cytoplasm (Fig. 1). This has been 
confirmed experimentally for MCT1 in erythrocytes [166]. The main regions of 
sequence variation between isoforms are in the C- and N-termini regions and the 
large intracellular loop between TMD 6-7. There are two highly conserved 
sequences can be identified as characteristic of the MCT family; these are 
[D/E]G[G/S][W/F][G/A]W which traverses the lead into TMD1; and 
YFxK[R/K][R/L]xLAx[G/A]xAxAG which leads into TMD5 [73]. The residues 
in bold are totally conserved, while those in plain text are the consensus residue. 
These consensus regions are found in all 14 members of human MCTs and in the 
non-mammalian MCT family.  
 
Knowledge of the molecular structure-function relationship of transporters is 
instrumental in producing accurate prediction of the effects of SNPs. Single-point 
mutations within these transmembrane domains have been shown to greatly affect 
the substrate specificity and transport activity of MCT1 transporter. The 
spontaneous nucleotide conversion of phenylalanine to cysteine at position 360 in 
TMD 10 of rat MCT1 converted major substrate specificity to mevalonic acid 
[167]. The roles of other residues have been investigated using site-directed 
mutagenesis (Table 7). A conversion of amino acid lysine to glutamine at position 
290 (extracellular loop between TMD 7 and 8) or 413 (extracellular loop between 
TMD 11 and 12) abolished the irreversible inhibition of MCT1 by DIDS [70].   
The substitution of arginine to threonine in TMD 8 (Arg306 in rat MCT1/Arg313 
in human) resulted in the reduction of MCT1’s substrate affinity as this arginine 
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residue was predicted to bind the carboxy group of the substrate [168]. Lastly, the 
amino acid substitution of Asp302 in rat (Arg 309 in human) MCT1 to glutamate 
























Table 7. The effects of mutating charged residues in potential TM helices of MCT1 











Position in Human 
MCT1 TM or loop 
Plasma membrane 
expression Activity Reference 
D15N D15 1 Yes Yes [170] 
K38Q K38 1 Yes Yes [169] 
K45Q K45 1 Yes Yes [169] 
R86Q R86 3 Yes Yes [169] 
R86E R86 3 Yes Yes [169] 
K137Q K137 4-5 Yes Yes [170] 
K141Q K141 4-5 Yes Yes [170] 
K142Q K142 4-5 Yes Yes [170] 
R143Q R143 5 Yes No [170] 
R143H R143 5 Yes Yes [170] 
R143K R143 5 Yes No [170] 
R143E R143 5 Yes No [170] 
R143E/E369R R143 5/10 Yes No [170] 
R175Q R175 5-6 Yes Yes [169] 
R196E R196 6 Yes Yes [169] 
R196Q R196 6 Yes Yes [169] 
K204E K204 6, 6-7 Yes Yes [169] 
K282Q K289 7-8 Yes Yes [169] 
K282R K289 7-8 Yes Yes [169] 
K290Q K297 7-8 Yes Yes [169] 
K290R K297 7-8 Yes Yes [169] 
D302E D309 8 Yes No [168] 
D302N D309 8 No No [168] 
R306T R313 8 Low ? [168] 
R306E R313 8 No No [169] 
D302R/R306E D309R/R313E 8 Yes No [169] 
H337Q H344 9 Yes Yes [168] 
E369R E376 10 Yes No [168] 
E391Q E398 11 Yes Yes [168] 
R404E R410 11 Yes Yes [169] 
K413R K420 11-12 Yes Yes [169] 
K413Q K420 11-12 Yes Yes [169] 
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1.4.5 MCT mutation and genetic syndromes  
Due to the importance of lactate transport in key metabolic processes, mutations in 
these transporters might provide an explanation for some pathophysiological 
conditions. In fact, the defects in MCT1 have already been associated with lactate 
transport deficiency in red blood cells and muscle tissues by Fishbein back in 1986 
[171]. In 2000, Merezhinskaya et al. reported three missense mutations in MCT1 in 
five patients with symptomatic deficiency in lactate transport (SDLT) [172]. Of 
these, Lys204Glu and Glu472Gly were presumably responsible for the subnormal 
lactate transport, while Asp490Glu was proven to be a common polymorphism in 
the normal cohort. The Lys204Glu was subsequently expressed in X. laevis oocyte 
system and shown no effect on lactate transport [91]. However, the subject was 
revisited more recently, and expression of the mutant form in X. laevis occytes was 
found to produce a marked decrease in maximum transport rate [74]. Although the 
study done by Merezhinskaya et al. did not comprehensively dissect the entire 
coding region of the gene and only selected SNPs (Lys204Glu, Glu472Gly and 
Asp490Glu) were screened in 79-90 normal subjects, Merezhinskaya et al. had 
nonetheless presented the first search for clinically relevant mutations in the MCT1 
gene [172].  
 
Recently, Otonkoski et al. identified two new mutations in the non-coding regions 
of MCT1 that leads to a dominantly inherited hypoglycemic disorder known as 
exercise-induced hyperinsulinism (EIHI) [173]. One group of patients had a 
mutation in the 5’ untranslated promoter region and the other group had a mutation 
in the non-coding exon 1, each resulting in increased promoter binding and 
abnormally high transcript levels. MCT1 is not normally transcribed in pancreatic 
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cells. The increased transcription was presumed to lead to pyruvate uptake and 
metabolism upon exercise. This resulted in inappropriate insulin secretion despite 
the falling blood glucose [173].  
 
1.4.6 Regulation of MCT Isoforms 
MCT1 is ubiquitously expressed but is especially prominent in oxidative skeletal 
muscle, where it is up-regulated in response to chronic stimulation or exercise in 
rats and humans [75, 158, 174, 175]. Conversely, MCTs are down-regulated in 
response to denervation of muscle or spinal injury [158]. The mechanism of MCT1 
regulation in skeletal muscle has not been established. Recently, Narumi et al. 
investigated the possible regulation of MCT1 by the major signaling pathways in 
human skeletal muscle rhabdomyosarcoma cells (RD cells) [176]. The effects of 
five major signaling pathways, namely protein kinase A, C, and G (PKA, PKC and 
PKG), protein tyrosine kinase (PTK) and Ca2+/calmodulin-mediated pathway on 
the regulation of MCT1 were examined. The data showed that the PKG-, PTK- and 
Ca2+/calmodulin-mediated pathway do not involve in the regulation of MCT1. The 
results showed that PMA, a PKC activator, increased the expression of MCT1 
protein. In contrast, 8-Br-cAMP, a PKA activator, significantly decreased the 
MCT1 protein level in RD cells treated with 8-Br-cAMP for 24 hours. It has been 
reported that muscle contraction increase PKC activity [177]. Besides, there is 
information showing that muscle denervation leads to intracellular cAMP 
accumulation and stimulates PKA activity in muscle [178]. Therefore, these results 
indicate the possible involvement of a PKC- and PKA- mediated pathways 
associated with MCT1 expression in skeletal muscle [176]. The expression of 
MCT4 has been shown to be up-regulated by AMP-activated protein kinase 
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(AMPK) pathway [179]. In this study, the AMPK activation induced expression of 
MCT4 in RD cells and rat skeletal muscle in a fiber-type specific manner [179].  
 
In human colon, there is evidence for up-regulation of MCT1 expression mediated 
by butyrate [180]. The basis of this regulation is a butyrate-induced increase in 
MCT1 mRNA level, resulting from the dual control of MCT1 gene transcription 
and stability of the MCT1 transcript. Borthakur et al. have cloned the promoter 
region of the MCT1 gene and identified the cis element for key transcription 
factors [181]. The results demonstrated the involvement of NF-κB pathway in the 
regulation of MCT1 promoter activity by butyrate. In contrast, the PKC, PKA and 
tyrosine kinase pathways played no role in butyrate-induced MCT1 regulation 
[181]. Recently, the effects of somatostatin on butyrate absorption and MCT1 
expression in intestinal Caco-2 cells have been examined [182]. Somatostatin is an 
important anti-inflammatory neuropeptide in the gastrointestinal tract, which is 
known to act as a neurotransmitter and hormone [183, 184]. The study showed that 
somatostatin increased the membrane levels of MCT1 and CD147 and enhanced 
association of MCT1 with CD147 in Caco-2 cells via the p38 MAPK-mediated 
pathway [182].  
 
MCT1, MCT2 and MCT4 are expressed in human adipose tissue. A recent study 
reported that hypoxia results in increased lactate release and modulates the 
expression of specific MCTs by human adipocytes in  a type-specific manner, with 
MCT1 and MCT4 expression being hypoxia-inducible transcription factor-1  
(HIF-1) [83]. Hypoxia increased the mRNA levels of MCT1 and MCT4 in human 
adipocytes, but reduced the mRNA level of MCT2. MCT1 protein was increased 
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by 2.7-fold by 48 hours hypoxia, but the expression of MCT4 protein level 
remained unchanged. The changes in hypoxia-induced MCT gene expression was 
found to be reversible when the cells return to normaxia [83]. However, the result 
of this study was inconsistent with the finding of Ullah et al. [185]. Ullah et al. 
concluded that MCT4, but not MCT1, is regulated by hypoxia through a  
HIF-1α-mediated mechanism. In addition, the HIF-1 transcription factor binding 
site is only found in the promoter region of MCT4, but not in the MCT1 and MCT2 
genes. Therefore, the modulation of hypoxia in MCT1 and MCT2 expressions may 



















1.4.7 Roles of MCTs in drug and xenobiotic distribution 
MCTs may also have a role in the transport of pharmacologically active 
compounds, which generally consist of weak organic monovalent acids, with a 
carboxyl attached to a relatively small R group [91]. These include statins such as 
lovastatin, simvastatin and atorvastatin. Nagasawa et al. have reported that 
lovastatin is taken up into bovine kidney NBL-1 cells and rat mesangial cells via 
MCT, with kinetic evidence suggesting that MCT4 is the isoform responsible for 
lovastatin uptake [186, 187]. However, the rat cultured mesangial cells and bovine 
kidney NBL-1 cells used by Nagasawa et al. were also shown to express other 
MCT isoforms; the involvement of other MCT isoforms cannot thus be excluded. 
MCTs might also mediate simvastatin uptake into the brain as simvastatin transport 
is competitively inhibited by acetate [105, 188]. Several weak organic acids have 
been experimentally proven to be transported by rat MCT1. The uptake of benzoic 
acid across intestinal and blood-brain barrier has been reported to be mediated by 
rat MCT1 [125, 189]. Furthermore, MCT1 has been reported to play a part in the 
uptake of gamma-hydroxybutyrate (GHB) across the blood-brain barrier [190], the 
absorption of nicotinic acid in the intestine [191], as well as the transportation of 










1.5 THESIS RATIONALE 
Given that MCT1 and MCT4 have been implicated in lactate transport, any 
impairment in transporter activity may have far reaching consequences. One of the 
main objectives of this project was therefore to describe the genetic polymorphisms 
in the promoter, exons and exon-intron junctions of SLC16A1 and SLC16A3 genes 
that may be present in the ethnic Chinese and Indian groups of the Singapore 
population. The effects of SNPs reported in this study will be predicted using 
bioinformatics tools. To our knowledge, this is the first report on the 
comprehensive analysis of SLC16A1 and SLC16A3 genes in any population. 
Although Merezhinskaya et al. had presented the first search of clinically relevant 
mutations in SLC16A1 gene, the study done by Merezhinskaya et al. had screened 
only selected SNPs (Lys204Glu, Glu472Gly and Asp490Glu) in 79-90 normal 
subjects and did not comprehensively dissect the entire coding region of the gene.  
 
The complex actions of transporters during drug-transporter or food-transporter 
interactions may have far-reaching consequences. Given the roles of MCT1 in 
transporting endogenous monocarboxylates as well as clinically important drugs 
[105, 192, 193], these interactions can cause serious consequences. The diet-drug 
interactions via MCT1 inhibition may affect lactate shuttling and drug disposition 
in the body. Several dietary and pharmacological compounds have been shown to 
serve as the substrate and/or inhibitor for MCT1 [108, 194, 195]. Therefore, the 
second objective of this study is to examine the effects of various dietary 
compounds and pharmacological agents on human monocarboxylate transporter 1 




We are interested in the RBC lactate influx assay because it is an excellent model 
to study human MCT1 transporter. Unlike most cell-lines that express other MCT 
isoforms, MCT1 is the only isoform found in the human RBC and it accounts for 
90% of lactate transport [72, 107]. Besides, RBC samples can be easily obtained 
and the techniques for preparation of RBCs and lactate influx measurement are 
well established [164, 196-200]. 
 
The role of different carriers and the rate of total lactate influx vary among tissues 
and also among animal species. However, variation in lactate transport within a 
single species has not been studied. It has been reported that the muscle-plasma 
lactate concentration gradients in human subjects vary widely between individual 
subjects [201]. However, it remained unknown whether the rate of lactate influx 
into the RBC exhibits similar interindividual variation. The third aim of this study 
was therefore to examine whether the rate of lactate influx into RBC varies among 
individual. We have previously screened the genetic variants in the SLC16A1 gene 
in ethnic Chinese and Indian groups of the Singapore population and a common 
nonsynonymous SNP, 1470 T>A (Asp490Glu) had been identified in SLC16A1 
(Table 10). In light of this, it would be intriguing to explore the effect of this SNP 
on erythrocyte lactate transport.  
 
We have previously examined the inhibitory effects of several drugs on MCT1-
mediated L-lactate influx. Therefore, it will be beneficial to clinically examine the 
physiological effect of MCT1 in mediating lactate influx from plasma to 
erythrocyte. Hence, the fourth objective of this study was to evaluate the potential 
influence of MCT1 on distribution of lactate in plasma and erythrocyte and the 
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effect of MCT1 inhibitor, diflunisal, on lactate distribution in blood. The result of 
this study will increase our understanding of the clinical relevance of MCT1 

























1.6 SPECIFIC AIMS OF THE STUDY 
1. To detect and describe the genetic polymorphisms in the SLC16A1 and 
SLC16A3 genes encoding MCT1 and MCT4 proteins that may be 
present in the ethnic Chinese and Indian groups of the Singaporean 
population 
The methods and approaches used to achieve this aim were: 
 Genetic screening by PCR amplification of genomic DNA followed by 
direct sequencing 
 Determination of genotype and allelic frequencies by gene counting 
 Examine ethnic differences in allele frequencies by Chi Square analysis 
 Reconstruction of haplotypes and estimation of population haplotype 
frequencies using SNPAnalyzer 
 Examine ethnic differences in haplotype frequencies by Chi Square 
analysis 
 
2. To examine the effects of pharmaceutical agents and phytochemical 
compounds on human erythrocyte MCT1 
The methods and approaches used to achieve this aim were: 
 The inhibitory potencies of these compound were examined by 
determined the IC50 by making measurements over a broad range of 
inhibitor concentrations  





3. To explore interindividual variation in erythrocyte lactate transport 
activity 
The methods and approaches used to achieve this aim were: 
 Performing human erythrocyte influx assay to measure transporter 
activity 
 Genotyping of healthy volunteer using methods and approaches 
described in (1) 
 Examine the relationship of 1470 T>A (Asp490Glu) variant with 
erythrocyte lactate transport activity 
 
4. To evaluate the potential influence of MCT1 on the distribution of 
lactate in plasma and erythrocyte and the effects of the MCT1 
inhibitor, diflunisal, on lactate distribution in blood 
The methods and approaches used to achieve this aim were: 
 This was a single-centre, randomized, 2 periods crossover drug 
interaction study conducted in 12 healthy adult male volunteers 
 Sodium lactate infusion was used to raise the blood lactate level 
 Diflunisal was selected as MCT1 inhibitor to block MCT1 activity 
 The plasma, whole blood and erythrocyte lactate levels were measured 





























Part of this project has been published in: 
 
Lean, C. B. and E. J. Lee (2009). "Genetic variations in the MCT1 (SLC16A1) gene in the 
Chinese population of Singapore." Drug Metab Pharmacokinet 24(5): 469-474. 
 
The population genotyping of SLC16A3 gene has been accepted for publication under 
manuscript entitled:  
 





MCT1 (SLC16A1) is the first member of monocarboxylate transporter (MCT) and 
its family is involved in the transportation of metabolically important 
monocarboxylates such as lactate, pyruvate, acetate and ketone bodies. This study 
aimed to identify genetic variations of SLC16A1 in the ethnic Chinese (n = 95) and 
Indian (n = 96) groups of the Singaporean population. To our knowledge, this is the 
first report on the comprehensive analysis of SLC16A1 gene in any population. The 
promoter, coding region and exon-intron junctions of the SLC16A1 gene encoding 
the MCT1 transporter were screened for genetic variations in the study population 
by DNA sequencing. A total of 21 genetic variations of SLC16A1, including 14 
novel ones, were found: 6 in the promoter region, 4 in the coding exons  
(3 nonsynonymous variations and 1 synonymous variation), 4 in the 5’ untranslated 
region (5’UTR), 6 in the 3’ untranslated region (3’UTR) and 1 in the intron. Of the 
3 nonsynonymous variants, only 303T>G (Ile101Met) was predicted by PolyPhen 
and SIFT as having a potentially damaging effect on protein function, whereas 
1282 G>A (Val428Ile) and 1470 T>A (Asp490Glu) were speculated to be benign. 
Genotyping data was in accordance to Hardy Weinberg Equilibrium for all loci, 
except for the -363-100 C>G SNP which showed departure from HWE in Chinese 
(X2=6.267, p=0.012). Three reported SNPs, namely IVS3-17A>C, 1470T>A 
(Asp490Glu) and 2917(1414) C>T are the common polymorphisms found in the 
coding region of SLC16A1 gene in Chinese and Indian populations. Linkage 
disequilibrium analysis revealed strong association between these common variants 





MCT4 (SLC16A3) is the third member of monocarboxylate transporter and is 
involved in the transportation of metabolically important monocarboxylates such as 
lactate, pyruvate, acetate and ketone bodies. This study aimed to identify genetic 
variations of SLC16A3 in the ethnic Chinese (n = 95) and Indian (n = 96) groups of 
the Singaporean population. To our knowledge, this is the first report on the 
comprehensive analysis of SLC16A3 gene in any population. The promoter, coding 
region and exon-intron junctions of the SLC16A3 gene encoding the MCT4 
transporter were screened for genetic variations in the study population by DNA 
sequencing. A total of 46 genetic variants were detected in SLC16A3 gene, of 
which 33 are novel. Of these variants, 22 are located in the promoter regions, 2 in 
the 5’ untranslated region (UTR), 10 in the coding exons (5 nonsynonymous and 5 
synonymous variations), 6 in 3’UTR and 6 in the intron. Of the 5 nonsynonymous 
variants, only 44C>T (Ala15Val) was predicted by PolyPhen and SIFT as having a 
potentially damaging effect on protein function, whereas 55G>A (Gly19Ser), 
574G>A (Val192Met) and 916G>A (Gly306Ser) had conflicting results between 
the SIFT and PolyPhen algorithms. Finally, 641C>T (Ser214Phe) was predicted to 
be tolerated variant. Genotyping data was in accordance to Hardy Weinberg 
Equilibrium for all loci, except for the IVS2-149 G>T SNP which showed 









2.1 MATERIAL AND METHODS 
2.1.1 Study Populations 
Genetic materials used in this study were randomly selected from a previously-
developed cell repository from healthy volunteers of Chinese and Indian descent. 
The fully anonymized white cell lines developed from 192 individuals of the ethnic 
Chinese and Indian of the Singaporean population were screened in this study 
(Chinese, n = 96; Indian, n = 96). However, the DNA sample of one Chinese 
individual was not sufficient for the screening of the entire gene. Hence this subject 
has been excluded out from the study and only 95 ethnic Chinese individuals were 
participated in this study. All donors had been recruited previously in accordance 
with the requirements of the local ethics requirements (Institutional Review Board, 
National University Hospital, Singapore) and had provided written informed 
consent. The mean age was 24.0 ±5.2 (18-48) and 24.3±7.6 (17-52) for Chinese 
and Indian, respectively. The male:female sex ratio was 48:47 for Chinese and 
57:39 for Indians. All DNA samples were rendered anonymous by removing links 
with specific individual information, i.e., any ID, name, or address. Ethnicity was 
defined through self-declaration by the donors of similar ethnicity through three 
generations. 
 
2.1.2 DNA extraction 
Genetic materials used in this study were obtained from a previously-developed 
cell repository from healthy volunteers of Chinese and Indian descent. 45 ml of 
Buffer A (0.32 M sucrose, 10 mM Tris HCl pH 7.4, 5 mM MgCl2, and 1 % Triton-
X-100) was added to the white cell pellet and mixed by inversion. The solution was 
spun (4C, 20 min, 1500 g) and the supernatant was removed by aspiration. The 
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same procedure was repeated once. The pellet was resuspended in 5 ml of Buffer B 
(25 mM EDTA pH 8.0 and 75 mM NaCl). This is followed by the addition of  
250 l of 10 % Sodium Dodecyl Sulfate (SDS) and 20 l of 20 mg/ml proteinase 
K. The contents were vortexed briefly and incubated overnight at 37C with 
shaking in an oven. At the end of incubation, 1.4 ml of saturated NaCl (6 M) was 
added to the mixture and the mixture was vortexed vigorously for 15 seconds. The 
solution was spun (15 min, 1500 g) and the supernatant was transferred to a new  
50 ml falcon tube containing 15 ml of absolute ethanol. The mixture was mixed 
gently by inversion to precipitate DNA. The mixture was spun (20 min, 1500 g) 
and the supernatant was removed. The DNA pellet was washed with 5 ml of 70% 
ethanol and was spun (15 min, 1500 g). The supernatant was removed and the 
pellet for air-dried for 30 minutes. The recovered DNA was dissolved in 200 l of 
TE solution (10 mM Tris HCl pH 7.5 and1 mM EDTA pH 7.5) and was dissolved 
at 4C overnight. The DNA was transferred to an Eppendorf tube and stored at  
-20C. The isolated DNA was quantified using Quant Universal Microplate 
Spectrophotometer (ITS) and absorbance readings were taken at 260 nm 
wavelength. Optical Density (OD), which determines the purity of the DNA, was 
obtained by measuring the ratio of 260 nm/280 nm (DNA maximum absorbance= 
260 nm wavelength). OD readings between 1.7 – 1.8 were accepted as a lower or 
higher ratio indicates protein or ribonucleic acid contamination respectively. 
Finally, the DNA was diluted with DNase-free water to a concentration of  





2.1.3Primer Selection  
2.1.3.1 Monocarboxylate Transporter 1 (SLC16A1) 
The SLC16A1 gene spans approximately 44 kb and is mapped onto chromosome 
band 1p13.2-p12 in human. MCT1 comprises 5 exons and 4 introns, encoding an 
mRNA approximately 15,000 base pairs. The promoter and exonic fragments for 
the SLC16A1 gene were generated using self-designed primer sequences. These 
primers were designed using Primer3 software (Whitehead Institute for Biomedical 
Research, Cambridge, MA, USA). A section between bases -1418 and + 217 was 
screened for SLC16A1 promoter region (GenBank accession: NM_003051). The 
primer sequences and annealing temperatures for the promoters and exonic 
fragments of SLC16A1 gene are summarized in Table 8. 
 
2.1.3.2 Monocarboxylate Transporter 4 (SLC16A3) 
SLC16A3 gene spans approximately 11 kb and is mapped onto chromosome band 
17q25.3 in human. According to NCBI, six transcript variants have been described 
for this gene, of which all three transcripts have functional protein products 
(http://www.ncbi.nlm.nih.gov/gene/9123).  The six transcript variants are created 
by alternative promoter usage and alternative splicing at the 5’ end of the gene, 
therefore the protein products for all three transcript variants are identical.  The 
promoter and exonic fragments for the SLC16A3 genes were generated using self-
designed primer sequences. These primers were designed using Primer3 software. 
The regions between bases -1534 and +159 of the SLC16A3 transcript variant 2 
(GenBank accession: NM_001042422.2), -531 and +14 of the SLC16A3 transcript 
variant 3 (GenBank accession: NM_004207.3) and -1685 and +87 of the SLC16A3 
transcript variant 4 (GenBank accession: NM_001042423.2) were screened for 
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SLC16A3 promoter regions. The primer sequences and annealing temperatures for 




































Table 8. Primer sequences and PCR conditions used for the analysis of promoter, 5’-UTR, coding and 3’-UTR regions of SLC16A1 gene 
Amplified or 
sequenced region Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Amplified region 




Promoter a CTCAGTCGCTTCCCGCTAC CTCGTTTGCTTGTTCCAGTACC 9406444 - 9406939 496 60 




9406789 - 9407242 454 58 
Promoter c CGGGTCCCTTATTTACAAAATGT GAAGTGGCGACAGTAGTAGAACC 9407120 - 9407479 368 54 
Promoter d AGCAGCAAGTGCTCAACAGAT TCACCCGGATTATCCTCTCTAAT 
 
9407411 - 9407766 356 54 
Promoter e CCTTTCTCCGTGTTTATCAAATG AAGTTTTTGGGGGAGACTTAGG 9407709 - 9408078 370 54 
Promoter f CTGAGGACACAGAGCTGGTAAGT TATTAGAAGACAGTGTGGCATCC 9407990 - 9408349 397 58 
Exon 1 CTGCAGTTCGGATGTCTGTGT AAGGTCTCCTTCACCAGCACT 9406154 - 9406622 469 58 
Exon 2 TTCACAAAAGAGTTTTATAGGTGTGC CTAATACAGACACTCTGGCTGCTTC 9379337 - 9379723 387 50 
Exon 3 CTTGTGTAGATGTGAGGGAGC CAGGTAAATACAAAATAGCCAGCC 9372234 - 9372500 266 55 
Exon 4a GGATTTATATCCTATTCCTTCCATTA TCCAGCTTTCTCAAGGGATG 9368059 - 9368449 390 56 
Exon 4b CAGCCCTGTGTTCCTCTGTA ACCAAAGGTGCAAAGAGTCC 9367864 -9368254 466 59 
Exon 4c TGGAAGACACCCTAAACAAGAGA CCAAAGAATCCCGCATAGAC 9367622 - 9368011 390 50 
Exon 4d TGGGACTTGTAGCCAACACA TTGCTTTCTGTCAGCATTCC 9367410 - 9367766 357 55 
Exon 5a GGATCCTTAAGCTTTGCTTGG ATTTGCATTGAGCACCACTG 
 
9364101 - 9364551 451 50 




9363729 - 9364223 494 56 








Table 9. Primer sequences and PCR conditions used for the analysis of promoter, 5’-UTR, coding and 3’-UTR regions of transcript variants of SLC16A3 
gene 
 
 Amplified or sequenced 
region Forward primer (5’ to 3’) Reverse primer (5’ to 3’) Amplified region





























400006 - 400558 493 60 




399670 - 400123 527 58 




399253- 399779 454 60 




398866 - 399358 553 58 






















Promoter 3a GTCTGCGGGGGTCAGAG GTCTGCGGGGGTCAGAG 430685 - 431181 497 60 
Promoter 3b CCTCCCGGTCTTCACCTT AAGGAAGGAGCAGTGAGCAA 430203 - 430826 624 60 
Promoter 3c GCCCTGTGGCTTCGAG CCTCCACCCTAAAGCCAGT 429804 - 430333 522 60 
Promoter 3d AGTGACCCTTATGCCAGGCT GGACGCTACCGTAATTGCC 429410 - 429898 489 60 
Exon 1 GAAACGAATTACCCTTTTCCTG 
 
GGGACCTCTCCAGAAACCTC 430980 - 431279 300 54 
 Exon 2 CCACCAGACACCAGGTCAG TTGCTGAGCCCAGCTACAC 407812 - 408295 484 60 
 Exon 3 GTTCCTGAAAAGGTGGCTGTT AAAGCCCGAGACCCTCATCT 408478 - 409077 600 63 
 Exon 4a AGATGAGGGTCTCGGGCTTT GAAGACGCTCAGGTCTAGCAG 409058 - 409422 365 60 
 Exon 4b GTAGCCCTGTCTTCCTGTGTG AACATGGAGAAGCTGAAGAGG
TAG 
409217 - 409661 445 60 
 Exon 4c CTGGGCTTCATTGACATCTTC CCAGCTCTGAGTCCCACACT 409561 - 409994 434 60 
 Exon 5a CACAAGCTCAGAGGCAGACAG GAGCCAGTCCAGTTTGTAAAAT
AAA 
410560 - 411043 484 60 
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 Exon 5b GAGCATTTCCTGAAGGCTGAG CATTAAAGTCACGTTGTCTCGA
AG 
410891 - 411285 395 60 
 Exon 5c CAAGGTTACAAGGCATCCTCAC GACAGAGCCACGGTAGGAAC 
 





























2.1.4 Polymerase Chain Reaction Amplification 
The polymerase chain reaction (PCR) amplifications were performed in a total 
volume of 30 l containing 1 X Master Mix (Promega, Madison, WI, USA),  
0.4 M of each primer (Sigma-Aldrich, St. Louis, MI, USA) and 60 ng of DNA on 
the MJ Research Peltier Thermal Cycle (DNA Engine Dyad; MJ Research Inc, 
Waltham, MA, USA). The PCR conditions were pre-denaturation at 95°C for  
5 min, followed by 35 cycles of denaturation at 95°C for 1 min, annealing for  
1 min, and extension at 72°C for 1 min, and then a final extension at 72°C for  
10 min. The annealing temperatures for the fragments of SLC16A1 and SLC16A3 
genes are summarized in Table 8 and Table 9, respectively. Cycle sequencing was 
performed on the MJ Research Peltier Thermal Cycler using the following 
conditions: initial denaturation at 96C for 10 seconds, 50C for 5 seconds, and 
60C for 4 minutes.  
 
2.1.5 Agarose Gel Electrophoresis 
After PCR amplifications, the PCR products obtained were verified by 
electrophoresis through 1% agarose gels stained with 0.2 g/ml ethidium bromide. 
They were subjected to electrophoresis at 100 V for 1 hour and visualized under 
UV illumination. PCR amplifications that were found to produce poor DNA yield 
were discarded and repeated because it would lead to downstream problems such 






2.1.6 DNA Sequencing  
2.1.6.1 PCR Product Clean Up 
Prior to sequencing, PCR products were cleaned up to remove excess primers and 
unincorporated dNTPs. 12 l of PCR products were being added to one unit of 
Shrimp Alkaline Phosphatase (Promega) and two units of Exonuclease I (New 
England Biolabs, Beverly, MA, USA). The reaction mix was incubated at 37C for 
15 minutes and followed by enzyme deactivation at 80C for 20 minutes. 
 
2.1.6.2 Cycle Sequencing  
In this study, all PCR products were subjected to DNA sequencing. Mutational 
analysis of the candidate genes was performed using BigDye Terminator v3.1 
Cycle Sequencing Kit. Extension reactions were performed in a total volume of 20 
l containing 10 l of purified PCR products, 0.5 l of BigDye Terminator reagent, 
2 l of 5x sequencing buffer, 2 l of oligonucleotide primer (5 pmole/l) and  
3.5 l of water. Primers for cycle sequencing were similar to the primers for PCR 
(Table 8 and Table 9). Amplification of cycle sequencing products was generated 
using MJ Research Peltier Thermal Cycle with cycling profile: denaturation at 
96C for 1 min, 25 cycles of denaturation at 96C for 10 seconds, annealing at 
50C for 5 seconds, extension at 60C for 4 minutes. The extension products were 







2.1.6.3 DNA Precipitation 
After cycle sequencing, the 96-well reaction plate was removed from the thermal 
cycler and briefly spun. The sequencing products in each well were added with 2 l 
of 125 mM EDTA, followed by 2 l of 3 M sodium acetate. The contents were 
mixed and added with 50 l of absolute ethanol. The contents were gently mixed 
and incubated in the dark at room temperature for 25 minutes. After the incubation, 
the samples were spun at 3000 g for 30 minutes. The supernatant was discarded by 
inverting the plate and spun up to 185 g for 1 minute. This followed by added 70 l 
of 70 % ethanol to each well, and spun at 1650 g for 15 minutes. The supernatant 
was discarded and the DNA pellets were dried at 72C for 10 minutes. To store, the 
plate was cover with aluminum foil and stored at 4C for a period of 2 weeks prior 
to sequencing analysis. Alternatively, 12 l of HiDi was added to into each well 
containing DNA pellet and run on the automated ABI Prism Model 3100 Avant 
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).  
 
2.1.7 Mutational Analysis of DNA Sequences 
The sequences were analyzed with a Mutation SurveyorTM v2.61 (Softgenetics, 
State College, PA, USA) and Chromas (Techelysium software). All mutations 
flagged by the software were checked by visual inspection to avoid any false 
positives. PCR was repeated and bidirectional sequencing performed on all 
detected variants to rule out PCR-induced mutations and sequencing artefacts. 
SNPs detected were input into SNP analysis software, SNPAnalyser 
(http://snp.istech.info/istech/board/login_form.jsp, version 1.2A: Istech 
Corporation, Korea) to compute statistical calculations of Hardy-Weinberg 
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equilibrium, linkage disequilibrium and haplotype estimation. Putative 
transcription factor binding sites were identified using the MatInspector licensed 
software (Library version: Matrix Library 8.0). SNPInspector licensed software 
was used to identify transcription factor binding sites affected by SNPs. The 
PolyPhen (http://genetics.bwh.harvard.edu/pph/) and SIFT (http://sift.jcvi.org/) 
programs were used to predict the possible impact of amino acid substitution on 
































2.2.1 Genetic variations in the SLC16A1 gene in the Chinese and Indian 
populations of Singapore 
2.2.1.1 Overview of Genetic Screening Data 
This study identifies genetic variations in SLC16A1 in the ethnic Chinese and 
Indian groups of the Singapore population (n = 191). The promoter, coding region 
and the exon-intron junctions of the SLC16A1 gene encoding the MCT1 transporter 
were screened for genetic variation in the study population by direct DNA 
sequencing. A total of 21 genetic variations of SLC16A1, including 14 novel ones, 
were found: 6 in the promoter region, 4 in the coding exons (3 nonsynonymous 
variations and 1 synonymous variation), 4 in the 5’ untranslated region (5’UTR),  
6 in the 3’ untranslated region (3’UTR) and 1 in the intron (Table 10). Of the 3 
nonsynonymous variants, only 303T>G (Ile101Met) was predicted by PolyPhen 
and SIFT as having a potentially damaging effect on protein function, whereas  
1282 G>A (Val428Ile) and 1470 T>A (Asp490Glu) were speculated to be benign.  
 
The allele frequencies of each polymorphism are summarized in Table 10. The 
nucleotide numbering of polymorphisms reported in this study is according to the 
NCBI Genbank sequence accession NM_003051.3. The “A” of the translation 
initial codon ATG was numbered 1 and the transcription initiation site is 
designated as -363 as it is 363 bases upstream of translation start site. The 
outcomes of data quality check (goodness of fit to the Hardy Weinberg 
Equilibrium) are presented in Table 11. The inter-ethnic differences in allele 




Table 10. The description and frequency of SLC16A1 gene polymorphisms identified in the Chinese and Indian populations of Singapore 
SNP ID  
Location 
Position 
Nucleotide change Amino acid change PolyPhen SIFT 
Allele frequency  




or from the 






-363-855 T > C Novel Promoter -363-885 CTGGGCTGTCT/C GGAAAGTTAC    0.005 - 
-363-345 G > T rs73000320 Promoter -363-345 TACAGCGCCGG/T CCCCCAGCGT    - 0.016 
-363-307 C > T Novel Promoter -363-307 GCACCCGCATC/T CATTCAAATG    - 0.005 
-363-289 T > G Novel Promoter -363-289 ATGCTGCCCAT/G TCCCCGCTCC    - 0.005 
-363-222 T > C Novel Promoter -363-222 TCTCGGTGACT/C TTTCCTTTTT    - 0.005 
-363-100 C > G rs60844753 Promoter -363-100 TCTGGCAGGGC/G GTGGTAGCTC    0.068 0.005 
-298 G > C Novel 5'-UTR -298 GTGTGGCGGGG/C AGGGGGCGGC    - 0.01 
-297 A>C Novel 5'-UTR -297 TGTGGCGGGGA/C GGGGGCGGCC    - 0.005 
del (-207-




   - 0.005 
-136 A>G Novel 5'-UTR -136 GCAGCGAGCGA/G AGGACGGGAG    - 0.005 
303 T>G Novel Exon 3 303 GTGGCTTGATT/G GCAGCTTCTT Ile101Met 
Possibly 
damage Intolerant - 0.01 
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IVS3 -17 A>C rs74411643 Intron 3 E4 -17 TTATTTATTTA/C TTTATTGTCT    0.621 0.427 
1080 G>A Novel Exon 4 1080 GTGTCTATGCG/A GGATTCTTTG    - 0.005 
1282 G>A Novel Exon 5 1282 GGCATGTGGCG/A TCGTCCTAAT Val428Ile Benign Tolerant 0.021 - 
1470 T>A rs1049434 Exon 5 1470 AAGACACAGAT/A GGAGGGCCCA Asp490Glu Benign Tolerant 0.653 0.573 
1748 T>G rs11585690 3'UTR 1748 (145) TGATGGGATTT/G TTGTTTGACT    - 0.021 
1835 T>C Novel 3'UTR 1835 (332) CTTAAACCATT/C TTTGCTGAATTC    - 0.016 
2132 C>T Novel 3'UTR 2132 (629) GTTCTAGACAC/T AGTGTACTTG    - 0.005 
2258 A>G Novel 3'UTR 2258 (755) ATGCATTTTGA/G GTGTTTATAG    0.005 - 
2917 C>T rs7169 3'UTR 2917 (1414) CAGAAAGATAC/T AGACATTCAA    0.642 0.578 
3445 T>C rs9429505 3'UTR 3445 (1942) CTCTGCGTACT/C TCTTCTCTCT    - 0.099 
“A” of the translation codon ATG is numbered 1 (NM_003051.3 was used as the reference sequence). 
The transcription initiation site is designated as -363 as it is 363 bases upstream of translation start site. The nucleotide upstream of transcription initiation site is 








Table 11. SLC16A1 data quality check: goodness of fit to Hardy Weinberg Equilibrium 
 
Polymorphisms 
Chinese  Indians 
Chi Square HWE p-value  Chi Square HWE p-value 
-363-855 T > C 0.003 0.959  - - 
-363-345 G > T - -  0.024 0.876 
-363-307 C > T - -  0.003 0.959 
-363-289 T > G - -  0.003 0.959 
-363-222 T > C - -  0.003 0.959 
-363-100 C > G 6.267 0.012*  0.003 0.959 
-298 G > C - -  0.011 0.918 
-297 A>C - -  0.003 0.959 
del (-207-210) 
CAGA 
- -  0.003 0.959 
-136 A>G - -  0.003 0.959 
303 T>G - -  0.011 0.918 
IVS3 -17 A>C 0.512 0.474  0.045 0.831 
1080 G>A - -  0.003 0.959 
1282 G>A 0.044 0.834  - - 
1470 T>A 0.438 0.508  2.144 0.143 
1748 T>G - -  0.043 0.835 
1835 T>C - -  0.024 0.876 
2132 C>T - -  0.003 0.959 
2258 A>G 0.003 0.959  - - 
2917 C>T 0.272 0.602  0.207 0.650 
3445 T>C - -  1.158 0.282 
Departure of observed genotype distributions from expected frequencies were analyzed using Chi Square 
goodness of fit test. Expected genotype frequencies were calculated from allele frequencies (p, q) 
according to the HWE formula where p2 + 2pq + q2. For population genetics, the degree of freedom (d.f.) 
is determined by number of genotypes – number of alleles. 












Table 12. SLC16A1inter-ethnic difference in allele frequency 
Polymorphism 
  Allele Frequency   Ethnic Difference 
  Chinese Indian   Chi Sq P-value 
-363-855 T > C   0.005 -   - - 
-363-345 G > T - 0.016 - - 
-363-307 C > T - 0.005 - - 
-363-289 T > G - 0.005 - - 
-363-222 T > C - 0.005 - - 
-363-100 C > G 0.068 0.005 0.621 0.427 
-298 G > C - 0.01 - - 
-297 A>C - 0.005 - - 
del (-207-
210)CAGA  - 0.005  - - 
-136 A>G - 0.005 - - 
303 T>G - 0.01 - - 
IVS3 -17 A>C 0.621 0.427 14.4 0.0001* 
1080 G>A - 0.005 - - 
1282 G>A 0.021 - - - 
1470 T>A 0.653 0.573 2.557 0.11 
1748 T>G - 0.021 - - 
1835 T>C - 0.016 - - 
2132 C>T - 0.005 - - 
2258 A>G 0.005 - - - 
2917 C>T 0.642 0.578 0.142 0.2 
3445 T>C   - 0.099   - - 












2.2.1.2 Genetic Variants Detected in the Promoter and 5’-UTR Regions of 
SLC16A1 gene 
A total of 10 genetic variations were found: 6 in the promoter and 4 in the 5’UTR 
region. The location of each polymorphism and putative regulatory elements within 
the amplified 5’ flanking region are presented in Figure 5. The predictive effects of 
SNPs on the transcription factor binding sites of SLC16A1 gene are summarized in 
Table 13. The representative sequencing electropherograms and description of 




















Figure 5 Nucleotide sequence of the 5’-flanking region of the SLC16A1 gene and location 
of polymorphisms identified. The noncoding first exon sequence is shown in uppercase 
letters. Intron and flanking sequences are shown in the lowercase letters. The transcription 
start site (A) is designated as +1. Variant loci are highlighted. Underlined sequences 
correspond to the putative transcription factor binding sites.  
 
-1800 taataaccct gaggtaggta ttatccttgt tttacagagt tgggagtgag gcttggaaag 
-1740 gtaaaatgac ttgcctgagg acacagagct ggtaagtgca agaatcaaat ttggaactga 
-1680 acagatctgg ctctcaggtc tatagtgtga atctaccacc ctatggggct ctataagcct 
-1620 tcttttgagg tttcctggga ttcatcttat ttaaccactt ctcactacat tccatagaac 
-1560 aggcccttat atatttactt ctgaaccaga ctgaggatcc tgtctctcta acttaattct 
-1500 ccttaccatc tacctgaatg ctgctgccac cctagcactg ctcttataag tcctagctgc 
    -1440 cccaatgacc cgaaatgcct tccctttctc cgtgtttatc aaatgtaaaa agcaattact 
    -1380 gtattactca ctagtagtac ttggccgtgg atgccacact gtcttctaat atactgaact 
    -1320 gttattggaa agcacatggg acctctcagg atctgatcct ccaatctcta ctcttcttca 
    -1260 atctcaggtt cttcatttgc aaaacagaaa ccataaggcc tacctcccag ggttgctgtg 
    -1200 agaattgagg gggagggtaa gtgaggggga gggtaagtga gggggtgagt cctggaaggg 
    -1140 aggaagacac gaggggaagg gcagggtcct ggcaagcagc aagtgctcaa cagatgttgg 
    -1080 ttaatttgtg cctaagtctc ccccaaaaac ttgcaagctc tttgaaggca ggggccttgc 
    -1020 ctcatatttt tcggtatttc tcaaaagtcc tggacatcaa agacactcca tggttatttg 
     -960 atcacttcaa cacacacgtt ggttatgcgg tcacagcggc tattatgtta aaaacaggct 
     -900 ctggagtgtg acttcaaatg ctggccgctg acgagctggg ctgtctggaa agttacttca 
     -840 cctctctgag cctcgggtcc cttatttaca aaatgttcag ggcagtgccc acttcacagg 
     -780 gctgaggatt agagaggata atccgggtga ggagcatcag ccccagcgcc gcctgccaca 





     -660 tccacgtggc cgaggtgcac accccaaccc actgggccag tctccccacc ctcttacctg 
     -600 ctcttctttc ccgactcgtc tttaataccc accaggcgcc aaccgccgcg ggcctggctc 
     -540 tatggtggca agttgcatgg gttctcccat caggacctcc cgatgagcct acgaggtcgg 
     -480 ttctactact gtcgccactt cagagggagg aaacaggccc ggagggttgg ggaacttccc 
     -420 gaggtcactg aactggtgtc aggcccggat tggaatccaa acacatccca gcccatgccc 
     -360 ggctctacag cgccggcccc cagcgtcttc ccgggtgcca gcggcacccg catccattca 
     -300 aatgctgccc attccccgct cctcagtcgc ttcccgctac tccgcacgcg catctccccc 
     -240 acccgtcagg gtcaggcctc tcggtgactt ttcctttttc tctggcagaa actgaggggt 
     -180 gagaccgatg gttgtgtccc gaacgagggc agattgccta gagctcgtca gacagggacc 
     -120 caagggcgag tctggcaggg cgtggtagct ccgcgccgct cagcaggggc gcagcgcgcg 
      -60 ggtcggactg ggacgccggt cacgtggcgg ggagggggcg ccggcgcgcg cgggcgagct 
        1 AGAGGGCGCG CGCGGCTGAA AGCGTGTGGA GGCGCGGGCT GCAGTTCGGA TGTCTGTGTG 
       61 GCGGGGAGGG GGCGGCGGCC GGGAGAGACG ACTCCGCCCC CTGCGCGCAT GCTCCGGCCC 
      121 CGGCGGGTTA TAAGGCAGCC TCGCTGGCCC GGCCAGACAA AGTGGTGAGC TGCGACGTGA 
      181 CTGGCTAGCT GCGTGGGTAC TGGAACAAGC AAACGAGGCA GCGAGCGAAG GACGGGAGCC 




















Table 13. The predictive effects of SNPs on the transcription factor binding sites of 
SLC16A1 gene. For each SNP allele the transcription factor binding sites either deleted or 
generated by the nucleotide exchange.  
Polymorphism Lost Family/Matrix New Family Matrix 
-363-855 T > C - Elk-1 
-363-345 G > T Nuclear respiratory factor 1 (NRF1) - 
-363-307 C > T 
Cut-like homeodomain protein (Cut 
Repeat III / homeodomain) HMG box-containing protein 1 
Homeobox protein engrailed (en-1) Homeobox transcription factor Nanog 
Cellular and viral CCAAT box HMG box-containing protein 1 
-363-289 T > G 
Homeobox transcription factor Nanog 
Core promoter-binding protein (CPBP) 
with 3 Krueppel-type zinc fingers 
LBP-1c (leader-binding protein-1c), 
LSF (late SV40 factor), CP2, SEF 
(SAA3 enhancer factor) 
TEA domain-containing factors, 
transcriptional enhancer factors 1,3,4,5 
-363-222 T > C Nuclear factor of activated T-cells 5 
Retinoic acid receptor / retinoid X 
receptor heterodimer, DR5 sites 
RAR-related orphan receptor alpha 
HepG2-specific P450 2C factor-1, DR1 
sites 
Estrogen-related receptor beta 
Monomers of the nur subfamily of 
nuclear receptors (nur77, nurr1, nor-1) 
Peroxisome proliferator-activated 
receptor gamma, DR1 sites 
Interferon regulatory factor 3 (IRF-3) 
Gut-enriched Krueppel-like factor 
-363-100 C > G 
Aryl hydrocarbon / Arnt heterodimers, 
fixed core 
Kruppel-like zinc finger protein 219 
Myogenic regulatory factor MyoD  
Basic transcription element (BTE) 
binding protein, BTEB3, FKLF-2 
Zinc finger transcription factor ZBP-89 
Zinc finger protein insulinoma-
associated 1 (IA-1) functions as a 
transcriptional repressor 
Member of b-zip family, induced by 
ER damage/stress, binds to the ERSE 
in association with NF-Y 
Kruppel-like factor 6 
Zic family member 2 
X gene core promoter element 1 
-298 G > C 
Kidney-enriched kruppel-like factor, 
KLF15 
Myogenic regulatory factor MyoD 
(myf3) 
Myc associated zinc finger protein 
(MAZ) 
Collagen krox protein  
(zinc finger protein 67 - zfp67) 
Myeloid zinc finger protein MZF1 
Stimulating protein 1 
Kidney-enriched kruppel-like factor 
MYC-associated zinc finger protein 
related transcription factor 
Purine-rich element binding protein A 
-297 A>C 
Myc associated zinc finger protein 
(MAZ) 
Core promoter-binding protein (CPBP) 
with 3 Krueppel-type zinc fingers 
Collagen krox protein  
(zinc finger protein 67 - zfp67) EGR1, early growth response 1 
Myeloid zinc finger protein MZF1 X gene core promoter element 1 Kruppel-like factor 6 
Purine-rich element binding protein A EGR1, early growth response 1 
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2.2.1.2.1 -363-100 C>G 
The -363-100 C>G single nucleotide polymorphism is located 100-bp upstream of 
the transcription start site. Representative sequencing electropherograms of AA and 






The genotypes distribution of CC, CG and GG amongst 95 Chinese sample are 84 
(88.4%), 9 (9.5%) and 2 (2.1%) respectively. The genotypes distribution is 
departure from the HWE predicted distribution (X2 = 6.27, p = 0.012). Amongst the 
96 Indian samples, 95 (99%) samples were homozygous wildtype and 1 (1%) was 
heterozygous mutant. This observed distribution is in accordance to HWE  
(X2 = 0.003, p = 0.959). The C nucleotide is the dominant allele in all two ethnic 
groups, which is consistent with the ancestral C allele reported in the NCBI SNP 
database (Reference SNP ID: rs60844753). The minor allele frequency (MAF) 
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observed in the Chinese and Indian population was 0.068 and 0.005, respectively. 
Statistically significant inter-ethnic difference in allele frequency is observed when 
analyzed with Chi square test of independence (X2 = 10.81, p = 0.001).  
 
A substitution from C to G at position 100-bp upstream of the transcription start 
site may result in the loss and generation of several putative transcription factor 
binding sites (Table 12).   
 
2.2.1.2.2 -363-222 T>C 
The -363-222 T>C single nucleotide polymorphism is located 222-bp upstream of 
the transcription start site. Representative sequencing electropherograms of AA and 







The -363-222 T>C is a novel SNP and was found as heterozygotic in one Indian 
subject. The distribution of TT, TC and CC genotypes in Indian were 95 (99%),     
1 (1%) and 0 (0%), respectively. The observed genotype distribution is in 
accordance to HWE (X2 = 0.003, p = 0.959). This variant was not found in the 
ethnic Chinese group of Singapore population.  The substitution was predicted to 
result in the loss of putative nuclear factor of activated T-cells 5 (NFAT5) binding 
site. It was also predicted that the substitution might lead to the generation of 
several putative transcription factor binding sites (Table 13).  
 
2.2.1.2.3 -363-289 T>G 
The -363-289 T>G SNP is located 289-bp upstream of the transcription start site. 







The -363-289 T>G is a novel SNP and was only detected in Indian population. The 
distribution of TT, TG and GG genotypes in Indian were 95 (99%), 1 (1%) and 0 
(0%), respectively. No deviation from HWE was observed (X2 = 0.003, p = 0.959).  
The substitution was predicted to result in the loss of homeobox transcription factor 
Nanog (NANOG) and TEA domain-containing factors (TEAD) binding sites. This 
SNP might also lead to the generation of new putative core promoter-binding 
protein (CPBP) with 3 Krueppel-type zinc fingers binding site.  
 
2.2.1.2.4 -363-307 C>T 
The -363-307 C>T SNP is located 307-bp upstream of the transcription start site. 







The -363-307 C>T is a novel SNP and was only detected in the Indian population. 
The distribution of CC, CT and TT genotypes in Indian were 95 (99%), 1 (1%) and 
0 (0%), respectively. No deviation from HWE was observed (X2 = 0.003, 
 p = 0.959). The effects of SNP on transcription binding sites are summarized in 
Table 13.  
 
2.2.1.2.5 -363-345 G>T 
The -363-345 G>T SNP is located 345-bp upstream of the transcription start site. 





This variant was not found in the ethnic Chinese group of Singapore population. In 
the Indian population studied, 93 (96.8%) were GG, 3 (3.2%) were GT and 0 (0%) 
was TT. This distribution is in accordance to HWE (X2 = 0.024, p = 0.876). The G 
nucleotide is the dominant allele in Indian population, consistent with the ancestral 
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G allele reported in the NCBI database (Reference SNP ID: rs73000320). The 
substitution was predicted to result in the loss of putative nuclear respiratory factor 
1 (NRF1) transcription factor binding site.  
 
2.2.1.2.6 -363-855 T>C 
The -363-855 T>C SNP is located 855-bp upstream of the transcription start site. 




This SNP was found as heterozygotic in one Chinese subject. It is a novel SNP and 
was not detected in the ethnic Indian group of Singapore population. The 
distribution of TT, TC and CC genotypes in Indian were 95 (99%), 1 (1%) and  
0 (0%), respectively. No deviation from HWE was observed for this polymorphism  
(X2 = 0.003, p = 0.959). The substitution may lead to the generation of new 




2.2.1.2.7 -136 A>G 
The -136 A>G SNP is positioned 136-bp upstream of the translational start site. 





The -136 A>G is a novel polymorphism and 5’-UTR region of SLC16A1 gene. It 
was found as heterozygotic in one Indian subject. The distribution of AA, AG and 
GG genotypes were 95 (99%), 1 (1%) and 0 (0%), respectively. This observed 










2.2.1.2.8 del (-207-210) CAGA 
This novel polymorphism consisting of an CAGA sequence deletion is located 207 
to 210-bp upstream of the translation start site and within the 5’-UTR of SLC16A1 
gene. Representative sequencing electropherograms of homozygous wildtype and 




The del (-207-210) CAGA was found as heterozygotic in one Indian subject. The 
distribution of wildtype/wildtype, wildtype/deletion and deletion/deletion 
genotypes were 95 (99%), 1 (1%) and 0 (0%), respectively. No deviation from 








2.2.1.2.9 -297 A>C 
The -297 A>C SNP is positioned 297-bp upstream of the translational start site. 





The -297 A>C is a novel polymorphism. It was found as heterozygotic in one 
Indian subject. The distribution of AA, AC and GG genotypes were 95 (99%),  
1 (1%) and 0 (0%), respectively. This observed distribution is in accordance to 
HWE (X2 = 0.003, p = 0.959). The effects of the substitution on transcription 









2.2.1.2.10 -298 G>C 
The -298 G>C is a novel polymorphism and is located 298-bp upstream of the 
translational start site. Representative sequencing electropherograms of AA and 




The distribution of AA, AC and GG genotypes in Indian population were 94 
(97.9%), 2 (2.1%) and 0 (0%), respectively. This observed distribution is in 
accordance to HWE (X2 = 0.011, p = 0.918). This SNP was not found in the 
Chinese group of Singapore population. It was also predicted that the substitution 
might lead to the loss and generation of several putative transcription factor 









2.2.1.3 Genetic Variants Detected in the Exon, Intron and 3’-UTR Regions of 
SLC16A1 gene 
A total of 11 single nucleotide polymorphisms were detected: 4 in the exons  
(3 nonsynonymous and 1 synonymous variations), 1 in intron and 6 in the 3’-UTR 
region. The effects of nonsynonymous SNPs reported in this study were predicted 
using bioinformatics tools. The topological location of nonsynonymous SNPs is 
presented in Figure 6. The representative electropherograms showing the 
homozygous wildtype and heterozygous variants and the description of 



















Figure 6. Topological location of SLC16A1 non-synonymous mutations detected in this 
study and retrieved from the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/). The 
mutations highlighted in black are the genetic variants found in the Chinese and Indian 

















2.2.1.3.1 303 T>G (Ile101Met) 
The 303 T>G (Ile101Met) and is located 303-bp downstream of the translational 
start site. Representative sequencing electropherograms of AA and AB genotypes 




The 303 T>G (Ile101Met) polymorphism is a novel SNP that only detected in the 
Indian group of Singapore population. The distribution of TT, TG and GG 
genotypes in Indian were 94 (97.9%), 2 (2.1%) and 0 (0%), respectively. No 
deviation from HWE was observed for this polymorphism (X2 = 0.011, p = 0.918).  
 
Based on the putative protein topology, 303 T>G (Ile101Met) is located at the 
transmembrane (TM) 3 (Fig.6). A substitution from T to G at position 303 resulted 
in the conversion of amino acid isoleucine to methionine at position 101 of MCT1 
protein. The PolyPhen and SIFT sequence homology-based tools were used to 
predict whether the amino acid substitution affects protein function based on 
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sequence homology and the physical property of amino acid. The 303 T>G 
(Ile101Met) variant was predicted to be probably damaging by both programs. 
 
2.2.1.3.2 IVS3 -17 A>C  
The IVS3 -17 A>C is a common polymorphism located in the intron 3 of SLC16A1 




The distribution of AA, AC and CC genotypes in Chinese were 12 (12.5%),  
48 (50.0%) and 35 (36.5%), respectively. In Indians, the frequencies of AA, AC 
and CC observed were 31 (32.3%), 48 (50%), and 17 (17.7%), respectively. No 
deviation from HWE were observed for all ethnic groups (Chinese X2 = 0.512,  
p = 0.474; Indian X2 = 0.045, p = 0.831). The A nucleotide is the dominant allele in 
Indians, consistent with the ancestral allele reported in the NCBI SNP database 
(Reference SNP ID: rs74411643). In contrast, the C allele is the dominant form in 
our Chinese population (0.621). The observed inter-ethnic difference in allele 




2.2.1.3.3 1080 G>A  
The 1080 G>A is a novel synonymous SNP that located at exon 4 of MCT1 
protein. Representative sequencing electropherograms of AA and AB genotypes 




It was found as heterozygotic in one Indian subject. The distribution of GG, GA 
and AA genotypes were 95 (99%), 1 (1%) and 0 (0%), respectively. This observed 










2.2.1.3.4 1282 G>A (Val428Ile) 
The 1282 G>A (Val428Ile) is a novel nonsynonymous variants that located at the 
exon 5 of SLC16A1 gene. Representative sequencing electropherograms of AA and 




This variant was only detected in the Chinese group of Singapore population. The 
genotype distribution of GG, GA and AA amongst 95 Chinese samples were  
91 (95.8%), 4 (4.2%), and 0 (0%), respectively. This is in accordance with the 
HWE distribution (X2 = 0.844, p = 0.834). Based on putative protein topology,  
1282G>A (Val428Ile) is located at the TM12 of MCT1 protein (Fig. 6). A 
substitution from G to A at position 1282 resulted in the conversion of amino acid 
valine to isoleucine at position 428 of MCT1 protein. Both amino acid residues are 
non-polar and thus this mutation is unlikely to affect the functions of the protein. 
This is consistent with the results obtained using the PolyPhen and SIFT 
programmes. The 1282 G>A (Val428Ile) variant was predicted to be benign by 
both programs.  
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2.2.1.3.5 1470 T>A (Asp490Glu) 
The 1470 T>A (Asp490Glu) is a novel nonsynonymous variants that located at the 
exon 5 of SLC16A1 gene. Representative sequencing electropherograms of AA and 




The 1470 T>A (Asp490Glu) polymorphism was detected as a common 
polymorphism in both ethnic Chinese and Indian groups of Singapore population. 
This SNP was previously reported by Merezhinskaya et al. Amongst the 96 Indian 
samples analyzed, 10 (10.4%) samples were homozygous wildtype, 46 (48%) 
samples were heterozygous mutants and 39 (40.6%) were homozygous mutants. 
This observed distribution is in accordance to HWE (X2 = 0.438, p = 0.508). The 
genotype distribution of TT, TA and AA amongst 96 Indian samples were  
14 (15%), 54 (56%) and 28 (29%). No deviation from HWE were observed for 
both ethnic groups (Chinese X2 = 0.438, p = 0.508; Indian X2 = 2.144, p = 0.143). 
The A allele is the dominant allele in Chinese and Indians, consistent with the 
ancestral A allele reported in the NCBI SNP database (Reference SNP ID: 
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rs1049434). No ethnic difference in allele frequency is observed in our study 
population (X2 = 2.557, p = 0.110).  
 
The 1470 T>A (Asp490Glu) is located at the cytoplasmic C-terminal end of MCT1 
protein (Fig. 6). A substitution from T to A at position 1470 resulted in the 
conversion of amino acid aspartic acid to glutamic acid at position 490 of MCT1 
protein. As glutamic acid and aspartic acid are both acidic amino acids with similar 
physicochemical properties, it is likely that substitution will not result in 
fundamental change. This is consistent with the results obtained using PolyPhen 
and SIFT which predicted this SNP to be benign and unlikely to have any 
significant effect on the protein function. 
 
2.2.1.3.6 1748 T>G 
The 1748 T>G SNP is located at the 3’-UTR of the SLC16A1 gene. Representative 






The 1748 T>G was found as heterozygotic in 4 Indians. The distribution of TT, TG 
and GG genotypes were 92 (95.8%), 4 (4.2%) and 0 (0%), respectively. This 
observed distribution is in accordance to HWE (X2 = 0.043, p = 0.835). The A 
allele is the ancestral allele reported in the NCBI SNP database (Reference SNP 
ID: rs11585690). 
 
2.2.1.3.7 1835 T>C 
The 1835 T>C is a novel SNP locates at the 3’-UTR of MCT1 gene. 




The 1835 T>C polymorphism was only found in the ethnic Indian group of 
Singapore population. The frequencies of TT, TC, and CC genotypes observed 
were 93 (96.9%), 3 (3.1%), 0 (0%), respectively. This observed distribution is in 





2.2.1.3.8 2132 C>T 
The 2132 C>T is a novel polymorphism locates at the 3’-UTR of SLC16A1 gene. 




This variant was only detected in Indian group. The genotype distribution of CC, 
CT and TT were 95 (99%), 1 (1%) and 0 (0%), respectively. This observed 












2.2.1.3.9 2258 A>G  
The 2258 A>G is a novel variant locates at the 3’-UTR of SLC16A1 gene. 





This SNP was found as heterozygotic in one Chinese subject. The frequencies of 
AA, AG and GG were 95 (99%), 1 (1%) and 0 (0%), respectively. No deviation 











2.2.1.3.10 2917 C>T 
The 2917 C>T SNP is located at the 3’-UTR of SLC16A1 gene. Representative 
sequencing electropherograms of AA and AB genotypes are as presented: 
 
 
The 2917 C>T was found to be common polymorphism in the local Chinese and 
Indian populations. In Chinese, the frequencies of CC, CT, and TT genotypes were  
11 (12%), 46 (48%), and 38 (40%). Amongst the 96 Indian samples analysed,  
16 (17%) samples were homozygous wildtype, 49 (51%) samples were 
heterozygous mutants and 31 (32%) were homozygous mutants. No deviation from 
HWE were observed for both ethnic groups (Chinese X2 = 0.272, p = 0.602; Indian 
X2 = 0.207, p = 0.650). The NCBI SNP database (Reference SNP ID: rs7169) has 
reported this SNP as a C/T variant, and the ancestral allele is reported T nucleotide, 
which corresponds with the T nucleotide being the dominant allele in both ethnic 
groups. The minor C allele is occurring at a frequency of 0.422 Indians as 
compared to 0.358 in Chinese. No ethnic difference in allele frequency is observed 




2.2.1.3.11 3445 T>C 
The 3445 T>C is located at the 3’-UTR of SLC16A1 gene. Representative 




This SNP was only detected in the Indian group of Singapore population.  
The observed frequencies of TT, TC and CC genotypes were 77 (80.2%),  
19 (19.8%) and 0 (0%). No deviation from HWE was observed for this 











2.2.1.4 Linkage Disequilibrium (LD) Analysis 
Linkage disequilibrium (LD) refers to association between tightly linked SNPs. 
Alleles at different loci are sometimes found together more or less often than 
expected based on their frequencies. Two alleles are said to be in LD if their alleles 
are in statistical association.  
 
In this study, the significance of the associations was assessed by Chi square test. 
The LD for each of the pairs of segregating sites was quantified by the D’. The  
D’ = 1 is known as complete LD, which indicates that the two SNPs have not been 
separated by recombination, recurrent mutation or gene conversion. Detailed pair-













Table 14. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A1 bi-allelic promoter polymorphisms in ethnic Indian population. The 
statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs that lack the 
power to detect significant association are indicated by ns. The number in bold represents LD value. 
 
Position -363-345 G>T -363-307 C>T -363-289 T>G -363-222 T>C -363-100 C>G -298 G>C -297 A>C del (-207-210) -136 A>G 
-363-345 G>T -- ns ns ns <0.0001 0.495 ns ns ns ns 
-363-307 C>T -- -- ns ns ns ns ns ns ns 
-363-289 T>G -- -- -- ns ns ns ns ns ns 
-363-222 T>C -- -- -- -- ns ns ns ns ns 
-363-100 C>G -- -- -- -- -- ns ns ns ns 
-298 G>C -- -- -- -- -- -- ns ns ns 
-297 A>C -- -- -- -- -- -- -- ns ns 
del (-207-210) -- -- -- -- -- -- -- -- ns 














Table 15. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A1 bi-allelic coding region polymorphisms in ethnic Chinese population. The 
statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs that lack the 
power to detect significant association are indicated by ns. The number in bold represents LD value. 
 
Position IVS -17 A>C 1282 G>A 1470 T>A 2258 A>G 2917 C>T 
IVS -17 A>C -- ns <0.0001 1.000 ns 
<0.0001 
1.000 
1282 G>A -- -- ns ns ns 
1470 T>A -- -- -- ns <0.0001 1.000 
2258 A>G -- -- -- -- ns 




















Table 16. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A1 bi-allelic coding region polymorphisms in ethnic Indian population. The 
statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs that lack the 
power to detect significant association are indicated by ns. The number in bold represents LD value. 
 
Position 303 T>G IVS3 -17 A>C 1080 G>A 1470 T>A 1748 T>G 1835 T>C 2132 C>T 2917 C>T 3445 T>C 
303 T>G -- ns ns ns ns ns ns ns ns 





1080 G>A -- -- -- ns ns ns ns ns ns 





1748 T>G -- -- -- -- -- ns ns 0.0091 1.000 ns 
1835 T>C -- -- -- -- -- -- ns ns ns 
2132 C>T -- -- -- -- -- -- -- ns ns 
2917 C>T -- -- -- -- -- -- -- -- <0.0001 1.000 
3445 T>C -- -- -- -- -- -- -- -- -- 
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2.2.1.5 Haplotype Construction and Frequency Estimation  
The single nucleotide polymorphisms identified in the 5’-flanking promoter and 
untranslated exon 1 region were regarded as a single block because of the high 
degree of linkage equilibrium and close physical distance of the loci. Several 
studies have interpreted the linkage disequilibrium pattern of polymorphisms in the 
ABCA1 promoter as a region of low recombination probability and thus considered 
the 5’-flanking region to be a single haplotype to be analyzed separately from the 
coding region [202, 203]. The linkage disequilibrium between promoter and coding 
region is very weak. Therefore, the haplotype analysis was performed in the 
promoter and the coding region separately.  
 
Haplotye structures were constructed from population genotype data separately for 
each ethnic group, and their respective frequencies were estimated using SNP 
analysis software, SNPAnalyser. The haplotype frequency was not performed in 
the promoter region of MCT1 due to the low prevalence of SNPs identified in this 
region (Table 10). In the coding region of SLC16A1, three common 
polymorphisms (IVS-17 A>C, 1470 T>A and 2917 C>T) were identified in the 
ethnic Chinese and Indian of Singapore population. These SNPs were input into 
SNPAnalyser to compute statistical calculation of haplotype estimation. These 
variants comprised of 6 statistically inferred haplotypes, of which accounted for 
100% of chromosomes analyzed. The haplotypes and the relative frequencies of 
three commonest SNPs in the coding region of SLC16A1 are summarized in    




The six SLC16A1 haplotypes in the ethnic Chinese and Indian group of Singapore 
population and their frequency distributions between ethnic groups are presented 
graphically in Figure 7. The distribution of haplotypes 1 and 3 were statistically 
significant different amongst the Chinese and Indian ethnic groups; haplotype 1 
was estimated to be approximately 26% more common in Chinese than Indians 
(frequency of 0.621 versus 0.415; X2 = 15.98, p < 0.0001). Haplotype 3 was 
estimated to occur in approximately 13.6% of Indians. In contrast, it had an 
estimated frequency of approximately 2% of Chinese (X2 = 17.26, p < 0.0001). The 
haplotype that was most common in the Singapore population and predicted to 
occur at a relatively high frequency in both ethnic groups is haplotype 1; haplotype 
1 had an estimated frequency of 0.621 and 0.415 in Chinese and Indians, 
respectively. The second common haplotype, haplotype 2, also occurred at similar 
frequencies of 0.348 and 0.400 in Chinese and Indians, respectively. Haplotype 3 
was more common in Indians, but was considerably rare in Chinese  
(2% frequency). Haplotype 4, differing only at the 2917 C>T site, was occurred at 
relatively low frequencies at both ethnic groups (Chinese = 1.1% and  










Figure 7. Ethnic distribution of SLC16A1 haplotypes. The frequencies of six haplotypes 
identified in the ethnic Chinese and Indian of Singapore population.  


































Table 17. Haplotype structure defined by 3 commonest SNPs in the SLC16A1 5’flanking coding region in Singapore population 
 
Haplotype No. 
Polymorphisms Estimated Haplotype Frequencies Chi sq 
value p-value IVS -17 A>C 1470 T>A 2917 C>T Chinese n = 190 
Indian 
n = 192 
1 C A T 0.621 0.415 15.98  < 0.0001* 
2 A T C 0.348 0.400 1.18 0.278 
3 A A T 0.021 0.136 17.26 < 0.0001* 
4 A A C 0.011 0.022 0.66 0.418 
5 A T T 0.000 0.015 - - 
6 C T T 0.000 0.012 - - 
Haplotye structures were constructed and frequencies estimated using SNPAnalyser software. The six haplotypes listed here accounts for 100% of all 
chromosomes. Observed frequencies for haplotypes 5 and 6 are too small to be considered for chi square statistical test of independence.  











2.2.2 GENETIC VARIATIONS IN THE MCT4 (SLC16A3) GENE IN THE 
CHINESE AND INDIAN POPULATIONS OF SINGAPORE 
2.2.2.1 Overview of Genetic Screening Data 
This study identifies genetic variations in SLC16A3 in the ethnic Chinese and 
Indian groups of the Singapore population (n = 191). The promoter, coding region 
and the exon-intron junctions of the SLC16A3 gene encoding the MCT4 transporter 
were screened for genetic variation in the study population by direct DNA 
sequencing. Sequencing analysis of SLC16A3 from 191 Asian subjects resulted in 
the identification of 46 genetic variations, of which 33 are novel mutations  
(Table 18 and Table 19). Of these variants, 22 are located in the promoter region, 
2 in the 5’-UTR, 10 in the coding exons (5 nonsynonymous and 5 synonymous 
variations), 6 in 3’-UTR and 6 in the intron. Of the 5 nonsynonymous variants, 
only 44C>T (Ala15Val) was predicted by PolyPhen and SIFT as having a 
potentially damaging effect on protein function, whereas 55G>A (Gly19Ser), 
574G>A (Val192Met) and 916G>A (Gly306Ser) had conflicting results between 
the SIFT and PolyPhen algorithms. Finally, 641C>T (Ser214Phe) was predicted to 
be tolerated variant. 
 
Previously, three transcript variants have been described for SLC16A3 gene, of 
which three transcripts have functional protein products. However, the database has 
recently been updated and additional three transcript variants have been deposited 
(http://www.ncbi.nlm.nih.gov/gene/9123; Fig. 8).  The six transcript variants are 
created by alternative promoter usage and alternative splicing at the 5’ end of the 
gene, therefore the protein products for all six transcript variants are identical. As 
this project was performed prior to the update of SLC16A3 gene sequence, we 
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intended to screen the promoter regions associated with the transcript variant 2, 3 
and 4 of SLC16A3 gene. However, we were unable to sequence the promoter 
region of transcript variant 3 because of the GC-rich content of this region. The 
amplification was unsuccessful despite several primer pairs were designed and 
commercial PCR kit was utilized to amplify this region. Therefore, the genotype 
information of this region is not included in this report. For transcript variant 2, the 
“A” of the translation initial codon ATG was numbered 1 and the transcription 
initiation site is designated as -139 as it is 139 bases upstream of translation start 
site (Reference ID: NM_001042422.2). For transcript variant 4, the transcription 
initiation site is designated as -118 as it is 118 bases upstream of translation start 
site (Reference ID: NM_001042423.2). The allele frequencies of each 
polymorphism are summarized in Table 18 and Table 19. The outcomes of data 
quality check (goodness of fit to the Hardy Weinberg Equilibrium) are presented in 
Table 20 to 22. The inter-ethnic difference in allele frequencies of each 
polymorphism are summarized in Table 23 to 25.
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Figure 8. Six transcripts have been described for SLC16A3 gene (http://www.ncbi.nlm.nih.gov/gene/9123). All transcript variants are created by 






























Transcript Variant 1 
Transcript Variant 2 
Transcript Variant 3 
Transcript Variant 4 
Transcript Variant 5 









Table 18. The description and frequency of SLC16A3 polymorphisms detected in the promoter and 5’-UTR regions of two transcript variants identified in the 







 Name dbSNP (NCBI) 
From the 
translational 
initiation site or 
from the end of 





Transcript variant 2 
-139-1374 C > G Novel Promoter -139-1374a CCCCTCCCCTC/GTGAGGGCAGG 0.005 - 
-139-1281 G > A Novel Promoter -128-1281a AGGCCTGGGG/AGTCAGAACCA - 0.083 
-139-1105 C > T rs11077983 Promoter -139-1105a TGCTGCTCTAC/TGGTGGGGGTT 0.916 0.875 
-139-845 G > A Novel Promoter -139-845a AGGAAGATGGG/AAGCACCACCT - 0.005 












-139-540 C > T Novel Promoter -139-540a GGGCTTGTAAC/TATTACATAGA 0.005 - 
-139-518 G > A Novel Promoter -139-518a AGAACAGGCGG/ACCTTACTGGA - 0.005 
-139-477 G > T Novel Promoter -139-477a GGCTGCAGATG/TGAGAGCCAAG 0.011 - 
-139-304 C > T Novel Promoter -139-304a TTCCTGTGGCC/TCTGGCAGGG - 0.005 
-139-246 C > G rs75888222 Promoter -139-246a AGGCCTTACTC/GCCTGGAGCCA - 0.094 
-139-45 G > T Novel Promoter -139-45a GGCTGGAGTCG/TGTGGCTTTGT 0.005 - 
-139-40 C > G Novel Promoter -139-40a GAGTCGGTGGC/GTTTGTAGGGC 0.005 - 
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-41 G > A Novel 5'UTR -41 CACCGGGACCG/AGAGAGGAAGC - 0.005 
IVS+100 C > T Novel Intron 1 E1 +100 GCGCGCACCTC/TCCCACCAAAG - 0.005 
Transcript variant 4 
-118-115 G > A Novel Promoter -118-115b TCCAGGAAGG/AAAACGAATTA 0.005 - 
-118-130 A > C rs3176828 Promoter -118-130b CAGGCAGCTCA/CTGGGATCCAG 0.937 0.875 
-118-249 C > T rs79034755 Promoter -118-249b ACAGGGGCTGC/TGGGGGAAGAA 0.079 0.156 
-118-331 G > A rs60910743  Promoter -118-331b TGCAAGCTCGG/ACCCCGACACC 0.163 0.161 
-118del(-436-437) AG rs58263941  Promoter -118(-436-437)b GCGGACACAGdel(ag)CGGCAGGGCA 0.105 0.146 
-118-502 A > G rs12450761 Promoter -118-502b GGAGTGGCCAA/GTCCGCAAATG 0.147 0.146 
-118-554 A > T rs56043453  Promoter -118-554b GCCCAGCCCCA/TCTTGGGGCA 0.926 0.875 
-118-1131 C > A Novel Promoter -118-1131b CCCCACGTCCC/AGCGGCTGGCG - 0.005 
-118-1416 C > T Novel Promoter -118-1416b TGGGCCACGCC/TGGGCAGCCGC - 0.01 
-86 A > G rs3176827 5'UTR -86 ACGGGCTGACA/GGTCCAGCAGA 0.926 0.875 
 IVS1+21 G > C Novel Intron 1 E1 +21 TGCAGGTCCAG/CACGCCTGAGG 0.005 - 
a The transcription initiation site is designated as -139 as it is 139 bases upstream of translation start site. The nucleotide upstream of transcription initiation site is 
designated as -139-n accordingly. n= number of nucleotide (NM_001042422.2 was used as the reference sequence). 
b The transcription initiation site is designated as -118 as it is 118 bases upstream of translation start site. The nucleotide upstream of transcription initiation site is 
designated as -118-n accordingly. n= number of nucleotide (NM_001042423.2 was used as the reference sequence). 
c One of the heterogeneous deletion is deleted from 726 to 773 bp upstream of transcription initiation start site.  
Search completed: August 2010 
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Table 19. The description and frequency of SLC16A3 variations detected in the coding and 3’-UTR regions of three transcript variants identified in the 





Nucleotide change Amino acid change PolyPhen SIFT 
Allele frequency 




or from the 






21 C > T Novel Exon 2 21 CCGTGGTGGAC/TGAGGGCCCCA    - 0.005 
44 C > T Novel Exon 2 44 GGCGTCAAGGC/TCCCTGACGGC Ala15Val 
Probably 
damaging Intolerant 0.011 0.042 
55 G > A Novel Exon 2 55 CCCTGACGGCG/AGCTGGGGCTG Gly19Ser Benign Intolerant - 0.005 
117 C > T Novel Exon 2 117 ACGCCTTCCCC/TAAGGCCGTCAG    - 0.005 
IVS2-149 G > T Novel Intron 2 E3 -149 GCCTGCGCTCG/TGGGAGCCTGC    0.021 - 
IVS2-114 C > T rs72634335 Intron 2 E3 -114 TGGTGCCCCGC/TGGGGGGAGGG    0.095 - 
IVS2-52 G > A Novel Intron 2 E3 -52 GAGCTCAGTCG/AGCTGGCGGGG    0.005 - 
IVS3+29 G > A rs7215409 Intron 3 E3 +29 TGGGCCGCACG/ATGCCAGGAGG    0.005 0.042 
574 G > A Novel Exon 4 574 CAACTGCTGCG/ATGTGTGCCGC Val192Met Benign Intolerant - 0.005 
609 G > A Novel Exon 4 609 TGGTGGTCACG/AGCCCAGCCGGG    - 0.005 
641 C > T Novel Exon 4 641 CCGCGACCCTC/TCCGGCGCCTG Ser214Phe Benign Tolerant 0.005 0.005 
831 G > A Novel Exon 4 831 ACATCTTCGCG/ACGGCCGGCCG    - 0.031 
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916 G > A Novel Exon 4 916 GTTCTTCAACG/AGCCTCGCGGA Gly306Ser Benign Intolerant 0.005 - 
1176 G > A Novel Exon 5 1176 TCCTGGCGGGG/AGCCGAGGTGC    0.005 - 
1494 C > T Novel 3”UTR 1494 (96) GGCAGGGCCAC/TGGCTGGGCTC    - 0.005 
1512 C > T rs78825758 3'UTR 1512 (114) CTCCAGCTGCC/TGGCCCAGCGG    0.005 - 
1594 C > T Novel 3'UTR 1594 (196) AGTGGATCTGC/TGGTGAAGCCA    0.058 0.005 
1608 C > T Novel 3'UTR 1608 (210) GAAGCCAAGCC/TGCAAGGTTAC    - 0.005 
1713 G > A Novel 3'UTR 1713 (315) TCGAGACAACG/ATGACTTTAAT    - 0.005 
1899 G > A Novel 3'UTR 1899 (501) TGGAGTGTTAG/AGACCAACGGT    0.016 - 












Table 20. The SLC16A3 promoter transcript variant 2 population data quality check: goodness of fit to Hardy Weinberg Equilibrium 
 
Polymorphisms Chinese  Indians Chi Square HWE p-value  Chi Square HWE p-value 
-139-1374 C > G 0.003 0.959  - - 
-139-1281 G > A - -  0.793 0.373 
-139-1105 C > T 0.188 0.664  0.218 0.641 
-139-845 G > A    0.594 0.441 




0.698 0.403  1.500 0.221 
-139-540 C > T 0.003 0.959  - - 
-139-518 G > A - -  0.003 0.959 
-139-477 G > T 0.011 0.917  - - 
-139-304 C > T - -  0.003 0.959 
-139-246 C > G - -  1.027 0.311 
-139-45 G > T 0.003 0.959  - - 
-139-40 C > G 0.003 0.959  - - 
-41 G > A - -  0.003 0.959 
IVS+100 C > T - -  0.003 0.959 
Departure of observed genotype distributions from expected frequencies were analyzed using Chi Square 
goodness of fit test. Expected genotype frequencies were calculated from allele frequencies (p, q) according to 
the HWE formula where p2 + 2pq + q2. For population genetics, the degree of freedom (d.f.) is determined by 
number of genotypes – number of alleles. 










Table 21. The SLC16A3 promoter transcript variant 4 population data quality check: goodness of fit to Hardy Weinberg Equilibrium 
 
Polymorphisms Chinese  Indians Chi Square HWE p-value  Chi Square HWE p-value 
-118-1416 C > T - -  0.011 0.918 
-118-1131 C > A - -  0.003 0.959 
-118-554 A > T 0.235 0.628  0.113 0.737 
-118-502 A > G 0.003 0.959  0.001 0.973 
-118del(-436-437) 0.028 0.867  0.728 0.393 
-118-331 G > A 0.158 0.691  0.144 0.705 
-118-249 C > T 0.698 0.403  0.258 0.611 
-118-130 A > C 0.432 0.511  0.218 0.641 
-118-115 G > A 0.003 0.959  - - 
-86 A > G 0.601 0.438  0.218 0.641 
IVS1+21 G > C 0.003 0.959  - - 
Departure of observed genotype distributions from expected frequencies were analyzed using Chi Square 
goodness of fit test. Expected genotype frequencies were calculated from allele frequencies (p, q) according to 
the HWE formula where p2 + 2pq + q2. For population genetics, the degree of freedom (d.f.) is determined by 
number of genotypes – number of alleles. 















Table 22. The SLC16A3 coding region population data quality check: goodness of fit to Hardy Weinberg Equilibrium 
Polymorphisms Chinese  Indians Chi Square HWE p-value  Chi Square HWE p-value 
21 C > T - -  0.003 0.959 
44 C > T 0.011 0.917  0.181 0.670 
55 G > A - -  0.003 0.959 
117 C > T - -  0.003 0.959 
IVS2-149 G > T 22.74 0.000*  - - 
IVS2-114 C > T 1.040 0.308  - - 
IVS2-52 G > A 0.003 0.959  - - 
IVS3+29 G > A 0.003 0.959  0.181 0.670 
574 G > A - -  0.003 0.959 
609 G > A - -  0.003 0.959 
641 C > T 0.003 0.959  0.003 0.959 
831 G > A - -  0.100 0.752 
916 G > A 0.003 0.959  - - 
1176 G > A 0.003 0.959  - - 
1494 C > T - -  0.003 0.959 
1512 C > T 0.003 0.959  - - 
1594 C > T 0.359 0.549  0.003 0.959 
1608 C > T - -  0.003 0.959 
1713 G > A - -  0.003 0.959 
1899 G > A 0.024 0.876  - - 
Departure of observed genotype distributions from expected frequencies were analyzed using Chi Square 
goodness of fit test. Expected genotype frequencies were calculated from allele frequencies (p, q) according to 
the HWE formula where p2 + 2pq + q2. For population genetics, the degree of freedom (d.f.) is determined by 
number of genotypes – number of alleles. 





Table 23. SLC16A3 inter-ethnic difference in allele frequency of polymorphisms in transcript variant 2 of promoter region  
 
Polymorphism   Allele Frequency   Ethnic Difference 
  Chinese Indian   Chi Sq P-value 
-139-1374 C > G 0.005 - - - 
-139-1281 G > A - 0.083 - - 
-139-1105 C > T 0.916 0.875 1.695 0.193 
-139-845 G > A - 0.005 
-139-804 C > T 0.853 0.673 13.89 0.001* 
-139del(-727-795) 0.921 0.833 6.81 0.009* 
-139-540 C > T 0.005 - - - 
-139-518 G > A - 0.005 - - 
-139-477 G > T 0.011 - - - 
-139-304 C > T - 0.005 - - 
-139-246 C > G - 0.094 - - 
-139-45 G > T 0.005 - - - 
-139-40 C > G 0.005 - - - 
-41 G > A - 0.005 - - 
IVS+100 C > T - 0.005 - - 









Table 24. SLC16A3 inter-ethnic difference in allele frequency of polymorphisms in transcript variant 4 of promoter region  
 
Polymorphism 
  Allele Frequency   Ethnic Difference 
  Chinese Indian   Chi Sq P-value 
-118-115 G > A 0.005 - - - 
-118-130 A > C 0.937 0.875 4.279 0.039* 
-118-249 C > T 0.079 0.156 5.491 0.019* 
-118-331 G > A 0.163 0.161 0.002 0.964 
-118del(-436-437) AG 0.105 0.146 1.065 0.302 
-118-502 A > G 0.147 0.146 0.002 0.964 
-118-554 A > T 0.926 0.875 2.807 0.094 
-118-1131 C > A - 0.005 - - 
-118-1416 C > T - 0.01 - - 
-86 A > G 0.926 0.875 2.807 0.09 
IVS1+21 G > C   0.005 - - - 









Table 25. The inter-ethnic difference in allele frequency of polymorphisms in the coding region of SLC16A  
 
Polymorphism   Allele Frequency   Ethnic Difference 
  Chinese Indian   Chi Sq P-value 
21 C > T - 0.005 - - 
44 C > T 0.011 0.042 3.633 0.057 
55 G > A - 0.005 - - 
117 C > T - 0.005 - - 
IVS2-149 G > T 0.021 - - - 
IVS2-114 C > T 0.095 - - - 
IVS2-52 G > A 0.005 - - - 
IVS3+29 G > A 0.005 0.042 5.501 0.019* 
574 G > A - 0.005 - - 
609 G > A - 0.005 - - 
641 C > T 0.005 0.005 0.000 1.000 
831 G > A - 0.031 - - 
916 G > A 0.005 - - - 
1176 G > A 0.005 - - - 
1494 C > T - 0.005 - - 
1512 C > T 0.005 - - - 
1594 C > T 0.058 0.005 8.712 0.003* 
1608 C > T - 0.005 - - 
1713 G > A - 0.005 - - 
1899 G > A   0.016 - - - 
* p value is significant (p < 0.05)
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2.2.2.2 Genetic Variants Detected in the Promoter and 5’-UTR Regions of 
Transcript Variant 2 of SLC16A3 gene 
A total of 15 genetic variations were found in the 5’-flanking region of transcript 
variant 1: 13 in the promoter, 1 in the 5’-UTR region and 1 in the intron region. 
The representative sequencing electropherograms and description of polymorphism 
distribution are discussed in section 2.2.2.2.1 to 2.2.2.2.15. The predictive effects 
of SNPs on the transcription factor binding sites of SLC16A3 gene are summarized 




















Table 26. The predictive effects of SNP on the transcription factor binding sites of MCT4. 
For each SNP allele the transcription factor binding sites either deleted or generated by 
the nucleotide exchange.  
 











-139-1374 C > G 
Insulator protein CTCF (CCCTC-binding 
factor) 
Olfactory neuron-specific factor 
 
Myeloid zinc finger protein MZF1 
Myeloid zinc finger protein MZF1 
Glial cells missing homolog 1 
B-cell-specific activator protein 
-139-1281 G > A Glial cells missing homolog 1 PAX6 paired domain and homeodomain are required for binding to this site 
-139-1105 C > T X-box binding protein RFX1 Wilms Tumor Suppressor 
-139-845 G > A 
MEL1 (MDS1/EVI1-like gene 1) DNA-
binding domain 2 Transcription factor yin yang 2 
Myogenic bHLH protein myogenin (myf4) c-Rel 
-139-804 C > T 
Stimulating protein 1 Egr-2/Krox-20 early growth response gene product 
Carbohydrate response element binding 
protein (CHREBP) and Max-like protein X 
(Mlx) bind as heterodimers to glucose-
responsive promoters 
Wilms Tumor Suppressor 
-139-540 C > T 
Doublesex and mab-3 related transcription 
factor 4 
Special AT-rich sequence-binding 
protein 1, predominantly expressed in 
thymocytes, binds to matrix attachment 
regions (MARs) Albumin D-box binding protein 
-139-518 G > A Binding sites for homodimers of large Maf-proteins - 
-139-477 G > T Neurogenin 1 and 3 (ngn1/3) binding sites Meis homeobox 1 
-139-304 C > T - - 
-139-246 C > G Olfactory neuron-specific factor - 
-139-45 G > T - - 
-139-40 C > G - Spermatogenic Zip 1 transcription factor 











-118-115 G > A Nuclear factor of activated T-cells 5 
Interferon regulatory factor 7 (IRF-7) 
LIM homeobox 4, Gsh4 
Homeobox and leucine zipper encoding 
transcription factor 
-118-130 A > C - - 
-118-249 C > T Human zinc finger protein ZNF35 Myeloid zinc finger protein MZF1 
-118-331 G > A - - 
-118-502 A > G 
Autoimmune regulator 
- 
Transcriptional repressor CDP 
Nuclear factor Y (Y-box binding factor) 
FAST-1 SMAD interacting protein 
-118-554 A > T H6 homeodomain HMX3/Nkx5.1 transcription factor Kruppel-like factor 6 
-118-1131 C > A 
bHLH-PAS type transcription factors 
NXF/ARNT heterodimer Activator protein 4 
Hypoxia induced factor-1 (HIF-1) Myf5 myogenic bHLH protein 
-118-1416 C > T - - 
-86 A > G - 







2.2.2.2.1 -139-40 C>G 
The -139-40 C>G single nucleotide polymorphism is located 40-bp upstream of the 
transcription start site and does not reside in any transcription factor binding site. 





This is a novel SNP and was found as heterozygotic in one Chinese subject. The 
genotype distribution of CC, CG and GG were 94 (98.9%), 1 (1.1%) and 0 (0%), 
respectively. The observed genotype distribution is in accordance to HWE  
(X2 = 0.003, p = 0.959). This variant was not found in the ethnic Indian group of 
Singapore population. A substitution from C to G at position 40-bp upstream of the 
transcription start site may result in the generation of new putative Spermatogenic 





2.2.2.2.2 -139-45 G>T 
The -139-45 G>T is located 45-bp upstream of the transcription start site. 




This variant was only detected in Chinese group. The genotype distribution of GG, 
GT and TT were 94 (98.9%), 0 (0%) and 1 (1.1%), respectively. This observed 
distribution is in accordance to HWE (X2 = 0.003, p = 0.959). This SNP does not 










2.2.2.2.3 -139-246 C>G 
The -139-246 is located 246-bp upstream of the transcription start site. 





This variant was only detected in Indian group of Singapore population. Amongst 
the 96 Indian samples analyzed, the frequencies of CC, CG, and GG genotypes 
were 78 (81.3%), 18 (18.7%) and 0 (0%). This observed distribution is in 
accordance to HWE (X2 = 1.027, p = 0.311). The ancestral allele is reported as “C” 
nucleotide, which corresponds with the C nucleotide being the dominant allele in 
both ethnic groups (Reference SNP ID: rs75888222). The minor G allele was 
occurring at a frequency of 0.094 in Indian while this G allele was not present in 
Chinese. A substitution from C to G at position 246-bp upstream of the 
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transcription start site may result in the loss of putative olfactory neuron-specific 
factor binding site (OLF1).  
 
2.2.2.2.4 -139-304 C>T 
The -139-304 C>T is located 304-bp upstream of the transcription start site. This 
SNP does not reside in any transcription factor binding site. Representative 




The -139-304 C>T is a novel SNP and was only found in Indian group. The 
genotype frequencies of the CC, CT and TT were 95 (99%), 1 (1%) and 0 (0%), 
respectively. No deviation from HWE was observed for this polymorphism  
(X2 = 0.003, p = 0.959). This SNP does not have any consequence on the 




2.2.2.2.5 -139-477 G>T 
The -139-477 G>T is located 477-bp upstream of transcription start site. 






This SNP is novel and was only present in Chinese group. The genotype 
distribution of GG, GT and TT were 93 (97.9%), 2 (2.1%) and 0 (0%), respectively. 
The observed genotype distribution is in accordance to HWE (X2 = 0.011, 
 p = 0.917).  The substitution of G to T at position 477-bp upstream of the 
transcription start site may cause the loss of putative neurogenin 1 and 3 (ngn1/3) 
binding site (NEUROG) and the generation of new putative binding site for a 




2.2.2.2.6 -139-518 G>A 
The -139-518 G>A is located 518-bp upstream of transcription start site and within 
a putative androgene receptor binding site (ARE). Representative sequencing 




This SNP was found as heterozygotic in one Indian subject. The genotype 
frequencies of the GG, GA and AA were 95 (99%), 1 (1%) and 0 (0%), 
respectively. No deviation from HWE was observed for this polymorphism  
(X2 = 0.003, p = 0.959). The substitution of nucleotide G to A at position 518-bp 
upstream of transcription start site was predicted to result in the loss of putative 







2.2.2.2.7 -139-540 C>T 
The -139-540 C>T is located 540-bp upstream of transcription start site. 





This SNP was found as heterozygotic in one Chinese subject but was not detected 
in Indian group. The genotype distribution of CC, CT and TT were 94 (98.9%),  
1 (1.1%) and 0 (0%), respectively. This observed distribution is in accordance to 
HWE (X2 = 0.003, p = 0.959). The substitution of nucleotide C to T at position 
540-bp upstream of transcription start site may result in the loss of two putative 
transcription factor binding sites, doublesex and mab-3 related transcription factor 
4 (DMRT4) and albumin D-box binding protein (DBP). The substitution may also 
lead to the generation of special AT-rich sequence-binding protein 1 (SATB) 
binding site.  
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2.2.2.2.8 -139- del (727-795) 
The large deletion polymorphism consisting of an 
CACCTGCCCTGGGCGGGAGCAC tandem repeat sequence deletion is located 
727 to 795-bp upstream of the transcription start site. Representative sequencing 




The distribution of homozygous wildtype, heterozygous deletion and homozygous 
deletion genotypes in Chinese were 0 (0%), 15 (15.8%) and 80 (84.2%), 
respectively. In Indians, the frequencies of homozygous wildtype, heterozygous 
deletion and homozygous deletion observed were 1 (1%), 30 (31.2%) and  
65 (67.8%), respectively. No deviations from HWE were observed for all ethnic 
groups (Chinese X2 = 0.698, p = 0.403; Indian X2 = 1.500, p = 0.221). The large 
deletion form is the dominant allele in both ethnic groups. Ancestral allele 
information on this polymorphism is not available in the NCBI SNP database 
(Reference SNP ID: rs10704992). The homozygous wildtype was not found in 
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Chinese and only one sample was identified in Indians. Statistically significant 
inter-ethnic differences in allele frequency is observed when analysed with Chi 
square test of independence (X2 = 6.81, p = 0.009).   
 
2.2.2.2.9 -139-804 C>T 
The -139-804 C>T is located 804-bp upstream of transcription start site. 




This SNP was identified as a common polymorphism in the local Chinese and 
Indian populations. In Chinese, the frequencies of CC, CT, and TT genotypes were 
4 (4.2%), 20 (20.8%), and 71 (75%). Amongst the 96 Indian samples analysed, the 
frequencies of CC, CT, and TT genotypes were 8 (8.3%), 43 (44.8%) and  
45 (46.9%), respectively. No deviation from HWE were observed for both ethnic 
groups (Chinese X2 = 2.501, p = 0.114; Indian X2 = 0.261, p = 0.610). The NCBI 
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SNP database (Reference SNP ID: rs12453976) has reported this SNP as a C/T 
variant, and the ancestral allele is reported “T” nucleotide. However, the ancestral 
allele information on this polymorphism is not available. The observed inter-ethnic 
difference in allele frequency is statistically significant (X2 = 13.89, p < 0.001). 
 
The substitution of nucleotide C to T at position 804-bp upstream of transcription 
start site was predicted to result in the loss of putative stimulating protein 1 (SP1) 
and carbohydrate response element binding protein (CHREBP)/ Max-like protein X 
(Mlx) heterodimer  (CHREBP_MLX) transcription factor binding sites. The 
substitution also leads to in the generation of putative Egr-2/Krox-20 early growth 
response (EGR2) and Wilms Tumor Suppressor (WT1) binding sites.  
 
2.2.2.2.10 -139-845 G>A 
The -139-845 C>T is located 845-bp upstream of transcription start site. 






The -139-845 G>A is a novel SNP and only found as heterozygotic in one Indian 
sample. The genotype frequencies of the GG, GA and AA were 95 (99%), 1 (1%) 
and 0 (0%), respectively. No deviation from HWE was observed for this 
polymorphism (X2 = 0.003, p = 0.959). The substitution of nucleotide G to A at 
position 845-bp upstream of transcription start site was predicted to result in the 
loss of putative MDS1/EVI1-like gene 1 DNA-binding domain 2 (MEL1) and 
Myogenic bHLH protein myogenin (myf4) (MYOGENIN) binding sites. The 
substitution was predicted to result in the generation of putative Transcription 
factor yin yang 2 (YY2) and c-Rel (CREL) binding sites.  
 
2.2.2.2.11 -139-1105 C>T 
The -139-1105 C>T is located 1105-bp upstream of transcription start site. 




The -139-1105 C>T was found to be a common polymorphism in the local Chinese 
and Indian populations. The genotype distribution of CC, CT and TT amongst 95 
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Chinese samples were 1 (1.1%), 14 (14.7%) and 80 (84.2%), respectively. The 
distribution of CC, CT and TT in Indian were 2 (2.1%), 20 (20.8%) and  
74 (77.1%), respectively. No deviation from HWE was observed for this 
polymorphism (Chinese X2 = 0.188, p = 0.664; Indian X2 = 0.218, p = 0.641). The 
T nucleotide is the dominant allele in both ethnic groups, which is consistent with 
the ancestral T allele reported in the NCBI SNP database (Reference SNP ID: 
rs11077983).  The minor C allele is least frequent in Chinese (0.168) compared to 
the Indian (0.125) population. This difference was however not statistically 
significant within our study population (X2 = 1.695, p = 0.193). The substitution of 
nucleotide C to T was predicted to result in the loss of putative regulatory factor X 
protein 1 (RFX1) and the generation of putative Wilms Tumor Suppressor (WT1) 












2.2.2.2.12 -128-1281 G>A 
The -128-1281 G>A is a novel SNP locates at 1281-bp upstream of transcription 
start site. Representative sequencing electropherograms of AA and AB genotypes 
are as presented:  
 
 
This SNP was only detected in the Indian group. The genotype distribution of GG, 
GA and AA were 80 (83%), 16 (17%) and 0 (0%), respectively. The observed 
distribution is in accordance to the HWE (X2 = 0.793, p = 0.373). This substitution 
was predicted to result in the loss of Glial cells missing homolog 1 (GCM1) and 









2.2.2.2.13 -128-1374 C>G 
The -128-1374 C>G is a novel SNP locates at 1374-bp upstream of transcription 
start site. Representative sequencing electropherograms of AA and AB genotypes 





This SNP was only found in Chinese. The genotype distribution of CC, CG and 
GG were 94 (98.9%), 1 (1.1%) and 0 (0%), respectively. This observed distribution 
is in accordance to HWE (X2 = 0.003, p = 0.959). The substitution of nucleotide C 
to G at position 1374-bp upstream of transcription start site was predicted to result 
in the loss and generation of several putative transcription factor binding sites 








2.2.2.2.14 -41 G>A 
The -41 G>A polymorphism is positioned 41-bp upstream of the translational start 





The -41 G>A is a novel polymorphism and 5’-UTR region of SLC16A3 gene. It 
was found as heterozygotic in one Indian subject. The distribution of GG, GA and 
AA genotypes were 95 (99%), 1 (1%) and 0 (0%), respectively. This observed 
distribution is in accordance to HWE (X2 = 0.003, p = 0.959). The nucleotide 
substitution was predicted to result in the generation of new putative neuron-







2.2.2.2.15 IVS +100 C>T 
The IVS +100 C>T polymorphism is positioned at 100-bp downstream of exon 1 
of transcript variant 1. Representative sequencing electropherograms of AA and 
AB genotypes are as presented: 
 
 
The IVS +100 C>T is a novel SNP and was only identified in one Indian sample. 
The distribution of GG, GA and AA genotypes were 95 (99%), 1 (1%) and 0 (0%), 
respectively. This observed distribution is in accordance to HWE (X2 = 0.003,  










2.2.2.3 Genetic Variants Detected in the Promoter and 5’-UTR Regions of 
Transcript Variant 4 of SLC16A3 gene 
A total of 11 genetic variations were found in the 5’-flanking region of transcript 
variant 3: 9 in the promoter, 1 in the 5’-UTR and 1 in the intron region. The 
representative sequencing electropherograms and description of polymorphism 
distribution are discussed in section 2.2.2.3.1 to 2.2.2.3.11. The predictive effects 
of SNPs on the transcription factor binding sites of SLC16A3 gene are summarized 
in Table 26. 
 
2.2.2.3.1 -118-115 G>A 
The -118-115 G>A is located 115-bp upstream of transcription start site. 




This SNP was found as heterozygotic in one Chinese subject but was not detected 
in Indian group. The genotype distribution of GG, GA and AA were 94 (98.9%),  
1 (1.1%) and 0 (0%), respectively. This observed distribution is in accordance to 
HWE (X2 = 0.003, p = 0.959). The substitution of nucleotide G to A at position  
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115-bp upstream of transcription start site may result in the loss of a putative 
transcription factor binding sites, Nuclear factor of activated T-cells 5 (NFAT5). 
The substitution may also lead to the generation of three putative binding sites, 
namely Interferon regulatory factor 7 (IRF-7), LIM homeobox 4 (LHX4) and 
Homeobox and leucine zipper encoding transcription factor (HOMEZ).  
 
2.2.2.3.2 -118-130 A>C 
The -118-130 A>C is located 130-bp upstream of transcription start site. 




The -118-130 A>C was found to be common polymorphism in the local ethnic 
Chinese and Indian groups. The distribution of AA, AC and CC in Chinese were  
0 (0%), 12 (12.6%) and 83 (87.4%), respectively. The genotype distribution of 
 AA, AC and CC amongst 96 Indian samples were 2 (2.1%), 20 (20.8%) and  
74 (77.1%), respectively. No deviation from HWE were observed for both ethnic 
groups (Chinese X2 = 0.432, p = 0.511; Indian X2 = 0.218, p = 0.641). The C 
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nucleotide is the dominant allele in both ethnic groups, which is consistent with the 
ancestral C allele reported in the NCBI SNP database (Reference SNP ID: 
rs3176828).  The observed inter-ethnic difference in allele frequency is statistically 
significant (X2 = 4.279, p = 0.039). This SNP does not have any consequence on the 
transcription factor binding site.  
 
2.2.2.3.3 -118-249 C>T 
The -118-249 C>T is located 249-bp upstream of transcription start site. 




The -118-249 C>T is a reported SNP that detected in both ethnic groups. The 
genotype distribution of CC, CT and TT amongst 95 Chinese samples were  
80 (84.2%), 15 (15.8%) and 0 (0%), respectively. The distribution of CC, CT and 
TT in Indian were 69 (71.9%), 24 (25%) and 3 (3.1%), respectively. No deviation 
from HWE was observed for this polymorphism (Chinese X2 = 0.698, p = 0.403; 
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 Indian X2 = 0.258, p = 0.611). The C nucleotide is the dominant allele in both 
ethnic groups, which is consistent with the ancestral C allele reported in the NCBI 
SNP database (Reference SNP ID: rs79034755).  The observed inter-ethnic 
difference in allele frequency is statistically significant (X2 = 5.491, p = 0.019). The 
nucleotide substitution was predicted to result in the loss of Human zinc finger 
protein ZNF35 (ZNF35) and the generation of new putative myeloid zinc finger 
protein (MZF1) binding site.  
 
2.2.2.3.4 -118-331 G>A 
The -118-331 G>A is located 331-bp upstream of transcription start site. 




This SNP was detected in both ethnic groups. The distribution of GG, GA and AA 
in Chinese were 66 (69.5%), 27 (28.4%) and 2 (2.1%), respectively. The genotype 
distribution of GG, GA and AA amongst 96 Indian samples were 67 (69.8%),  
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27 (28.1%) and 2 (2.1%), respectively. No deviation from HWE were observed for 
both ethnic groups (Chinese X2 = 0.158, p = 0.691; Indian X2 = 0.144, p = 0.705). 
The G nucleotide is the dominant allele in both ethnic groups, which is consistent 
with the ancestral G allele reported in the NCBI SNP database (Reference SNP ID: 
rs60910743).  The observed inter-ethnic difference in allele frequency is not 
statistically significant (X2 = 0.002, p = 0.964). This SNP does not have any 
consequence on the transcription factor binding site.  
 
2.2.2.3.5 -118 del (-436-437) AG 
The deletion polymorphism consisting of an AG deletion is located 436 to 437-bp 
upstream of the transcription start site. Representative sequencing 




The distribution of homozygous wildtype, heterozygous deletion and homozygous 
deletion genotypes in Chinese were 75 (78.9%), 19 (20%) and 1 (1.1%), 
respectively. In Indians, the frequencies of homozygous wildtype, heterozygous 
deletion and homozygous deletion observed were 69 (71.9%), 26 (27.1%) and  
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1 (1%), respectively. No deviations from HWE were observed for all ethnic groups 
(Chinese X2 = 0.028, p = 0.867; Indian X2 = 0.728, p = 0.393). Ancestral allele 
information on this polymorphism is not available in the NCBI SNP database 
(Reference SNP ID: rs58263941). The observed inter-ethnic difference in allele 
frequency is not statistically significant (X2 = 1.065, p = 0.302). 
 
2.2.2.3.6 -118-502 A>G 
The -118-502 A>G is located 502-bp upstream of transcription start site. 




This reported SNP only found in both ethnic Chinese and Indian groups of 
Singapore population. The distribution of GG, GA and AA in Chinese were         
69 (72.6%),  24 (25.3%) and 2 (2.1%), respectively. The distribution of AA, AG 
and GG in Indian were 70 (72.9%), 24 (25%) and 2 (2.1%), respectively. No 
deviations from HWE were observed for all ethnic groups (Chinese X2 = 0.003,     
p = 0.959; Indian X2 = 0.001, p = 0.973). The A nucleotide is the dominant allele in 
Indian, which is consistent with the ancestral A allele reported in the NCBI SNP 
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database (Reference SNP ID: rs12450761). The substitution of nucleotide from A 
to G at position 502-bp upstream of transcription start site may result in the loss of 
several transcription factor binding sites, namely autoimmune regulator (AIRE), 
transcription repressor CDP (CDP), nuclear factor Y (NFY) and FAST-1 SMAD 
interacting protein (FAST1).  
 
2.2.2.3.7 -118-544 A>T 
The -118-544 A>T is located 544-bp upstream of transcription start site. 




This SNP was found to be a common single nucleotide polymorphism present in 
the ethnic Chinese and Indian groups of Singapore population. Among the 95 
Chinese samples studied, 0 (0%) samples were homozygous wildtype, 9 (9.5%) 
samples were heterozygous mutants and 86 (90.5%) were homozygous mutants. 
The genotype distribution of AA, AT and TT amongst 96 Indian samples were  
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2 (2.1%), 21 (21.9%) and 73 (76%), respectively. No deviation from HWE were 
observed for both ethnic groups (Chinese X2 = 0.235, p = 0.628; Indian X2 = 0.113, 
p = 0.737). The T nucleotide is the dominant allele in both ethnic groups, which is 
consistent with the ancestral T allele reported in the NCBI SNP database 
(Reference SNP ID: rs56043453).  The observed inter-ethnic difference in allele 
frequency is statistically significant (X2 = 8.082, p = 0.004).  This SNP was 
predicted to result in the loss of putative H6 homeodomain HMX3/Nkx5.1 
(HMX3) transcription factor and the generation of putative Kruppel-like factor 6 
(KLF6) transcription factor.  
 
2.2.2.3.8 -118-1131 C>A 
The -118-1131 C>A is located 1131-bp upstream of the transcription start site. 






The -139-1131 C>T is a novel SNP and was only found in Indian group. The 
genotype frequencies of the CC, CA and AA were 95 (99%), 1 (1%) and 0 (0%), 
respectively. No deviation from HWE was observed for this polymorphism  
(X2 = 0.003, p = 0.959). This SNP may result in the loss of the putative bHLH-PAS 
type transcription factors NXF/ARNT heterodimer (NXF_ARNT) and Hypoxia 
induced factor-1 (HIF1) binding sites. Furthermore, this SNP may also lead to the 
generation of new putative activator protein 4 (AP4) and Myf5 myogenic bHLH 
protein (MYF5) transcription factor binding sites.  
 
2.2.2.3.9 -118-1461 C>T 
The -139-1461 C>T is located 1461-bp upstream of the transcription start site. 




The -118-1461 C>T is a novel SNP and was only found in Indian group. The 
genotype frequencies of the CC, CT and TT were 94 (97.9%), 2 (2.1%) and 0 (0%), 
respectively. No deviation from HWE was observed for this polymorphism 
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(X2 = 0.011, p = 0.918). This SNP does not have any consequence on the 
transcription factor binding site.  
 
2.2.2.3.10 -86 A>G 
The -86 G>A polymorphism is positioned 86-bp upstream of the translational start 




This SNP was found to be a common single nucleotide polymorphism present in 
the ethnic Chinese and Indian groups of Singapore population. Among the 95 
Chinese samples studied, 0 (0%) samples were homozygous wildtype, 14 (14.7%) 
samples were heterozygous mutants and 81 (84.7%) were homozygous mutants. 
The genotype distribution of AA, AG and GG amongst 96 Indian samples were  
2 (2.1%), 20 (20.8%) and 74 (77.1%), respectively. No deviation from HWE were 
observed for both ethnic groups (Chinese X2 = 0.601, p = 0.438; Indian X2 = 0.218, 
p = 0.641). The G nucleotide is the dominant allele in both ethnic groups. 
However, the ancestral allele reported in the NCBI SNP database is A allele 
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(Reference SNP ID: rs3176827).  The observed inter-ethnic difference in allele 
frequency is not statistically significant (X2 = 2.807, p = 0.090). 
 
2.2.2.3.11 IVS+21 G>C 
The IVS+21 G>C polymorphism is positioned at 21-bp downstream of exon 1 of 
transcript variant 3. Representative sequencing electropherograms of AA and AB 
genotypes are as presented: 
 
 
The IVS+21 G>C is a novel SNP and was only identified in one Chinese sample. 
The distribution of GG, GC and CC genotypes were 94 (98.9%), 1 (1.1%) and 
0 (0%), respectively. This observed distribution is in accordance to HWE  







2.2.2.4 Genetic Variants Detected in the Exon, Intron and 3’-UTR Regions of 
SLC16A3 gene 
A total of 20 variants were detected: 10 in the exons (5 nonsynonymous and 5 
synonymous variations), 4 in introns and 6 in the 3’-UTR region. The effects of 
nonsynonymous SNPs reported in this study were predicted using bioinformatics 
tools, PolyPhen and SIFT. The representative electropherograms showing the 
homozygous wildtype and heterozygous variants and the description of 




















Figure 9. Topological location of SLC16A3 non-synonymous mutations detected in this 
study and retrieved from the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/). The 
mutations highlighted in black are the genetic variants found in the Chinese and Indian 


















2.2.2.4.1 21 C>T 
The 21 C>T is a novel synonymous SNP that located at exon 2 of MCT4 protein. 




It was found as heterozygotic in one Indian subject. The distribution of CC, CT and 
TT genotypes were 95 (99%), 1 (1%) and 0 (0%), respectively. This observed 












2.2.2.4.2 44C>T (Ala15Val) 
The 44C>T (Ala15Val) is a novel nonsynonymous variant that located at exon 2 of 
MCT4 protein. Representative sequencing electropherograms of AA and AB 
genotypes are as presented: 
 
 
This SNP was identified in both ethnic Chinese and Indian groups of Singapore 
population. The distribution of CC, CT and TT genotypes in Chinese were 
93 (97.9%), 2 (2.1%) and 0 (0%), respectively. In Indians, the frequencies of CC, 
CT and TT observed were 88 (91.7%), 8 (8.3%), and 0 (0%), respectively. No 
deviation from HWE were observed for all ethnic groups (Chinese X2 = 0.011, 
 p = 0.917; Indian X2 = 0.181, p = 0.670). The observed inter-ethnic difference in 
allele frequency is not statistically significant (X2 = 3.633, p = 0.057). 
 
Based on putative protein topology, the 44C>T (Ala15Val) is located at the 
intracellular N-terminal of MCT4 protein (Fig. 9). A substitution from C to T at 
position 44 resulted in the conversion of amino acid alanine to valine at position 15 
of MCT4 protein. Although both amino acid residues are non-polar, the 44C>T 
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(Ala15Val) was predicted to be probably damaging by PolyPhen and SIFT 
programs.  
 
2.2.2.4.3 55G>A (Gly19Ser) 
The 55G>A (Gly19Ser) is a novel nonsynonymous variant that located at exon 2 of 
MCT4 protein. Representative sequencing electropherograms of AA and AB 
genotypes are as presented: 
 
 
This variant was only present as heterozygotic in one Indian subject and was not 
found in Chinese population. The distribution of GG, GA and AA genotypes were  
95 (99%), 1 (1%) and 0 (0%), respectively. This observed distribution is in 
accordance to HWE (X2 = 0.003, p = 0.959).  
 
The 55G>A (Gly19Ser) variant is located at the intracellular N-terminal of the 
MCT4 molecule (Fig. 9). The non-polar glycine is replaced by the polar serine. 
Although SIFT program predicted this substitution is intolerant, it was inconsistent 
with the results obtained using PolyPhen program which predicted this mutation 
was expected to be benign.  
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2.2.2.4.4 117 C>T 
The 117 C>T is a novel synonymous SNP that located at exon 2 of MCT4 protein. 




It was found as heterozygotic in one Indian subject. The distribution of CC, CT and 
TT genotypes were 95 (99%), 1 (1%) and 0 (0%), respectively. This observed 













2.2.2.4.5 IVS-149 G>T  
The IVS-149 G>T located at 149-bp upstream of exon 3 of MCT4 molecule. 




This variant was only found in Chinese. The genotype distribution of GG, GT and 
TT were 92 (96.8%), 2 (2.1%) and 1 (1.1%), respectively. This observed 












2.2.2.4.6 IVS-114 C>T  
The IVS-114 G>T located at 114-bp upstream of exon 3 of MCT4 molecule. 





This SNP was only identified in the Chinese subjects. The distribution of CC, CT 
and TT in Chinese were 77 (81.1%), 18 (18.9%) and 0 (0%), respectively. No 
deviation from HWE was observed for this polymorphism (X2 = 1.040, p = 0.308). 
The C nucleotide is the dominant allele in ethnic Chinese group, which is 
consistent with the ancestral C allele reported in the NCBI SNP database 









2.2.2.4.7 IVS-52 G>A 
The IVS-52 G>A located at 52-bp upstream of exon 3 of MCT4 molecule. 




This variant was only found in Chinese. The genotype distribution of GG, GA and 
AA were 94 (98.9%), 1 (1.1%) and 0 (0%), respectively. This observed distribution 













2.2.2.4.8 IVS+29 G>A 
The IVS+29 G>A located at 29-bp downstream of exon 3 of MCT4 molecule. 




The IVS+29 G>A is a reported SNP that was found in both ethnic Chinese and 
Indian groups of Singapore population. The distribution of GG, GA and AA 
genotypes in Chinese were 94 (98.9%), 1 (1.1%) and 0 (0%), respectively. In 
Indians, the frequencies of GG, GA and AA observed were 88 (91.7%), 8 (8.3%), 
and 0 (0%), respectively. No deviation from HWE were observed for all ethnic 
groups (Chinese X2 = 0.003, p = 0.959; Indian X2 = 0.181, p = 0.670). The G 
nucleotide is the dominant allele in Indians. However, the ancestral allele reported 







2.2.2.4.9 574 G>A (Val192Met) 
The 574 G>A (Val192Met) is a novel nonsynonymous variant that located at exon 
4 of MCT4 protein. Representative sequencing electropherograms of AA and AB 
genotypes are as presented: 
 
 
This variant was only present as heterozygotic in one Indian subject and was not 
found in Chinese population. The distribution of GG, GA and AA genotypes were  
95 (98.9%), 1 (1.1%) and 0 (0%), respectively. This observed distribution is in 
accordance to HWE (X2 = 0.003, p = 0.959).  
 
The 574 G>A (Val192Met) polymorphism is located at the TM6 of the MCT4 
protein. A substitution from G to A at position 574 resulted in the conversion of 
amino acid valine to methionine at position 192 of MCT4 protein (Fig. 9). 
Although both amino acid residues are non-polar, this variant has conflicting 
results between the SIFT and PolyPhen algorithms. PolyPhen program predicted 




2.2.2.4.10 609 G>A 
The 609 C>T is a novel synonymous SNP that located at exon 4 of MCT4 protein. 




It was found as heterozygotic in one Indian subject. The distribution of GG, GA 
and TA genotypes were 95 (99%), 1 (1%) and 0 (0%), respectively. This observed 












2.2.2.4.11 641 C>T (Ser214Phe) 
The 641 C>T (Ser214Phe) is a novel nonsynonymous variant that located at exon 4 
of MCT4 protein. Representative sequencing electropherograms of AA and AB 
genotypes are as presented: 
 
 
It was found as heterozygotic in one Chinese and one Indian. The distribution of 
CC, CT and TT in Chinese were 94 (98.9%), 1 (1.1%) and 0 (0%), respectively. 
The distribution of AA, AG and GG in Indian were 95 (99%), 1 (1%) and 0 (0%), 
respectively. No deviations from HWE were observed for all ethnic groups  
(Chinese X2 = 0.003, p = 0.959; Indian X2 = 0.003, p = 0.959). 
 
The 641 C>T (Ser214Phe) variant is located at the large intracellular loop between 
TM segments 6 and 7, which is least conserved among family members (Fig. 9). 
The polar serine is replaced by the non-polar phenylalanine. However, 641 C>T 






2.2.2.4.12 831 G>A 
The 831 G>A is a novel synonymous SNP that located at exon 4 of MCT4 protein. 





This SNP only detected in Indian subjects. The distribution of GG, GA and AA 
genotypes were 90 (93.8%), 6 (6.2%) and 0 (0%), respectively. This observed 











2.2.2.4.13 916 G>A (Gly306Ser) 
The 916 G>A is a novel nonsynonymous SNP that located at exon 4 of MCT4 
protein. Representative sequencing electropherograms of AA and AB genotypes 
are as presented: 
 
 
This variant was found as heterozygotic in one Chinese sample. The distribution of 
GG, GA and AA genotypes were 94 (98.9%), 1 (1.1%) and 0 (0%), respectively. 
No deviations from HWE were observed (Chinese X2 = 0.003, p = 0.959).  
 
The 916 G>A (Gly306Ser) variant is located at the TM9 of the MCT4 protein  
(Fig. 9). The non-polar glycine is replaced by the polar serine. This variant has 
conflicting results between the PolyPhen and SIFT programs. It was predicted by 
PolyPhen program that this substitution might not affect the transporter activity. 






2.2.2.4.14 1176 G>A 
The 1176 G>A is a novel synonymous SNP that located at exon 5 of MCT4 
protein. Representative sequencing electropherograms of AA and AB genotypes 
are as presented: 
 
 
This SNP only detected in Chinese. The distribution of GG, GA and AA genotypes 
were 94 (98.9%), 1 (1.1%) and 0 (0%), respectively. This observed distribution is 













2.2.2.4.15 1494 C>T 
The 1494 C>T is located at the 3’-UTR of SLC16A3 gene. Representative 
sequencing electropherograms of AA and AB genotypes are as presented: 
 
 
This SNP was only detected in the Indian group of Singapore population. The 
observed frequencies of CC, CT and TT genotypes were 95 (99%), 1 (1%) and 0 
(0%). No deviation from HWE was observed for this polymorphism (X2 = 0.003,  














2.2.2.4.16 1512 C>T 
The 1512 C>T is a reported SNP locates at the 3’-UTR of SLC16A3 gene. 




This SNP was only detected in the Chinese group of Singapore population. The 
observed frequencies of CC, CT and TT genotypes were 95 (99%), 1 (1%) and 0 
(0%). No deviation from HWE was observed for this polymorphism (X2 = 0.003,  
p = 0.959). The ancestral allele reported in the NCBI SNP database is C allele 










2.2.2.4.17 1594 C>T 
The 1594 C>T is a reported SNP locates at the 3’-UTR of SLC16A3 gene. 




The distribution of CC, CT and TT genotypes in Chinese were 84 (88.4%),  
11 (11.6%) and 0 (0%), respectively. In Indians, the frequencies of CC, CT and TT 
observed were 95 (99%), 1 (1%), and 0 (0%), respectively. No deviation from 
HWE were observed for all ethnic groups (Chinese X2 = 0.359, p = 0.549;  










2.2.2.4.18 1608 C>T 
The 1608 C>T is located at the 3’-UTR of SLC16A3 gene. Representative 
sequencing electropherograms of AA and AB genotypes are as presented: 
 
 
This SNP was only detected in the Indian group of Singapore population. The 
observed frequencies of CC, CT and TT genotypes were 95 (99%), 1 (1%) and  
0 (0%). No deviation from HWE was observed for this polymorphism (X2 = 0.003, 













2.2.2.4.19 1713 G>A 
The 1713 G>A is located at the 3’-UTR of SLC16A3 gene. Representative 
sequencing electropherograms of AA and AB genotypes are as presented: 
 
 
This SNP was only detected in the Indian group of Singapore population. The 
observed frequencies of GG, GA and AA genotypes were 95 (99%), 1 (1%) and  
0 (0%). No deviation from HWE was observed for this polymorphism  














2.2.2.4.20 1899 G>A 
The 1899 G>A is located at the 3’-UTR of SLC16A3 gene. Representative 
sequencing electropherograms of AA and AB genotypes are as presented: 
 
 
This SNP was only detected in the Chinese group of Singapore population. The 
observed frequencies of GG, GA and AA genotypes were 92 (96.8%), 3 (3.2%) and 
0 (0%). No deviation from HWE was observed for this polymorphism 













2.2.2.5 Linkage Disequilibrium (LD) Analysis 
Linkage disequilibrium (LD) refers to association between tightly linked SNPs. 
Alleles at different loci are sometimes found together more or less often than 
expected based on their frequencies. Two alleles are said to be in LD if their alleles 
are in statistical association.  
 
In this study, the significance of the associations was assessed by Chi square test. 
The LD for each of the pairs of segregating sites were quantified by the D’. The  
D’ = 1 is known as complete LD, which indicates that the two SNPs have not been 
separated by recombination, recurrent mutation or gene conversion. Detailed  

















Table 27. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A3 bi-allelic promoter (transcript variant 2) polymorphisms in ethnic Chinese 
population. The statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs 
that lack the power to detect significant association are indicated by ns. The number in bold represents LD value. 
 










C>T -139-45 G>T -139-40 C>G 
-139-1374 c>g -- ns ns ns ns ns ns ns 
-139-1105  c>t -- -- <0.0001 0.767 
<0.0001 
1.000 ns ns ns ns 
-139-804 c>t -- -- -- <0.0001 0.749 ns ns ns ns 
-139 del (-727-795) -- -- -- -- ns ns ns ns 
-139-477 g>t -- -- -- -- -- ns ns ns 
-139-540 c>t -- -- -- -- -- -- ns ns 
-139-45 g>t -- -- -- -- -- -- -- ns 















Table 28. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A3 bi-allelic promoter (transcript variant 2) polymorphisms in ethnic Indian 
population. The statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs 
that lack the power to detect significant association are indicated by ns. The number in bold represents LD value. 
 














C>G -41 G>A 
IVS 
+100 C>T 
-139-1281  G>A -- ns <0.0001 0.921 
<0.0001 
1.000 ns ns ns 
<0.0001 
1.000 ns ns 
-139-1105  C>T -- -- ns <0.0001 0.926 
<0.0001 
0.947 ns ns ns ns ns 
-139-845  G>A -- -- -- 0.0008 1.000 ns ns ns 
<0.001 
1.000 ns ns 
-139-804  C>T -- -- -- -- <0.001 0.891 ns ns 
<0.001 
1.000 ns ns 
-139 del (-727-795) -- -- -- -- -- ns ns 0.0373 1.000 ns ns 
-139-518  G>A -- -- -- -- -- -- ns ns ns ns 
-139-304  C>T -- -- -- -- -- -- -- ns ns ns 
-139-246  C>G -- -- -- -- -- -- -- -- ns ns 
-41 G>A -- -- -- -- -- -- -- -- -- ns 












Table 29. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A3 bi-allelic promoter (transcript variant 4) polymorphisms in ethnic Chinese 
population. The statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs 
that lack the power to detect significant association are indicated by ns. The number in bold represents LD value. 
 
Position -118-554 A>T -118-502 A>G -118 del -(436-437) -118-331 G>A -118-249 C>T -118-130 A>C -118-115 G>A -86 A > G 
IVS1+21 
G > C 
-118-554 A>T -- ns ns ns ns <0.0001 0.876 ns 
<0.0001 
1.000 ns 




0.652 ns ns ns ns 
-118del- (436-437) -- -- -- <0.0001 0.816 ns ns ns ns ns 
-118-331 G>A -- -- -- -- <0.0001 0.911 ns ns ns ns 
-118-249 C>T -- -- -- -- -- ns ns ns ns 
-118-130 A>C -- -- -- -- -- -- ns <0.0001 0.816 ns 
-118-115 G>A -- -- -- -- -- -- -- ns ns 
-86 A>G -- -- -- -- -- -- -- -- ns 













Table 30. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A3 bi-allelic promoter (transcript variant 4) polymorphisms in ethnic Indian 
population. The statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs 
that lack the power to detect significant association are indicated by ns. The number in bold represents LD value. 
 














A>C -86 A>G 
-118-1416 C>T -- ns ns ns ns ns ns ns ns 
-118-1131 C>A -- -- ns ns ns ns ns ns ns 




























-118-249 C>T -- -- -- -- -- -- -- 0.0153 1.000 
0.0153 
1.000 
-118-130 A>C -- -- -- -- -- -- -- -- <0.0001 0.952 












Table 31. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A3 bi-allelic coding region polymorphisms in ethnic Chinese population. The 
statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs that lack the 
power to detect significant association are indicated by ns. The number in bold represents LD value. 
 






G>A 641C >T 916G >A 1176G>A 1512C >T 1594C >T 1899G>A 
44 C >T -- ns ns ns <0.0001 0.497 ns ns ns ns ns ns 
IVS2 -149 G>T -- -- ns ns ns ns ns ns ns ns ns 
IVS2 -114 C>T -- -- -- ns ns ns ns ns ns ns ns 
IVS2 -52 G>A -- -- -- -- ns ns ns ns ns ns ns 
IVS3 + 29 G>A -- -- -- -- -- ns ns ns ns ns <0.0001 0.495 
641C >T -- -- -- -- -- -- ns ns ns 0.0362 0.472 ns 
916G >A -- -- -- -- -- -- -- ns ns ns ns 
1176G>A -- -- -- -- -- -- -- -- ns ns ns 
1512C >T -- -- -- -- -- -- -- -- -- ns ns 
1594C >T -- -- -- -- -- -- -- -- -- -- ns 













Table 32. Pair-wise linkage disequilibrium (D’) coefficients between SLC16A3 bi-allelic coding region polymorphisms in ethnic Indian population. The 
statistical significance of linkage disequilibrium was assessed by Chi-square test. Statistical significance was defined as p < 0.05. Site pairs that lack the 
power to detect significant association are indicated by ns. The number in bold represents LD value. 
 
Position 21C>T 44C>T 55G>A 117C>T IVS3+29 G>A 574G>A 609G>A 641C>T 831G>A 1494C>T 1594C>T 1608C>T 1713G>A 
21 C>T -- ns ns ns ns ns ns ns ns ns ns ns ns 
44 C>T -- -- ns ns <0.00011.000 
0.0045 
0.481 ns ns ns ns ns ns ns 
55 G>A -- -- -- ns ns ns ns ns ns ns ns ns ns 
117 C>T -- -- -- -- ns ns ns ns ns ns ns ns ns 
IVS3 + 29 G>A -- -- -- -- -- 0.0045 0.481 ns ns ns ns ns ns ns 
574 G>A -- -- -- -- -- -- ns ns ns ns ns ns ns 
609 G>A -- -- -- -- -- -- -- ns ns ns ns ns ns 
641 C>T -- -- -- -- -- -- -- -- ns ns <0.0001 1.000 ns ns 
831 G>A -- -- -- -- -- -- -- -- -- ns ns ns ns 
1494 C>T -- -- -- -- -- -- -- -- -- -- ns ns ns 
1594 C>T -- -- -- -- -- -- -- -- -- -- -- ns ns 
1608 C>T -- -- -- -- -- -- -- -- -- -- -- -- ns 







2.2.2.6 Haplotype Construction and Frequency Estimation 
Haplotype structures were constructed in the promoter regions of transcript variant 
2 and 4 of SLC16A3 gene. The haplotype frequency was not performed in the 
coding region of SLC16A3 due to the low prevalence of SNPs identified in this 
region (Table 18). Three commonest polymorphisms were detected in the promoter 
regions of both transcripts. These SNPs were input into SNPAnalyser to compute 
statistical calculation of haplotype estimation. The haplotypes and relative 
frequencies of the three commonest SNPs in the promoter of transcript variant 2 
and 4 of SLC16A3 gene are summarized in Table 33 and 34.  
 
The six possible haplotypes with frequencies greater than 0.01 (1%) and 
accounting for approximately 99% of all chromosomes were estimated in the 
promoter of transcript variant 2 of MCT4. The frequency distributions between 
ethnic groups are presented graphically in Figure 10. Haplotypes 4 and 6 and were 
not predicted in the Chinese population. In contrast, haplotype 5 was not predicted 
in Indians. The distribution of haplotypes 1, 2 and 4 are statistically significant 
difference in ethnic Chinese and Indian groups. Of the two ethnic groups, 
haplotype 5 is predicted to be least common in the Chinese population while 
haplotype 6 is the least common haplotype in Indians. The most common 
haplotype is haplotype 1. Haplotype 1 predicted to occur at a relatively high 
frequency in both ethnic groups, with an estimated frequency of 0.836 and 0.674 in 
Chinese and Indians, respectively.  
 
In transcript variant 4 of SLC16A3 gene, five promoter haplotypes were estimated 
from the population genotype data. The frequency distributions between ethnic 
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groups are presented graphically in Figure 11. All five promoter haplotypes were 
predicted in the Chinese population. In contrast, haplotype 3 and 5 were not 
estimated in Indians. The distribution of haplotype 1, 3, 4 and 5 are not statistically 
significant difference amongst Chinese and Indians. Haplotype 1 predicted to occur 
at a relatively high frequency in both ethnic groups, with an estimated frequency of 





















Figure 10. Ethnic distribution of SLC16A3 haplotypes in the promoter region of transcript 
variant 2. The frequencies of six haplotypes identified in the ethnic Chinese and Indian of 
Singapore population. * p < 0.05, frequency distribution is statistically significant.  
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Figure 11. Ethnic distribution of SLC16A3 haplotypes in the promoter region of transcript 
variant 4. The frequencies of six haplotypes identified in the ethnic Chinese and Indian of 
Singapore population. * p < 0.05, frequency distribution is statistically significant.  
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Table 33. Haplotype structure defined by 3 commonest SNPs in the SLC16A3 5’flanking promoter region of transcript variant 2 in Singapore population 
 
Haplotype No. 
Polymorphisms Estimated Haplotype Frequencies Chi sq 
value p-value -139-1105 C > T -139-804 C>T -139 del (-727-795) Chinese n = 190 
Indian 
n = 192 
1 T T Deletion 0.836 0.674 14.01 0.000* 
2 T C Deletion 0.080 0.154 4.87 0.027* 
3 C C Wildtype 0.062 0.120 3.68 0.055 
4 T C Wildtype 0.000 0.034 7.06 0.008* 
5 C T Wildtype 0.017 0.000   
6 T T Wildtype 0.000 0.013   
                 Total       0.995                0.995 
 
Haplotye structures were constructed and frequencies estimated using SNPAnalyser software. The haplotypes listed here accounts for 99.5% of all 


















Table 34. Haplotype structure defined by 3 commonest SNPs in the SLC16A3 5’flanking promoter region of transcript variant 4 in Singapore population 
 
Haplotype No. 
Polymorphisms Estimated Haplotype Frequencies Chi sq 
value p-value 
-118-554 A>T -118-130 A>C -86 A > G 
Chinese 
n = 190 
Indian 
n = 192 
1 T C G 0.916 0.865 2.56 0.110 
2 A A A 0.042 0.120 7.73 0.005* 
3 T C A 0.016 0.000   
4 T A G 0.011 0.005   
5 T A A 0.010 0.000   
          Total       0.995                0.990 
 
Haplotye structures were constructed and frequencies estimated using SNPAnalyser software. The haplotypes listed here accounts for > 99% of all 











Monocarboxylates such as L-lactate, pyruvate and acetate are important 
intermediaries in body energy metabolism. The anions of these monocarboxylates 
are highly charged and transported across the plasma membrane via human  
MCT1-4 in a proton-mediated manner. MCT1 is found in a great majority of 
tissues in all species studied and it is the only MCT isoform expressed on the 
plasma membrane of human erythrocyte. Human MCT4 is highly expressed in 
glycolytic tissues such as white skeletal muscle fibres, in which MCT4 may work 
as an efflux transporter to mediate the transport of lactate out into the interstitial. 
Given the current understanding of the roles of lactate as a central player in cellular 
and whole body metabolism, mutations in MCT1 and MCT4 have been 
hypothesized to affect normal L-lactate homeostasis leading to altered body energy 
metabolism and exercise intolerance. In fact, mutations in MCT1 have been 
associated with lactate transport deficiency in red blood cells and muscle tissues 
[171]. Therefore, one of the objectives of this study was to describe the single 
nucleotide polymorphisms in the SLC16A1 and SLC16A3 genes that may be 
present in the ethnic Chinese and Indian groups of the Singapore population. In the 
context of global genetic diversity, Singapore Chinese, the HapMap Han Chinese 
in Beijing and HapMap Japanese in Tokyo were virtually indistinguishable, while 
Singapore Malays were observed to be highly similar to the East Asian populations 
in general [204]. Singapore Indians, on the other hand, are genetically closer to the 
samples with European ancestries than to the East Asian samples from Human 
Genome Diversity Project (HGDP) [204]. Therefore, with cost and time 




2.3.1 Genetic Variations in the MCT1 (SLC16A1) Gene in the Chinese and 
Indian Population of Singapore 
This study identified genetic variations in SLC16A1 in the ethnic Chinese and 
Indian groups of the Singapore population (n = 191). The promoter, coding region 
and the exon-intron junctions of the SLC16A1 gene encoding the MCT1 protein 
were screened for genetic variation in the study population by direct DNA 
sequencing. A total of 21 genetic variations of SLC16A1, including 14 novel ones, 
were found: 6 in the promoter region, 4 in the coding exons (3 nonsynonymous 
variations and 1 synonymous variation), 4 in the 5’ untranslated region (5’UTR),   
6 in the 3’ untranslated region (3’UTR) and 1 in the intron (Table 10). The full 
review of reported allele frequencies in SLC16A1 gene are summarized in  
Table 35.  The locations of nonsynonymous SNPs detected in SLC16A1 are 
presented in Figure 6.  
 
SLC16A1 gene spans approximately 44 kb and is mapped onto chromosome band 
1p13.2-p12 in humans [80]. MCT1 has 5 exons and 4 introns and is predicted to 
have 500 amino acids and 12 transmembrane spanning regions (Fig. 6) [70]. Of the 
three non-synonymous mutations detected, the 303 T>G (Ile101Met) and 1282 
G>A (Val428Ile) are novel SNPs, while the 1470 T>A (Asp490Glu) variant was 
found to be a common polymorphism in this study. The 303 T>G (Ile101Met) was 
only detected in the Indian group of Singapore population. Based on putative 
protein topology, 303 T>G (Ile101Met) is located at TM3 of MCT1 protein.          
A substitution from nucleotide T to G at position 303 resulted in the conversion of 
amino acid isoleucine to methionine at position 101 of MCT1 protein. The 
Polyphen and SIFT sequence homology-based tools were used to predict the effects 
192 
 
on amino acid substitution on protein function based on sequence homology and 
the physical property of amino acid. Although both amino acids are nonpolar in 
nature, the 303 T>G (Ile101Met) variant was predicted to be probably damage by 
both programs. The physiological role of this polymorphism is still indeterminate.  
 
The 1282 G>A (Val428Ile) was found as heterozygotic in four Chinese subjects. 
Based on putative protein topology, the1282 G>A (Val428Ile) is located at the 
TM12 [70]. A substitution from G to A at position 1282 resulted in the conversion 
of amino acid valine to isoleucine at position 428 of MCT1 protein. Both amino 
acid residues are non-polar and thus this mutation is unlikely to affect the functions 
of the protein. This is consistent with the results obtained using the PolyPhen and 
SIFT programs which predicted this SNP to be benign and unlikely to have any 
significant effect on protein function.  
 
Sequence analysis of MCT1 gene also revealed a common SNP, 1470 T>A 
(Asp490Glu). This SNP was previously reported by Merezhinskaya et al [172].  
In this study, the allele frequencies of T and A are 34.7% and 65.3% for Chinese, 
and 42.6% and 57.3%, respectively. No ethnic difference in allele frequency is 
observed in our study population when analyzed with Chi square test of 
independence. Besides, the observed allele frequencies in our populations are 
similar to the observed allele frequencies in the Han Chinese, Japanese and Utah 
populations (Table 35). The glutamate residue at position 490 is located in the 
signal sequence (asp-x-glu; aa 488-490) for release from the endoplasmic reticulum 
when downstream from a tyr-x-x- motif (aa 445-448) [205]. As glutamic acid and 
aspartic acid are both acidic amino acids with similar physico-chemical properties, 
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it is likely that aspartate may be as effective as the preferred glutamate. This is 
consistent with the results obtained using PolyPhen and SIFT which predicted this 
SNP to be benign and unlikely to have any significant effect on the protein 
function. Although this SNP has been predicted to have no detrimental effect on 
transporter activity by bioinformatics tools, a 40% reduction of lactate transport 
rate has been identified in the erythrocytes of both individual homozygous and 
heterozygous for this polymorphic variant [172]. Recently, Cupeiro et al. has 
performed a pilot study to examine the influence of this SNP in high intensity 
exercise performance [206]. In this study, ten men aged 20-26 performed three 
controlled circuit training (CWT) sessions at 60%, 70% and 80% of the 15 
repetition maximum (15RM), in non-consecutive days. The lactate measurements 
were performed immediately after each set had been completed. The carriers for 
MCT1 1470 T>A polymorphism showed higher lactate accumulation and higher 
maximal lactate concentration than non-carriers during the 80% CWT. The carriers 
of the 1470 T>A polymorphism seem to exhibit impaired functionality in MCT1, 
which would lead to impaired lactate transport into other cells for oxidation, thus 
resulted in the increased of blood lactate concentration [206].  
 
Two reported non-synonymous SNPs, 973A>G (Val325Ile) and 979C>T 
(Ser327Pro) are not detected in the ethnic Chinese and Indian groups of Singapore 
population. The 973A>G (Val325Ile) variant was predicted to be benign by 
PolyPhen and SIFT programs and unlikely to have any significant effects on the 
protein function. The 979C>T (Ser327Pro) variant, however, may have detrimental 
effect on the transporter activity. Both Polyphen and SIFT algorithms predicted 
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that the amino acid substitution from serine to proline is intolerant and probably 
damaging.  
 
A total of 10 genetic variations were found in the 5’ flanking region of MCT1, of 
which -363-222 T>C, -363-289 T>G, -363-307 C>T, -363-855 T>C, -298 G>C, 
-297 A>C, del(-207-210)CAGA and -136 A>G are novel. Recently, the promoter 
region of MCT1 has been characterized [207]. Analysis of a 1.5 kb fragment  
(-1525/+213) of the MCT1 5’-flanking region, shows an absence of the classical 
TATA-Box element found in many eukaryotic promoters. Secondly, the sequence 
is GC-rich, with the 200-bp upstream and downstream of the transcription initiation 
site having a 72% of GC-content. Thirdly, the -70/+213 region of the promoter 
contains the essential cis-acting elements necessary for basal transcription of 
MCT1. Lastly, several putative transcription factor binding sites were identified 
using the MatInspector (Library version: Matrix Library 2.2) (Fig. 5). The GC-rich 
sequence is a characteristic of TATA-less promoters that usually contain 
stimulating protein 1 (Sp1) binding sites. These Sp1 binding sites interact with the 
GC-box and play crucial roles in start site selection [208, 209]. In this study, three 
Sp1 binding sites were detected within the GC-rich region of the transcription 
initiation site. As the -363-100 C>G mutation is located at the consensus sequence 
of the Sp1 binding site, it is likely to affect the transcription regulation of the 
MCT1 gene. The SNPInspector licensed software was used to identify transcription 
factor binding sites affected by these SNPs (Table 13). For each SNP, the 
transcription factor binding sites are either deleted or generated by the nucleotide 
exchange. However, the prediction of the effects of SNPs on the putative 
transcription factor binding based on computational bioinformatics tools can only 
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be speculative at this moment. The actual role of SNPs can only be clarified 
through functional assays. Nevertheless, this information may provide a framework 
for understanding the fundamental functions of putative transcriptional factor 
binding sites in regulating the transcriptional regulation of MCT1.
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Table 35. Reported SLC16A1 genetic polymorphism allele frequencies 
 SNP dbSNP Location Chromosome Position 
Amino acid 
change Allele Reported Allele Frequencies 
1 1325+603 A>G rs114357382 Promoter 113500947  
A 0.966 a   
G 0.034   
2 1325+313 C>G rs74929506 Promoter 113500657  
C 0.966 a   
G 0.034   
3 1325+61G>A rs75737835 Promoter 113500405  
G 0.966 a   
A 0.034   
4 919A>T rs74111374 Promoter 113499938  
A 0.720 a   
T 0.280   
5 811A>G rs117282659 Promoter 113499830  
A 0.975 b   
G 0.025   
6 757C>A rs115748179 Promoter 113499776  
C 0.966 a   
A 0.034   
7 431G>A rs6699036 Promoter 113499450  
G 0.983 a   
A 0.017   
8 301C>A rs73000320 Promoter 113499320  
C 0.966 a   
A 0.034   
9 221C>T rs115304077 Promoter 113499240  
C 0.966 a   
T 0.034   
10 56G>C rs60844753 Promoter 113499075  
G 0.075 b 0.023 c  
C 0.925 0.977  
11 973A>G rs116216229 Exon 113460055 Ile325Val 
A 0.975 a   
G 0.025   
12 979C>T rs77373295 Exon 113460049 Pro327Ser 
C 0.922 a 0.980 d  
T 0.008 0.020  
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13 1002G>A rs114731222 Exon 113460026 Ala334Ala 
G 0.975 a   
A 0.025   
14 1470T>A rs1049434 Exon 113456546 Asp490Glu 
T 0.367 e 0.322 f 0.364 g 
A 0.633 0.678 0.636 
15 *145T>G rs11585690 3'UTR 113456368  
T 1.000 e 1.000 f 0.965 g 
G 0.000 0.000 0.035 
16 *1414C>T rs7169 3'UTR 113455099  
C 0.337 h 0.327 i 0.398 j 




a HapMap Yoruba in Ibadan, Nigeria(YRI), n = 59 
b HapMap Han Chinese in Beijing, China + Japanese in Tokyo, Japan, n = 60 
c PA151258406 study population from Pharmacogenomics Knowledge base, n = 514 
d HapMap Yoruba in Ibadan, Nigeria(YRI), n = 25 
e HapMap Han Chinese in Beijing, China, n=45 
f HapMap Japanese in Tokyo, Japan, n=45 
g Hapmap Utah residents with Northern and Western European ancestry from the CEPH collection, n=59 
h HapMap Han Chinese in Beijing, China, n=43 
i HapMap Japanese in Tokyo, Japan, n=84 





2.3.2 Genetic Variations in the MCT4 (SLC16A3) Gene in the Chinese and 
Indian Population of Singapore 
Sequencing analysis of SLC16A3 gene from 191 Asian subjects (Chinese, n = 95; 
Indian, n = 96) resulted in the identification of 46 genetic variations, of which 33 
are novel mutations (Table 18 and Table 19). Of these variants, 22 are located in 
the promoter regions, 2 in the 5’-UTR, 10 in the coding exons (5 nonsynonymous 
and 5 synonymous variations), 6 in 3’-UTR and 6 in the intron. The full review of 
reported allele frequencies in SLC16A3 gene are summarized in Table 36. The 
locations of nonsynonymous SNPs detected in SLC16A3 are presented in Figure 9. 
 
SLC16A3 gene spans approximately 11 kb and is mapped onto chromosome band 
17q25.3 in human. According to NCBI, three transcripts variants have been 
described for this gene, of which all three transcripts have functional protein 
products (http://www.ncbi.nlm.nih.gov/gebe/9123). The three transcript variants 
are created by alternative promoter usage and alternative splicing at the 5’ end of 
the gene, therefore the protein products for all three transcript variants are identical. 
Sequence analysis of promoter regions revealed 14 and 10 polymorphisms in 
transcript variant 2 and 4 of MCT4 gene, respectively. We intended to screen all 
three promoter regions associates with the transcript variants of SLC16A3 gene. 
However, due to some technical problems, we are unable to sequence the promoter 
region of transcript variant 3. Therefore, the genotype information of this region is 
not included in this thesis.  
 
The MCT4 protein product is predicted to have 465 amino acids and 12 
transmembrane spanning regions. Among the novel nonsynonymous variations, the 
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44C>T (Ala15Val) polymorphism is located at the intercellular N-terminal of 
MCT4 protein. It has been proposed that the two halves of the monocarboxylate 
molecule (TM helices 1-6 and 7-12) have different functional roles (Fig. 9). The  
N-terminal domains may be involved in energy coupling, maintenance structural 
integrity, and membrane insertion, whereas the C-terminus may be important for 
the determination of substrate specificity [73]. Therefore, this mutation is likely to 
affect transporter function in term of energy coupling. This is consistent with the 
results obtained using the PolyPhen and SIFT sequence homology-based tools. The 
44C>T (Ala15Val) polymorphism was predicted to be probably damaging by both 
algorithms. This allele was found in both ethic Chinese and Indian subjects with a 
frequency of 1.1% and 4.2%, respectively. No inter-ethnic difference in allele 
frequency is observed for this variant.  
 
The 55G>A (Gly19Ser) variant is also located at the intercellular N-terminal of the 
molecule. This variant was only presented as heterozygotic in on Indian subject and 
was not found in Chinese population. Although PolyPhen program predicted that 
the amino acid substitution is benign, it was inconsistent with the results obtained 
using SIFT program that predicted this mutation was expected to be intolerant. 
Recently, Meredith and Christian have aligned all 14 members of human MCT 
protein sequences using the DIALIGN sequence alignment program. The 55G>A 
(Gly19Ser) is located at the consensus region of the molecule [70]. Therefore, a 
substitution of nonpolar amino acid glycine to hydrophilic serine may have 
significant effect on protein function. Similarly, both 574G>A (Val192Met) and 
916G>A (Gly306Ser) variants have conflicting results between the SIFT and 
PolyPhen algorithms. The 574G>A (Val192Met) variant is located at the 
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transmembrane 6 of the MCT4 protein. This novel SNP was only present as 
heterozygotic in one Indian subject and was not found in Chinese population. A 
substitution from G to A at position 574 resulted in the conversion of amino acid 
valine to methionine at position 192 of MCT4 protein. Although both amino acid 
residues are non-polar, this variant has conflicting results between the SIFT and 
PolyPhen algorithms. PolyPhen program predicted that this substitution is benign 
while SIFT algorithm predicted this variant is intolerant. 
 
The SIFT algorithm uses sequence homology among related genes and domain 
across species to predict the impact of all 20 possible amino acids at a given 
position. SIFT relies solely on sequence for prediction, therefore it has the potential 
to analyze a large amount of non-synonymous SNPs than tools that use structures  
[210],[211],[212],[213],[214]. PolyPhen, on the other hand, uses a set empirical 
rules based on sequence, phylogenetic, and structural information characterizing a 
particular variant [215],[216]. One of the possible explanations as to why PolyPhen 
and SIFT have conflicting results could be that PolyPhen incorporates structural 
information of the protein to determine if a genetic polymorphism may have effect 
on protein function [214]. 
 
The 916G>A (Gly306Ser) is a novel nonsynonymous variant that located at 
transmembrane 9 of MCT4 protein. This variant was found as heterozygotic in one 
Chinese. It was predicted by PolyPhen program that this substitution might not 
affect the transporter activity. However, SIFT program predicted that this 
substitution is intolerant and may affect transporter function. The 641C>T 
(Ser214Phe) variant is located at the large intracellular loop between 
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transmembrane segments 6 and 7. The polar serine is replaced by the non-polar 
phenylalanine. This is also in agreement that 641C>T (Ser214Phe) variant is 
located at the large intracellular loop between transmembrane 6 and 7, which is 
least conserved among family members. Thus, it is likely that substitution may not 
result in fundamental change.  
 
The promoter regions of transcript variant 2 and 4 of SLC16A3 gene were screened 
for genetic variants. In the promoter and 5’-UTR regions of transcript variant 2, a 
total of 14 genetic variations were found. Of which, 10 are novel variants. The SNP 
profiles for promoter region of transcript variant 2 were found to be varied between 
the Chinese and Indians. Out of the 14 SNP detected, 11 variants was only detected 
in either Chinese or Indian ethnic group. Besides, these SNPs are rare and present 
in low frequencies. Three common SNPs, namely -139-1105 C>T, -139-804 C>T 
and -139del(-727-795), were detected in both ethnic groups (Table 18). 
Statistically significant inter-ethnic differences in allele frequency is observed in -
139-804 C>T and -139del(-727-795) variants when analyzed with Chi square test 
of independence.  
 
A total of 10 genetic variants were detected in the promoter region of transcript 
variant 4 of SLC16A3 gene, of which four are novel variants (Table 18). Three 
common polymorphisms, namely -118-554 A>T, -118-130 A>C and -86 A>G 
were detected in the promoter and 5’UTR region of transcript variant 4. 
Statistically significant inter-ethnic differences in allele frequency is observed in  




The SNPInspector licensed software was used to identify transcription factor 
binding sites affected by polymorphisms (Table 26). For each SNP, the 
transcription factor binding sites are either deleted or generated by the nucleotide 
exchange. However, the prediction of the effects of SNPs on the putative 
transcription factor binding based on computational bioinformatics tools can only 
be speculative at this moment. The actual role of SNPs can only be clarified 









Table 36. Reported SLC16A3 genetic polymorphism allele frequencies 
 SNP dbSNP Location Chromosome Position 
Amino acid 
change Allele Reported Allele Frequencies 
1 425288G>A rs73999811 Promoter 80184337  
G 0.907 b    
A 0.093    
2 425517G>A rs7215447 Promoter 80184566  
G 0.775 a 0.534 b 0.955 h  
A 0.225 0.466 0.045  
3 425534C>T rs74989597 Promoter 80184583  
C 0.983 a    
T 0.017    
4 425699C>T rs78765689 Promoter 80184748  
C 0.967 a    
T 0.033    
5 425728G>T rs73999812 Promoter 80184777  
G 0.898 b    
T 0.102    
6 425963G>A rs117548183 Promoter 80185012  
G 0.975 a    
A 0.025    
7 426139C>T rs11077983 Promoter 80185188  
C 0.102 b 0.333 a 0.085 h  
T 0.898 0.667 0.942  
8 425288G>A rs116429000 Promoter 80185273  
C 0.949 b    
T 0.051    
9 425517G>A rs117995894 Promoter 80185448  
G 0.967 a    
A 0.033    
10 425534C>T rs73999813 Promoter 80185979  
G 0.958 b    
C 0.042    
11 425699C>T rs116935257 Promoter 80185816  
G 0.983 d    
T 0.017    
12 425728G>T rs114201274 Promoter 80185958  
C 0.983 b    
T 0.017    
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13 425963G>A rs114967601 Promoter 80186013  
A 0.975 b    
C 0.025    
14 426139C>T rs75888222 Promoter 80186047  
C 0.967 a    
G 0.033    
15 425288G>A rs112712439 5'UTR 80193882  
G 0.932 b    
A 0.068    
16 425517G>A rs117720229 Exon 80193953 Ala23Ala 
C 0.983 a    
G 0.017    
17 425534C>T rs114195476 Exon 80195317 Arg224Gln 
G 0.983 b    
A 0.017    
18 425699C>T rs79525659 Exon 80195339 Tyr231Tyr 
C 0.966 b    
T 0.034    
19 1308G>A rs61730223 Exon 80196762 Ser436Ser 
G 0.958 b 0.974 c   
A 0.042 0.026   
20 25C>T rs114517919 3'UTR 80196877  
C 0.915 b    
T 0.085    
21 114C>T rs78825758 3'UTR 80196966  
C 0.992 d    
T 0.008    
22 196C>T rs116904469 3'UTR 80197048  
C 0.950 d    
T 0.05    
23 438C>T rs9916408 3'UTR 80197290  
C 0.915 b 1.000 e 1.000 f 1.000 g 
T 0.085 0.000 0.000 0.000 
24 497G>A rs1131633 3'UTR 80197349  
G 0.746 b 1.000 e 1.000 f 1.000 g 
A 0.254 0.000 0.000 0.000 
 
References: 
a Hapmap Utah residents with Northern and Western European ancestryfrom the CEPH collection, n=60 
b HapMap Yoruba in Ibadan, Nigeria(YRI), n = 59 
c Coriell Apparently Healthy Collection AGI_ASP_population, n=38 
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d HapMap Han Chinese in Beijing, China + Japanese in Tokyo, Japan, n = 60 
e HapMap Han Chinese in Beijing, China, n=41 
f HapMap Japanese in Tokyo, Japan, n=41 
g Hapmap Utah residents with Northern and Western European ancestry from the CEPH collection, n=57 
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The monocarboxylate transporter 1 (MCT1) has been thought to be responsible for 
the transportation of L-lactate across the human erythrocyte plasma membrane. 
According to the lactate shuttle hypothesis, lactate formation and its subsequent 
distribution throughout the body is a major mechanism whereby the coordination 
of intermediary metabolism in different tissues, and cells within those tissues, can 
be accomplished. During exercise, lactate and protons move out from exercising 
muscles and enter the plasma. From plasma, lactate is further transported into 
erythrocytes through MCT1. MCT1, the only MCT isoform found in the human 
erythrocyte, accounts for 80-90% of lactate transport. This study uses an 
erythrocyte model to characterize the kinetics of MCT1 mediated lactate transport 
and shows that MCT1 is a low affinity high capacity (Km = 123.9  24.6 mM;  
Vmax = 12079.0  722.3 nmol/mL of RBCs/min) process for the transport of 
lactate. Various drugs and dietary compounds interact with human erythrocytic 
monocarboxylate transporter 1. Several pharmacological agents and dietary 
compounds were screened for their inhibitory effects on MCT1 activity. Of these, 
diflunisal, diclofenac, mefenamic acid, meclofenamic acid, tolfenamic acid, 
luteolin, etodalac, phloretin and morin were the most potent with IC50 values of 
40.24  1.10, 1.33  1.17, 11.83  1.24, 9.68  1.10, 5.95  1.12, 2.71  1.28, 







3.1 MATERIALS AND METHODS 
3.1.1 Materials 
Sodium L-lactate, diflunisal, diclofenac, sulindac, indomethacin, etodalac, 
ibuprofen, naproxen, ketoprofen, mefenamic acid, meclofenamic acid, flufenamic 
acid, tolfenamic acid, piroxicam, luteolin, morin, naringin, phloretin, silibinin, 
caffeine, capsaicin and -cyano-4-hydroxycinnamic acid were purchased from 
Sigma Chemical Co. (St Loius, MO, USA). [14C]-L-lactate was purchased from 
PerkinElmer Inc. (Waltham, MA, USA). Cerivastatin, rosuvastatin, pravastatin and 
simvastatin were kindly donated by AstraZeneca (London, UK). 
 
3.1.2 RED BLOOD CELLS (RBCS) LACTATE INFLUX ASSAY 
3.1.2.1 Subjects 
A total of 4 subjects participated in this study.  All subjects had been recruited 
previously in accordance with requirements (Institutional Review Board, National 
University Hospital, Singapore). The mean age is 30 ± 2.5 (28 to 33).  The male: 
female sex ratio is 1:3. All DNA samples were rendered anonymous by removing 
links with specific individual information, i.e., any ID, name, or address. 
 
3.1.2.2 Preparation of RBCs for Lactate Influx Assay 
Techniques for RBC preparation and lactate influx measurement were adopted 
from previously published methods [72, 107, 162, 164]. Five milliliters of venous 
blood were drawn from each subject into heparinized vacutainers. An initial 
hematocrit (Hct) and hemoglobin concentration were determined for all blood 
samples. Three milliliters of blood sample were transferred to a 50 ml conical tube. 
The remaining portion of the blood sample was refrigerated at 4C and saved for 
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repeat measurements if required. The RBCs were isolated by centrifugation at 
room temperature (25C, 10 min, 2000g). The plasma and buffy coat were 
removed by aspiration, leaving only the RBC pellet. The pellet was mixed by 
inversion with 30 volumes of chloride buffer (150 mm NaCl, 10 mM Na-tricine, 
pH 8.0 at 37C, osmolality ~ 315mosmol/kg H2O) and incubation in water bath for 
30 min at 37C. This step was to ensure removal of endogenous lactate [102]. At 
the end of the incubation, the RBCs were sedimented at room temperature  
(25C, 10 min, 2000g) and the supernatant was removed by aspiration. The cell 
pellet was then washed two times. For each washing, four volumes of chloride 
buffer were added to the cell pellets, the pellet was mixed by inversion and then 
centrifuged (25C, 10 min, 2000g). The supernatant was removed after each wash. 
Lactate depletion from the RBCs (~0.20 mM in 30% hematocrit solution) was 
confirmed by analysis via the spectrophotometric technique (BioVison; MV, 
California). After the final wash, the RBC pellet was suspended in HEPES buffer 
(90 mM NaCl, 50 mM HEPES, pH 7.4, 37C, osmolality ~267 mosmol/kgH2O) 
equivalent to a 30% hematocrit (packed cell volume) to obtain the stock cell 
solutions for influx measurements. This suspension was divided into two aliquots, 
each containing one milliliter. One of the two stock cell suspensions contained no 
lactate transport inhibitors. Five millimolar -cyano-4-hydroxycinnamic acid 
(CHC) was added to the second stock cell suspension to inhibit the  
MCT1-mediated pathway. The two aliquots were incubated in a water bath for 30 







3.1.2.3 Total Lactate Influx 
A 25 l sample of stock cell solution was incubated in 75 l of HEPES influx 
buffer for 20 s at 37C. The HEPES buffer containing [14C]-lactate (0.2 Ci/ml) at 
thirteen unlabeled [La] values of 1.2, 3.7, 12.3, 37.0, 123.3, 370.0, 616.7 and  
986.7 mM. All HEPES influx buffers were adjusted to a pH 7.4. Because of 
dilution with the stock cell solution, the actual final [La] values were 1, 3, 10, 30, 
100, 300, 500 and 800 mM, respectively. The incubation was stopped with 2 ml of 
ice-cold stop solution [150 mM NaCl, 10 mM MES, pH 6.5] and tubes were 
immediately iced. The sample was spun by centrifugation (4C, 10 min, 2000 g) 
and was washed twice to eliminate extracellular radioactivity. After the final wash, 
the RBC pellet was lysed and deproteinized with 0.5 ml of 4.2% perchloric acid 
followed by centrifugation of the sample (4C, 10 min, 2000 g). Finally, 0.4 ml of 
the supernatant was pipetted into scintillation vials containing 5 ml of scintillation 
liquid (Amersham Bioscience; Amersham, UK) and the radioacitivity of the 
supernatant was measured with a liquid scintillation counter (Beckman Coulter, 
Kraemer Boulevard, USA). All measurements were made in triplicate.  
 
 
3.1.2.4 Time-dependent Total Lactate Influx 
A 25 l sample of stock cell solution was incubated in 75 l of HEPES influx 
buffer containing [14C]-lactate at three unlabeled [La] values of 5, 50 and 100 mM. 
Two milliliters of ice-cold stop solution were added to each tube to stop influx at 
10, 20, 30, 40, 50, 60, and 120 s. A time-course curve was drafted by plotting 
lactate influx against time of influx. The time at with lactate influx rate vs. time 
became nonlinear was determined by regression analysis. A single time point well 
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within the linear portion of the lactate influx vs. time curve was selected for 
subsequent lactate influx measurement. 
 
3.1.2.5 MCT1-mediated Lactate Influx 
The cells were suspended in HEPES containing CHC to block the MCT1 pathway. 
The samples were treated exactly as for the total lactate influx assay.  
 
3.1.2.6 Calculation of Lactate Influx 
To express the data as influx of lactate per milliliter of cells, the 25 l sample of 
stock solution was multiplied by its hematocrit fraction (0.30) to obtain a packed 
cell volume. The lactate influx per microliter is then mathematically converted to a 
per milliliter value. Lactate influx through MCT1 transport system was estimated 
as follows. The difference between the uninhibited flux and the CHC-inhibited flux 
was taken to estimate the flux through MCT1. Because CHC is not specific to the 
MCT only, this value somewhat overestimates the role of the MCT1.  
 
3.1.2.7 Data Analysis 
For kinetic studies, the Michaelis-Menten constant (Km) and maximum uptake rate 
(Vmax) of L-lactic acid were estimated using GraphPad Prism 5 software. IC50 is 
defined as the inhibitor concentration to achieve 50% inhibition on the uptake of       
L-lactate. The IC50 value was determined from the non-linear regression of a  






3.1.2.8 Statistical Analysis  
Unless otherwise indicated, all data are expressed as mean  SEM. Student’s t-test 
was used to determine the significance of differences between two group means. 
Statistical significance among means of more than two groups was determined by 
one-way analysis of variance (ANOVA). Statistical significance was defined as  























3.2.1 Time dependent Lactate Influx 
Figure 12a shows the uptake of L-lactate at three [La] values of 5, 50 and 100 
mM. The reactions were stopped at 10, 20, 30, 40, 50, 60, and 120 s. The time at 
which lactate influx rate vs. time became nonlinear was determined by regression 
analysis. A single time point well within the linear portion of the lactate influx vs. 
time curve was selected for subsequent lactate influx measurement. Based on 
regression analysis time course of total lactate influx is linear up to 30 s at 5, 50 



















Figure 12. Time course experiment depicting total lactate influx in nanomoles/milliliter of 
RBCs into human red blood cells (RBCs) at 5, 50 and 100 mM lactate concentration (a). 



















































































3.2.2 Human Erythrocyte Lactate Transport Activity 
The effect of lactate concentration on the rate of influx is shown in Fig. 13. Total  
L-lactate influx into erythrocytes increased with increasing [La] values, and 
saturated at high lactate concentration. The apparent Km and Vmax for total lactate 
uptake were 174.0  19.4 mM and 19228.0  740.0 nmol/mL of RBCs/min, 
respectively. MCT1-mediated lactate influx was estimated by subtracting the total 
lactate influx from the uptake in the presence of CHC at various substrate 
concentrations. The apparent Km and Vmax for MCT1-mediated lactate influx were 


















Figure 13. Effect of lactate concentration and MCT inhibitor on the lactate influx into 
RBCs. Lactate influx was measured at eight external lactate concentration at 37C for  
20 sec, in the presence or absence of CHC. Total lactate influx (blue) minus influx in the 
CHC-treated cells (green) represents influx via the monocarboxylate pathway (red).  
 










































3.2.3 Inhibitory Effects of Phytochemical and Pharmacological Agents on 
L-lactate Influx on Human Erythrocyte 
 
3.2.3.1 The inhibitory effects of various compounds on L-lactate uptake 
To investigate the effects of dietary and pharmacological compounds on L-lactate 
uptake, the uptakes of 100 mM of L-lactate were measured in the absence (control) 
or presence of 50 and 100 M of unlabeled test compounds (Table 37). L-lactate 
influx was significantly inhibited by several compounds tested in this study, 
namely diflunisal, diclofenac, mefenamic acid, meclofenamic acid, 
flufenami[102]c acid, tolfenamic acid, luteolin, morin, and phloretin. On the other 
hand, the inhibitory effects of pravastatin, rosuvastatin, simvastatin, naringin, 
capsaicin, coumorin, nicotine, salicylate and valproate on L-lactate influx were 
weak.  
 
3.2.3.2 The Inhibitor Potencies of Selected Compounds 
Several compounds exhibited inhibitory effects on the uptake of L-lactate  
(Table 37). The inhibitory potencies of these compounds were examined by 
determined the IC50 by making measurements over a broad range of inhibitor 
concentrations with substrate concentration fixed at 5 mM (Fig.14). The IC50 
values of tested compounds was summarized in Table 38, of which diflunisal, 
diclofenac, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, 
etodalac, luteolin, phloretin and morin exhibited a strong inhibition effect on the 
uptake of L-lactate with an IC50 value of 2 to 40 M. On the other hand, the 
inhibitory effects of indomethacin, cerivastatin, rosuvastatin were weaker  




Table 37. The inhibitory effects of various compounds on the uptake of L-lactate in human 
erythrocytes. The uptakes of 100 mM of L-lactate were measured in the absence (control) 
or presence of 50 and 100 M of unlabeled test compounds.  
*p < 0.05, **p < 0.01, and ***p < 0.001; ns = not statistically significant 
 
Compounds 50 M  (% Control) 100 M (% Control) 
NSAIDs   
Diflunisal 35.91  2.13 ** 23.87  1.46 *** 
Diclofenac  33.52  2.41 ** 28.77  1.21 ** 
Sulindac 80.89  2.77 * 71.86  5.19 * 
Indomethacin 62.26  0.61 ** 43.61  2.00 ** 
Etodalac 60.67  2.40 ** 51.29  1.57 ** 
Ibuprofen 63.18  0.87 ** 67.77  3.08 * 
Naproxen 73.71  6.97 * 62.56  1.84 ** 
Ketoprofen 75.97  3.59 * 70.92  2.49 * 
Mefenamic acid 26.38  2.72 ** 17.20  6.02 ** 
Meclofenamic acid 18.15  1.19 ** 12.68  2.35 ** 
Flufenamic acid 30.05  2.40 ** 18.15  1.82 ** 
Tolfenamic acid 23.44  2.04 ** 13.18  0.45 ** 
Piroxicam 72.9  2.12 ** 58.86  1.35 ** 
   
Statins    
Cerivastatin 71.66  0.59 ** 59.74  1.42 *** 
Pravastatin 107.74  3.57 ns 103.51  1.40 ns 
Rosuvastatin 89.34  4.53 ns 75.04  1.92 ** 
Simvastatin 95.60  4.34 ns 91.22  4.99 ns 
   
Phytochemicals   
Luteolin 53.26  2.05 ** 47.77  4.97 * 
Morin 72.79  0.79 ** 45.02  3.42 ** 
Naringin 94.29  1.49 ns 93.34  2.31** 
Phloretin 65.41  4.40 * 47.74  2.68 ** 
Silibinin 77.87  1.44 * 79.34  1.55 * 
Caffeine 86.83  2.85 ns 80.68  3.78 ns 
Capsaicin 56.61  8.31 ns 62.54  2.61 * 
Coumorin 94.94  6.66 ns 92.63  0.16 ns 
Nicotine 82.65  10.30 ns 80.77  5.38 ns 
   
Others   
Salicylate 111.96  3.88 ns 105.97  3.52 ns 
Valproate 100.89  0.94 ns 107.72  1.65 ns 








Figure 14. Inhibitory effects of NSAIDs (a) statins (b) and phytochemicals (c) on L-lactate  












































Table 38. The IC50 values of tested compounds on the uptake of L-lactate (5 mM) by 
human erythrocytes 
 
Compounds IC50 values (M) 
NSAIDs  
Diflunisal 40.24  1.10 
Diclofenac  1.33  1.17 
Indomethacin 210.0  1.11 
Etodalac 13.30  1.06 
Mefenamic acid 11.83  1.24 
Meclofenamic acid 9.68  1.10 
Flufenamic acid 11.42  1.05 
Tolfenamic acid 5.95  1.12 
  
Statins   
Cerivastatin 86.58  1.28 
Rosuvastatin 345.6  1.26 
  
Phytochemicals  
Luteolin 2.71  1.28 
Morin 44.53  1.08 
















3.2.4 Graphic and Software Determination of Inhibitor Type 
The double reciprocal, or Lineweaver-Burk, plot is the most straightforward means 
of diagnosing inhibitor modality. To diagnose the inhibitor type, the initial velocity 
as a function of substrate concentration at several fixed concentrations of the 
inhibitor of interest was measured. To select the inhibitor concentrations, first 
measured the effect of a broad range of inhibitors concentrations with substrate 
concentration fixed at the Km for MCT1-mediated L-lactate influx. From these 
results, the inhibitor concentrations that yielded between 30 and 75% inhibition 
were chosen. With the fixed inhibitor concentrations chosen, plot the data in terms 
of velocity as a function of substrate concentration for each inhibitor concentration. 
Finally, the reciprocal of initial velocity is plotted as a function of the reciprocal of 
substrate concentrations.  
 
The Lineweaver-Burk double-reciprocal plots of the selected inhibitors are 
presented in Figure 15, of which diclofenac, etodalac, mefenamic acid, 
meclofenamic acid, flufenamic acid, tolfenamic acid, cerivastatin and luteolin are 
competitive inhibitors. Diflunisal, on the other hand, inhibits MCT1-mediated 
lactate uptake in a noncompetitive manner. The Ki values of selected inhibitors are 
summarized in Table 39. 
 
The inhibitor modality of the tested compounds was verified using the mixed-
model inhibition model of GraphPad Prism 5 software (Table 40). The mixed 
model is a general equation that includes competitive, uncompetitive and 
noncompetitive inhibition as special cases. The model has one additional 
parameter, Alpha, that diagnoses the mechanism of inhibition. The value of Alpha 
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determines the degree to which the binding of inhibitor changes the affinity of the 
transporter to substrate. The value of Alpha is always greater than zero. When 
Alpha is equal to 1, the inhibitor does not alter the binding of transporter biding 
side to the substrate, and the mixed-model is identical to noncompetitive inhibition.  
When the value of Alpha is very large, the biding of inhibitor prevents binding of 
the substrate and the mixed model becomes identical to competitive inhibition. 
When Alpha is very small but greater than zero, the binding of inhibitor enhances 
transporter’s affinity to the substrate, and the mixed model becomes nearly 
identical to an uncompetitive model. The Alpha values of the selected inhibitors are 
summarized in Table 40. Of which, diclofenac, etodalac, mefenamic acid, 
meclofenamic acid, flufenamic acid, tolfenamic acid, cerivastatin and luteolin 
appear to be competitive inhibitors. Diflunisal inhibits MCT1-mediated lactate 
uptake in an uncompetitive manner, which is inconsistent with the result of 
Lineweaver-Burk double-reciprocal plot. The inconsistency in inhibitor modality of 
diflunisal diagnosed by both methods is yet to be elucidated. Nonetheless, the 
Lineweaver-Burk double-reciprocal plot and mixed-model inhibition model show 











Figure 15. Lineweaver-Burk plots of uptake of L-lactate at several fixed concentrations of 
inhibitor of interest 
 




















































































































































































































Table 39. The Ki values and mode of inhibitions of tested compounds on the uptake of  
L-lactate by human erythrocytes 
 
Compounds Ki values (M) Mode of Inhibition 
NSAIDs   
Diflunisal 29.56  3.46 Noncompetitive 
Diclofenac  6.17  0.61 Competitive 
Etodalac 341.7  64.3 Competitive 
Mefenamic acid 29.0  3.82 Competitive 
Meclofenamic acid 9.97  2.04 Competitive 
Flufenamic acid 23.29  2.81 Competitive 
Tolfenamic acid 8.95  0.93 Competitive 
   
Statins    
Cerivastatin 89.07  7.96 Competitive 
   
Phytochemicals   
Luteolin 75.68  8.01 Competitive 
Morin 42.63  3.21 Not done 
Phloretin 142.3  15.9 Not done 




Table 40. The mode of inhibition of tested compounds determined by Prism mixed-model 
inhibition model. The mode of inhibition is determined by the Alpha value 
 
  Goodness of fit, R2 Alpha Mode of Inhibition 
Diflunisal 0.9723 7.656 Uncompetitive 
Diclofenac 0.9757 ~ 1.311e+018 Competitive 
Etodalac 0.7298 ~ 4.034e+014 Competitive 
Mefenamic acid 0.9669 ~ 6.706e+021 Competitive 
Meclofenamic acid 0.9472 ~ 2.273e+015 Competitive 
Flufenamic acid 0.9491 ~ 6.707e+011 Competitive 
Tolfenamic acid 0.9114 ~ 4.303e+017 Competitive 
Cerivastatin 0.9828 ~ 6.454e+015 Competitive 






There is a growing recognition that transporters are important mediators in 
physiological processes and drug disposition. Our understanding of the 
contribution of transporters in drug disposition has exploded with the creation of a 
variety of cell-line and transgenic mouse models. For example, the breakthrough in  
p-glycoprotein (P-gp) and Mdr1a/b (-/-) knockout mice has substantially influenced 
pre-clinical drug development and provided a good model in examining the role of 
these efflux proteins in drug disposition.  
 
Food/drug-transporter interactions may be inhibitory, inductive, or both, and may 
involve influx and efflux transporters. Consequently, such interactions result in 
increased or decreased of systemic exposure and subsequently altered the efficacies 
and side effects of pharmacological compounds. Food/drug-interactions have 
increasingly been observed with increasing use of pharmacological agents, dietary 
supplements and herbal medicines. Therefore, detailed information about potential 
transporter interactions between drugs and dietary supplements is needed.  
 
The monocarboxylate transporter 1 (MCT1) has been thought to be responsible for 
the transportation of L-lactate across the human erythrocyte plasma membrane. 
According to the lactate shuttle hypothesis, lactate formation and its subsequent 
distribution throughout the body is a major mechanism whereby the coordination 
of intermediary metabolism in different tissues, and cells within those tissues, can 
be accomplished. During exercise, lactate and protons move out from exercising 
muscles and enter the plasma. From plasma, lactate is further transported into 
erythrocytes through MCT1. MCT1, the only MCT isoform found in the human 
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erythrocyte, accounts for 80-90% of lactate transport. Given the roles of MCT1 in 
endogenous monocarboxylates and clinically important drugs, alter in transporter 
activity may have far-reaching consequences. The diet-drug interactions via MCT1 
inhibition may affect lactate shuttling and drug disposition in the body. Several 
dietary and pharmacological compounds have shown to exhibit an inhibitory effect 
on human MCT1 activity [108, 110]. In this study, we further investigated the 
effects of various dietary and pharmacological agents on MCT1-mediated lactate 
influx into human erythrocytes.  
 
3.3.1 Human Erythrocyte L-lactate Uptake  
The apparent Km and Vmax for MCT1-mediated lactate influx found in this study 
were 123.9  24.6 mM and 12079.0  722.3 nmol/mL of RBC/min, respectively.  
The Km value of this study was much higher than the Km values reported by 
previous studies on human erythrocytes. On studying lactate influx into human 
erythrocytes, Dubinsky and Racker obtained a Km of 13.4 mM [102]. However, this  
Km value was estimated from experimental data where the transport activity was 
not assayed at saturation. The accurary of Km and Vmax estimations are critically 
dependent on the range of substrate concentrations over which the initial velocity 
has been determined. If the measurements are made only at low substrate 
concentrations, the data will appear to be first-order. In this concentration range, 
the transporter binding sites never reach saturation and the Km will be 
underestimated. In order to best characterize the steady state kinetic constants for a 
transport system, it is best to at least cover substrate concentration of 0.25-5.0 Km 
[217]. Similar erroneous estimations have been observed in several studies that 
characterized the kinetics of MCT1. In these studies, the Km of MCT1-mediated 
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transport lactate influx was estimated from uptake data measured at low substrate 
concentrations that had not reached saturation [87, 97, 100, 102, 161, 199]. The 
high Km value of L-lactate has not been recognized before and may suggest that 
MCT1 may have other preferential substrates (such as pyruvate, ketone bodies and 
acetate) other than L-lactate. The data of this study suggests that MCT1 is a low 
affinity but high capacity transport process for the transport of L-lactate.  
 
3.3.2 Inhibitory Effects of Dietary and Pharmacological Compounds on  
L-lactate Influx  
A previous study had reported that several non-steroidal anti-inflammatory drugs 
(NSAIDs), namely diflunisal, diclofenac, ketoprofen and naproxen, exhibited a 
strong inhibition effect on human MCT transport activity [108]. In this study, we 
further investigated the effects of other NSAIDs on MCT1-mediated lactate influx. 
As summarized in Table 38 and Figure 14a, diflunisal, diclofenac, mefenamic 
acid, meclofenamic acid, flufenamic acid, tolfenamic acid and etodalac exhibited a 
strong effect on the uptake of L-lactate with an IC50 value of 2 to 40 µM. In 
contrast to the study done by Choi et al., the inhibitory effects of ketoprofen and 
naproxen on MCT1-mediated L-lactate uptake were weak (Table 37).  
 
The inhibitory concentrations of tested NSAIDs (diflunisal, mefenamic acid, 
meclofenamic acid, flufenamic acid and tolfenamic acid) are in the range of 
physiologically relevant concentrations that are achievable from the oral intake.  
For example, the suggested dosage range of diflunisal is 500 mg to 1000 mg daily 
for osteoarthritis and rheumatoid arthritis. The peak plasma concentration of 
diflunisal achievable from single 500 mg oral dose was 87 g/mL, while the Ki of 
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diflunisal is 29.56 M (equivalent to 7.40 g/mL). Therefore, a strong inhibition of 
NSAIDs on MCT1 is achievable at the relevant plasma concentrations of diflunisal.  
 
Three NSAIDs, namely diclofenac, meclofenamic acid and tolfenamic acid 
exhibited strong inhibitory effects on L-lactate transport, with a Ki value of  
6.17 M (~1.96 g/mL), 9.97 M (~ 3.35 g/mL) and 8.95 M (~ 2.34 g/mL), 
respectively. The recommended dosage for diclofenac is 100-150 mg/day in 
divided doses for the relief of osteoarthritis. The peak plasma concentration of 
diclofenac achievable from single oral 50 mg dose is 0.8 g/mL, while the peak 
plasma level of diclofenac achievable from multiple doses (oral 50 mg was 
administered 3 times daily for 7 days) was 2.3 g/mL [218]. The recommended 
dosage of meclofenamate sodium for pain relief, arthritis and osteoarthritis is 200 
to 400 mg daily, administered in three or four equal doses. After the administration 
of 100 mg meclofenamate sodium for 18 days every 8 hours, the peak 
concentration was 4.8 g/mL for the parent compound on both day 1 and day 18. 
Lastly, tolfenamate is subscribed to patients suffering from acute migraine with a 
recommended dosage of 200mg. Pharmocokinetics data shows that a single oral 
dose of 200 mg, 400 mg and 800 mg of tolfenamic acid achieved a peak 
concentration of 2.97 g/mL, 6.15 g/mL and 12.2 g/mL in the plasma, 
respectively [219]. Taking this data together, it suggests that strong inhibition of 
NSAIDs on L-lactate transport on human erythrocyte is expected at the 




Although inhibitory effects of tested NSAIDs are achievable at clinically relevant 
concentrations, we have to take into the consideration of protein binding property 
of the pharmaceutical compound. High protein binding ( 99%) and small volume 
of distribution seem to be a common feature of the NSAIDs, namely diflunisal, 
diclofenac, mefenamic acid, meclofenamic acid and tolfenamic acid. A better 
comparison is with unbound plasma concentration. However, pharmacokinetics 
data reported the total plasma concentration rather than the unbound plasma 
concentration. The actual unbound plasma concentrations of tested NSAIDs may 
be below the Ki values reported in this study. The tested NSAIDs may not 
contribute significantly to the in vivo inhibition of MCT1 activity.  
 
Interestingly, recent studies associated NSAID use with increased cardiovascular 
risk in healthy individuals and in patients with established cardiovascular disease 
[220-225]. A nationwide cohort study was carried out by Schjerning Olsen et al. to 
examine the association between NSAID treatment duration and risk of 
cardiovascular disease [220]. Overall, NSAID treatment was significantly 
associated with an increased risk of death and recurrent myocardial infarction. 
Analyses of individual NSAIDs showed that the traditional NSAID diclofenac was 
associated with the highest risk from the beginning of the treatment, while 
ibuprofen showed an increased risk when used for more than one week [220]. The 
selective COX-2 inhibitors, refecoxib and celecoxib, were associated with 
increased risk of death after treatment. Naproxen, however, was not associated with 
an increased risk of death or myocardial infarction for the entire treatment duration. 
Lactate is an important fuel for myocardial energy. As MCT1 expression is 
abundant in heart tissue [7], one of the possible mechanism of NSAID-induced 
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cardiotoxicity could be due to inhibitory effect of NSAID on MCT1, which 
prevents the uptake of lactate by heart tissue. However, as the nature of NSAID-
induced cardiotoxicity is unknown, this proposed mechanism is purely speculative.  
 
The interaction of L-lactate and statins with MCT1 has also been examined in this 
study. Previously, Kobayashi et al. reported lipophilic statins significantly inhibited 
L-lactate uptake by MCT4 in a concentration-dependent manner [165]. However, 
the effects of statins on MCT1 transport system have yet to be evaluated. Out of the 
two hydrophilic (rosuvastatin and pravastatin) and two lipophilic (cerivastatin and 
simvastatin) statins examined in this study, only cerivastatin exhibited statistically 
significant inhibitory effect on MCT1. The inhibitory effects of simvastatin, 
pravastatin and rosuvastatin were very weak (Table 37). Statins are widely used 
cholesterol-lowering agents for prevention of cardiovascular diseases. Statins are 
well tolerated by most patients but can produce a variety of skeletal myopathies. 
One of the possible explanations of statin-induced cytotoxicity is associated with 
the inhibitory effects of statins on L-lactate mediated by MCT. It has been 
speculated that statins inhibit MCT-mediated efflux of L-lactate, resulting in 
induction of intracellular acidosis and apoptosis in myocytes [165, 226]. However, 
the finding in this study shows that rosuvastatin, simvastatin and pravastatin do not 
inhibit MCT1 transport activity. Besides, although cerivastatin exhibited certain 
degree of inhibition on MCT1, the peak plasma concentration of cerivastatin of 
multiple oral doses treatment (0.8 mg once daily for 10 days) was 0.0096 g/mL. 
The plasma concentration of cerivastatin is far below the Ki value, which is  
89.07 M (~ 42.88 g/mL). Therefore, impairment of MCT1 function is unlikely 
to contribute to statin-induced myotoxicity.  
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The popular use of dietary supplements and herbal medicine has raised the 
awareness of the potential diet-transporter interactions. Recently, Wang et al. 
reported that flavonoids, a class of polyphenolic compounds present in the diet and 
herbal products, are potent MCT1 inhibitors [110]. Therefore, the effects of several 
dietary compounds, including flavonoids on MCT1 were examined (Table 37). In 
this study, we demonstrated that luteolin, morin and phloretin were inhibitors of 
MCT1, whereas the effects of naringin, silibinin and coumorin on MCT1 were very 
weak. Our results are consistent with the results reported by Wang and Morris 
[110]. In their study, luteolin, morin and phloretin inhibited the uptake of  
-hydroxybutyrate (0.1 mM) by rat MCT1 gene-transfected MDA-MD231 cells 
with the IC50 values of 0.41  0.14, 6.21  2.01 and 2.57  0.48 M, respectively. 
However, we demonstrated higher IC50 values for luteolin, morin and phloretin, 
which were 2.71  1.28, 44.53  1.08 and 47.98  1.11, respectively  
(Table 38, Fig. 14c). In addition, Shim et al. had reported that silibinin exhibited 
strong inhibitory effect on MCT1 in Caco-2 cells. However, silibinin showed little 
effect on MCT1-mediated L-lactate influx in this study. The discrepancy of results 
could be due to the differences in the experimental conditions, the nature of 
substrate and concentration of substrate present in the assay. Therefore, it is not 
rigorously correct to compare the relative potencies of inhibitors of different 
modalities by use of IC50 values. Three dietary compounds were examined on their 
effects on MCT1. The in vivo inhibitory effects of these tested phytochemicals 
cannot be speculated as the pharmacokinetics data is not available. Nonetheless, the 




The limitation of this study is SNP mutation analysis was not performed in the 
subjects involved in this study. This was because the SLC16A1 gene is generally 
conserved in Singapore population and only one rare mutation was predicted to 
have detrimental effect on MCT1 transport activity (Table 10). Although           
1470 T>A (Asp490Glu) was suggested to have a defective effect on MCT1 
transport activity when the polymorphism-phenotype association was examined, 
this information was not yet available when this project was performance. 
Nonetheless, the individual variation was minimized by utilizing the erythrocytes 
samples from only four Chinese volunteers.  
 
Three pathways mediate the transport of lactate across erythrocyte membrane. It 
has been reported that in human erythrocyte, MCT1 transport system accounts for 
90% of lactate flux across membrane. The band 3 system and nonionic diffusion 
contributed 6% and 4%, respectively [107]. In this study, diflunisal, diclofenac, 
mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, 
indomethacin, etodalac and morin inhibited approximately 90-93 % of lactate 
influx at external L-lactate concentration of 5 mM. The observation demonstrates 











Food/drug-transporter interactions have increasingly been observed with 
increasingly use of pharmacological agents, dietary supplements and herbal 
medicines. Given the roles of MCT1 in transporting endogenous monocarboxylates 
as well as clinically important drugs [105, 192, 193, 227], these interactions can 
cause serious consequences. The diet-drug interactions via MCT1 inhibition may 
affect lactate shuttling and drug disposition in the body. On the other hand, these 
interactions can have favourable effects. Recent studies reported that certain tumor 
cells up-regulated the expression of MCT1 to prevent cellular acidosis, these 
inhibitors could be the potential candidate drugs in cancer therapy by promoting 
cellular acidosis via MCT1 inhibition [228-232]. Taken together, several 
pharmacological agents and dietary compounds exhibited strong inhibition on 
MCT1-mediated L-lactate influx. Given that the inhibitory concentrations of some 
of the tested compounds are in the range of physiologically relevant concentrations 
that are achievable from the daily intake, the study raises the awareness of the 
potential diet-drug interaction via MCT1 inhibition. However, due to high protein 
binding of the tested NSAIDs, the actual unbound plasma concentrations of tested 
NSAIDs may be below the Ki values reported in this study. The tested NSAIDs 
may not contribute significantly to the in vivo inhibition of MCT1 activity. 
Therefore, it will be beneficial to examine the inhibitory effects of NSAID on 
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The objective of this study was to examine the interindividual variation in total and 
MCT1-mediated lactate influx into human erythrocytes in the local Chinese 
population. A total of 10 healthy Chinese volunteers were recruited in this study. 
The 10-assay grouped data were plotted on the best-fit curve, and its Km and Vmax 
were estimated.  In the MCT-1 mediated lactate influx, the apparent Km and Vmax 
were 220.1±35.33 mM and 15877±968.1 nmol/ml of RBC/min, respectively. The 
main findings of the present study were that 1) no interindividual variations were 
observed in the total lactate influxes and MCT1-mediated lactate influx across 
RBC membrane in the local Chinese population; 2) human MCT1 system exhibited 
a low affinity but high capacity transport mechanism for the transport of lactate 
into RBC; and 3) the T allele of 1470 T>A (Asp490Glu) polymorphism may have a 















4.1 MATERIALS AND METHODS 
4.1.1 Subjects 
A total of 10 subjects participated in this study. All subjects had been recruited 
previously in accordance with requirements (Institutional Review Board, National 
University Hospital, Singapore) and provided written informed consent. The mean 
age is 24.7 ± 2.4 (21 to 29). The male:female sex ratio is 7:3. Ethnicity was defined 
through self-declaration by the donors of similar ethnicity through three 
generations. All DNA samples were rendered anonymous by removing links with 
specific individual information, i.e., any ID, name, or address. 
 
4.1.2 Erythrocytes Lactate Influx Assay 
4.1.2.1 Preparation of RBCs for Lactate Influx Assay 
Techniques for RBC preparation and lactate influx measurement were adopted 
from previously published methods [72, 107, 162, 164]. Five milliliters of venous 
blood were drawn from each subject into heparinized vacutainers. An initial 
hematocrit (Hct) and hemoglobin concentration were determined for all blood 
samples. Three milliliters of blood sample were transferred to a 50 ml conical tube. 
The remaining portion of the blood sample was refrigerated at 4C and saved for 
repeat measurements if required. The RBCs were isolated by centrifugation at 
room temperature (25C, 10 min, 2000g). The plasma and buffy coat were 
removed by aspiration, leaving only the RBC pellet. The pellet was mixed by 
inversion with 30 volumes of chloride buffer (150 mm NaCl, 10 mM Na-tricine, 
pH 8.0 at 37C, osmolality ~ 315mosmol/kg H2O) and incubation in water bath for 
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30 min at 37C. This step was to ensure removal of endogenous lactate [102]. At 
the end of the incubation, the RBCs were sedimented at room temperature  
(25C, 10 min, 2000g) and the supernatant was removed by aspiration. The cell 
pellet was then washed two times. For each washing, four volumes of chloride 
buffer were added to the cell pellets, the pellet was mixed by inversion and then 
centrifuged (25C, 10 min, 2000g). The supernatant was removed after each wash. 
Lactate depletion from the RBCs (~0.20 mM in 30% hematocrit solution) was 
confirmed by analysis via the spectrophotometric technique (BioVison; MV, 
California). After the final wash, the RBC pellet was suspended in HEPES buffer 
(90 mM NaCl, 50 mM HEPES, pH 7.4, 37C, osmolality ~ 267 mosmol/kgH2O) 
equivalent to a 30% hematocrit (packed cell volume) to obtain the stock cell 
solutions for influx measurements. This suspension was divided into two aliquots, 
each containing one milliliter. One of the two stock cell suspensions contained no 
lactate transport inhibitors. Five millimolar -cyano-4-hydroxycinnamic acid 
(CHC) was added to the second stock cell suspension to inhibit the MCT1-
mediated pathway. The two aliquots were incubated in a water bath for 30 min at 
37C, and Hct was determined in a sample of each stock cell suspension.  
 
 
4.1.2.2 Total Lactate Influx 
A 25 l sample of stock cell solution was incubated in 75 l of HEPES influx 
buffer for 20 s at 37C. The HEPES buffer containing [14C]-lactate (0.2 Ci/ml) at 
thirteen unlabeled [La] values of 2.5, 6.2, 12.3, 24.7, 49.3, 98.7, 123.3, 246.7, 
370.0, 493.3, 616.7, 740.0 and 863.3 mM. All HEPES influx buffers were adjusted 
to a pH 7.4. Because of dilution with the stock cell solution, the actual final [La] 
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values were 2, 5, 10, 20, 40, 80, 100, 200, 300, 400, 500, 600 and 700 mM, 
respectively. The incubation was stopped with 2 ml of ice-cold stop solution  
[150 mM NaCl, 10 mM MES, pH 6.5] and tubes were immediately iced. The 
sample was spun by centrifugation (4C, 10 min, 2000 g) and was washed twice to 
eliminate extracellular radioactivity. After the final wash, the RBC pellet was lysed 
and deproteinized with 0.5 ml of 4.2% perchloric acid followed by centrifugation 
of the sample (4C, 10 min, 2000 g). Finally, 0.4 ml of the supernatant was pipetted 
into scintillation vials containing 5 ml of scintillation liquid (Amersham 
Bioscience; Amersham, UK) and the radioacitivity of the supernatant was 
measured with a liquid scintillation counter (Beckman Coulter, Kraemer 
Boulevard, USA). All measurements were made in triplicate.  
 
4.1.2.3 MCT1-mediated Lactate Influx 
The cells were suspended in HEPES containing CHC to block the MCT1 pathway. 
The samples were treated exactly as for the total lactate influx assay.  
 
4.1.2.4 Calculation of Lactate Influx 
To express the data as influx of lactate per milliliter of cells, the 25 l sample of 
stock solution was multiplied by its haematocrit fraction (0.30) to obtain a packed 
cell volume. The lactate influx per microliter is then mathematically converted to a 
per milliliter value. Lactate influx through MCT1 transport system was estimated 
as follows. The difference between the uninhibited flux and the CHC-inhibited flux 
was taken to estimate the flux through MCT1. Because CHC is not specific to the 
MCT only, this value somewhat overestimates the role of the MCT1.  
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4.1.2.5 Data Analysis 
For kinetic studies, the Michaelis-Menten constant (Km) and maximum uptake rate 
(Vmax) of L-lactic acid were estimated using GraphPad Prism 5 software.  
 
4.1.3 DNA Amplification 
4.1.3.1 DNA extraction 
Genetic materials used in this study were obtained from a previously-developed 
cell repository from healthy volunteers of Chinese and Indian descent. 45 ml of 
Buffer A (0.32 M sucrose, 10 mM Tris HCl pH 7.4, 5 mM MgCl2, and 1 % Triton-
X-100) was added to the white cell pellet and mixed by inversion. The solution was 
spun (4C, 20 min, 1500 g) and the supernatant was removed by aspiration. The 
same procedure was repeated once. The pellet was resuspended in 5 ml of Buffer B 
(25 mM EDTA pH 8.0 and 75 mM NaCl). This is followed by the addition of  
250 l of 10 % Sodium Dodecyl Sulfate (SDS) and 20 l of 20 mg/ml proteinase 
K. The contents were vortexed briefly and incubated overnight at 37C with 
shaking in an oven. At the end of incubation, 1.4 ml of saturated NaCl (6 M) was 
added to the mixture and the mixture was vortexed vigorously for 15 seconds. The 
solution was spun (15 min, 1500 g) and the supernatant was transferred to a new  
50 ml falcon tube containing 15 ml of absolute ethanol. The mixture was mixed 
gently by inversion to precipitate DNA. The mixture was spun (20 min, 1500 g) 
and the supernatant was removed. The DNA pellet was washed with 5 ml of 70% 
ethanol and was spun (15 min, 1500 g). The supernatant was removed and the 
pellet for air-dried for 30 minutes. The recovered DNA was dissolved in 200 l of 
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TE solution (10 mM Tris HCl pH 7.5 and1 mM EDTA pH 7.5) and was dissolved 
at 4C overnight. The DNA was transferred to an Eppendorf tube and stored at  
-20C. The isolated DNA was quantified using Quant Universal Microplate 
Spectrophotometer (ITS) and absorbance readings were taken at 260 nm 
wavelength. Optical Density (OD), which determines the purity of the DNA, was 
obtained by measuring the ratio of 260 nm/280 nm (DNA maximum absorbance = 
260 nm wavelength). OD readings between 1.7 – 1.8 were accepted as a lower or 
higher ratio indicates protein or ribonucleic acid contamination respectively. 
Finally, the DNA was diluted with DNase-free water to a concentration of  
20 ng/l.  
 
4.1.3.2 Polymerase Chain Reaction Amplification 
The polymerase chain reaction (PCR) amplifications were performed in a total 
volume of 30 l containing 1 X Master Mix (Promega, Madison, WI, USA),  
0.4 M of each primer (Sigma-Aldrich, St. Louis, MI, USA) and 60 ng of DNA on 
the MJ Research Peltier Thermal Cycle (DNA Engine Dyad; MJ Research Inc, 
Waltham, MA, USA). The PCR conditions were pre-denaturation at 95°C for  
5 min, followed by 35 cycles of denaturation at 95°C for 1 min, annealing for  
1 min, and extension at 72°C for 1 min, and then a final extension at 72°C for  
10 min. The annealing temperatures for the fragments of MCT1 and MCT4 genes 
are summarized in Table 8 and Table 9, respectively. Cycle sequencing was 
performed on the MJ Research Peltier Thermal Cycler using the following 
conditions: initial denaturation at 96C for 10 seconds, 50C for 5 seconds, and 
60C for 4 minutes.  
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4.1.3.3 Agarose Gel Electrophoresis 
After PCR amplifications, the PCR products obtained were verified by 
electrophoresis through 1% agarose gels stained with 0.2 g/ml ethidium bromide. 
They were subjected to electrophoresis at 100 V for 1 hour and visualized under 
UV illumination. PCR amplifications that were found to produce poor DNA yield 
were discarded and repeated because it would lead to downstream problems such 
as ambiguous results from DNA sequencing.  
 
4.1.4 DNA Sequencing  
4.1.4 .1 PCR Product Clean Up 
Prior to sequencing, PCR products were cleaned up to remove excess primers and 
unincorporated dNTPs. 12 l of PCR products were being added to one unit of 
Shrimp Alkaline Phosphatase (Promega) and two units of Exonuclease I (New 
England Biolabs, Beverly, MA, USA). The reaction mix was incubated at 37C for 
15 minutes and followed by enzyme deactivation at 80C for 20 minutes. 
 
4.1.4.2 Cycle Sequencing  
In this study, all PCR products were subjected to DNA sequencing. Mutational 
analysis of the candidate genes was performed using BigDye Terminator v3.1 
Cycle Sequencing Kit. Extension reactions were performed in a total volume of 20 
l containing 10 l of purified PCR products, 0.5 l of BigDye Terminator reagent, 
2 l of 5x sequencing buffer, 2 l of oligonucleotide primer (5 pmole/l) and  
3.5 l of water. Primers for cycle sequencing were similar to the primers for PCR 
(Table 8 and Table 9). Amplification of cycle sequencing products was generated 
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using MJ Research Peltier Thermal Cycle with cycling profile: denaturation at 
96C for 1 min, 25 cycles of denaturation at 96C for 10 seconds, annealing at 
50C for 5 seconds, extension at 60C for 4 minutes. The extension products were 
stored at 4C for maximum of 3 days or immediately proceed to DNA 
precipitation.  
 
4.1.4.3 DNA Precipitation 
After cycle sequencing, the 96-well reaction plate was removed from the thermal 
cycler and briefly spun. The sequencing products in each well were added with 2 l 
of 125 mM EDTA, followed by 2 l of 3 M sodium acetate. The contents were 
mixed and added with 50 l of absolute ethanol. The contents were gently mixed 
and incubated in the dark at room temperature for 25 minutes. After the incubation, 
the samples were spun at 3000 g for 30 minutes. The supernatant was discarded by 
inverting the plate and spun at up to 185 g for 1 minute. This was followed by 
adding 70 l of 70 % ethanol to each well, and spinning at 1650 g for 15 minutes. 
The supernatant was discarded and the DNA pellets were dried at 72C for 10 
minutes. The plate was covered with aluminum foil and stored at 4C for a period 
of 2 weeks prior to sequencing analysis. Alternatively, 12 l of HiDi was added to 
into each well containing DNA pellet and run on the automated ABI Prism Model 
3100 Avant Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).  
 
4.1.4.4 Mutational Analysis of DNA Sequences 
The sequences were analyzed with a Mutation SurveyorTM v2.61 (Softgenetics, 
State College, PA, USA) and Chromas (Techelysium software). All mutations 
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flagged by the software were checked by visual inspection to avoid any false 
positives. PCR was repeated and bidirectional sequencing performed on all 
detected variants to rule out PCR-induced mutations and sequencing artefacts. 
 
4.1.5 Statistical Analysis  
Unless otherwise indicated, all data are expressed as mean  SEM. Mann Whitney 
U tests were performed to analyze the differences between TA and AA genotypes 
of the polymorphism for all the lactate variables, Michaelis-Menten coefficients 
(Km) and maximal lactate transport capacity (Vmax) in total and MCT1-mediated 



















4.2.1 Total and MCT1-mediated Lactate Influx into Human Erythrocytes 
The 10-assay grouped data were plotted on the best-fit curve, and its Km and Vmax 
were estimated (Fig. 16a and Fig. 16b). In the total L-lactate influx assay, the uptake 
increased with the increase in external [La], but did not reach saturation at highest 
concentration (Fig. 16a). We could not further increase the external lactate 
concentration as red cell haemolysis occurs at external lactate concentration higher 
than 700 mM. Therefore, the Km and Vmax of total L-lactate uptake into human 
RBC cannot be estimated. The MCT1-mediated lactate influxes also increased with 
external [La] and reached plateau at high concentration (Fig. 16b). The apparent 
Km and Vmax for MCT1-mediated lactate influx were 220.1  35.33 mM and 15877 
 968.1 nmol/ml of RBC/min, respectively. The mean (± s.d.) and Coefficient of 
Variation (%) of L-lactate influx into RBC are summarized in   Table 41 and 













Figure 16a. Total lactate influx into RBC of local Chinese population (n = 10). Values are 















Figure 16b. Monocarboxylate transporter 1- mediated lactate influx into RBC of local 







































































Table 41. The total lactate influx into RBC of local Chinese population (n = 10) 
 
L-lactate concentration (mM) 2 5 10 20 40 80 100 200 300 400 500 600 700 
Mean (nmol/mL RBC/min) 405 922.2 1560 2386 3579 5433 6417 9615 14178 17423 19965 22761 24076 
Std. Deviation 122.7 219.2 327 368.6 537.2 790.7 907.5 1255 1246 1518 1774 2006 3216 
Std. Error 38.8 69.32 103.4 116.6 169.9 250.1 287 396.8 393.9 480 560.9 634.4 1017 
























Table 42. The Monocarboxylate transporter 1- mediated lactate influx into RBC of local Chinese population (n = 10) 
 
L-lactate concentration (mM) 2 5 10 20 40 80 100 200 300 400 500 600 700 
Mean (nmol/mL RBC/min) 356.5 793 1311 1936 2765 4048 4841 6786 9056 10690 11504 11967 11408 
Std. Deviation 119 218.3 322.1 364.8 534.5 870.4 1186 1670 1594 2083 2079 2923 4706 
Std. Error 37.64 69.04 101.8 115.4 169 275.2 374.9 528 504 658.6 657.5 924.3 1488 







4.2.2 Polymorphism-phenotype association of SLC16A1 gene 
In this study, the effect of a common MCT1 polymorphism, 1470 T>A 
(Asp490Glu), was examined. Among the eight Chinese samples studied, none of 
the samples were homozygous wildtype, 4 (50%) samples were heterozygous 
mutants and 4 (50%) were homozygous mutants. The DNA samples of two 
subjects were contaminated with PCR inhibitors. We were unable to amplify the 
PCR fragments after several attempts. Therefore, the genotyping data of these two 
subjects were missing and were excluded from the analysis.  
 
The influence of genetic polymorphism in total lactate influx and MCT1-mediated 
lactate influx were compared at 2, 5, 10 and 20 mM of external L-lactate 
concentrations. Mann Whitney U tests were performed to analyze the differences 
between TA and AA genotypes of the 1470 T>A (Asp490Glu) polymorphism for 
all the lactate variables, Michaelis-Menten coefficients (Km) and maximal lactate 
transport capacity (Vmax) in total and MCT1-mediated lactate influx.. The TA 
group appeared to have lower values of the total influx into erythrocyte than the 
AA group at 2, 5 and 20 mM of lactate concentrations (Fig. 17).  However, the 
differences in lactate influx were not statistically significant. Similarly, the MCT1-
mediated lactate influx in TA group was lower than the AA group at external 
lactate concentration of 2, 5, 10 and 20 mM. The differences, however, were not 
significantly different at all lactate concentrations (Fig. 18). The Km and Vmax 
values of TA and AA groups in the total and MCT1-mediated uptakes were 
compared. There were no significant differences for the Km and Vmax between two 
genotype groups in the total and MCT1-mediated lactate influx (Fig.19 and 
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Fig.20).  Nonetheless, a higher Km value was observed in the TA group as 
compared to the AA group.   
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Figure 17. The total lactate influx into RBC at four external L-lactate concentration in TA and AA groups of SLC16A1 gene. There were no significant 
















































































































































Table 43. TheMann Whitney U tests were performed to analyze the differences between TA and AA genotypes of the 1470 T>A (Asp490Glu) polymorphism in 
total lactate influx. Statistical significance was defined as P < 0.05. 
   
TA versus AA 
Total L-lactate Uptake  
2mM 5mM 10mM 20mM 
P value 0.6857 0.6857 0.6857 0.3429 






















Figure 18. The MCT1-mediated lactate influx into RBC at four external L-lactate concentration in TA and AA groups of SLC16A1 gene. There were no 


















































































































































Table 44. The Mann Whitney U tests were performed to analyze the differences between TA and AA genotypes of the 1470 T>A (Asp490Glu) polymorphism in 
MCT1-mediated lactate influx. Statistical significance was defined as P < 0.05.  
 
TA versus AA 
MCT1 L-lactate Uptake  
2mM 5mM 10mM 20mM 
P value 0.6857 0.6857 0.6857 0.3429 


















Figure 19. The constant of Michaelis-Menten (Km) for the total and MCT1-mediated lactate influx in in TA and AA groups of SLC16A1 gene. There were no 




































































































Table 45. TheMann Whitney U tests were performed to analyze the differences of the Km between TA and AA genotypes of the 1470 T>A (Asp490Glu) 
polymorphism. Statistical significance was defined as P < 0.05.  
 
 
TA versus AA 
Total lactate influx MCT1-mediated lactate influx 
P value 0.6857 0.8857 






















Figure 20. The maximal lactate transport capacity (Vmax) for the total and MCT1-mediated lactate influx in in TA and AA groups of SLC16A1 gene. There 

















































































Table 46. TheMann Whitney U tests were performed to analyze the differences of the Vmax between TA and AA genotypes of the 1470 T>A (Asp490Glu) 
polymorphism. Statistical significance was defined as P < 0.05.  
 
  TA versus AA 
Total lactate influx MCT1-mediated lactate influx 
P value 0.8857 0.6857 




Transport of lactate across the erythrocyte membrane is mediated by three distinct 
pathways: 1) nonionic diffusion of lactic acid, 2) inorganic anion exchange (band 
3), and 3) a monocarboxylate-specific carrier mechanism [94, 162, 163]. The 
significance of each of these pathways with regard to lactate transport is varied 
among species [72, 94]. The monocarboxylate-specific carrier is the major pathway 
for lactate transport in the RBC of humans, rabbits, and rats. However, the band 3 
system is the preferred pathway in ox’s RBC, which contributed in 53% of lactate 
transport. In humans, MCT1 is the only MCT isoform expressed on the RBC 
membrane. The MCT1 mechanism accounts for 90% if lactate flux across human 
erythrocyte membrane, while band 3 system and passive diffusion contribute for 
the remaining 10% of the lactate influx [162].  
 
The first objective of this study was to examine the interindividual variation in total 
and MCT1-mediated lactate influx into human erythrocytes in the local Chinese 
population. We have previously genotyped the MCT1 gene in the ethnic Chinese 
and Indian groups of Singapore population and a common nonsynonymous 
polymorphism, 1470 T>A (Asp490Glu) had been identified in MCT1 gene  
(Table 10). With knowledge that MCT1 responsible up to 90% of lactate influx 
into RBC, it would be intriguing to correlate the in vitro uptake assay with the 
MCT1 polymorphism. Therefore, the second objective of this study was to examine 






4.3.1 Interindividual variation in Total and MCT1-mediated lactate influx 
Low interindividual variability was observed in the total lactate influx in the ten 
Chinese subjects as the Coefficient of Variation (CV) of total lactate influx at all 
external lactate levels were lower than 30% (Table 41). The MCT1-mediated 
lactate influx exhibits higher interindividual variability as compared to the total 
lactate influx (Table 41 and Table 42). Nonetheless, the CVs of lactate influx are 
lower than 30% at all external lactate levels except at 2 mM and 700 mM.  
Therefore, the variability in L-lactate influx into RBC is low in this 10-grouped 
data. In this study, the uptake measurements were performed by incubating the 
erythrocytes with lactate concentrations up to 700 mM. Even though incubation 
times were short (20 seconds), this is a hypertonic medium and might affect uptake 
the measurements. Unfortunately, we could not find a suitable control to elucidate 
this experimental limitation. However, as explain in Section 3.3.1, it is essential to 
estimate the Km and Vmax on the range of substrate concentrations over which the 
transport activity reaches saturation to prevent erroneous. Therefore, we further 
extended the exogenous L-lactate concentrations up to 700 mM. The Km value 
reported in this study was much higher than the Km values reported by previous 
study but in accordance to our previous finding (Fig. 13). The possible 
explanations of these disparities have been explained in Section 3.3.1. Nonetheless, 
the finding of this study suggests that lactate transport across RBC membrane is a 
low affinity but high capacity transport process. Low interindividual variability was 






4.3.2 Polymorphism-phenotype association of MCT1 gene 
The second objective was to examine the relationship of 1470 T>A (Asp490Glu) 
variant with erythrocyte lactate transport activity. In this study, we examined the 
effect of this polymorphism on lactate influx into human erythrocytes. Among the 
eight Chinese samples studied, 0 (0%) samples were homozygous wildtype (TT),  
4 (50%) samples were heterozygous mutants (TA) and 4 (50%) were homozygous 
mutants (AA). The influence of genetic polymorphism in total lactate influx and 
MCT1-mediated lactate influx were compared at 2, 5, 10 and 20 mM of external  
L-lactate concentrations. The total and MCT1-mediated lactate influx appeared to 
be lower in TA group (Fig. 17 and Fig. 18) as compared to AA group at all 
external lactate concentrations, but the differences were not statistically significant. 
In addition, a higher Km value was observed in the TA group as compared to the 
AA group in MCT1-mediated lactate influx (Fig. 19). However, no statistical 
difference was observed between two genotypic groups. Nonetheless, the finding 
of this data suggested that T allele may have a defective effect in transport function 
and appear to have a lower transport activity. The data in our study is supported by 
previous study[206]. Recently, the influence of 1470 T>A (Asp490Glu) 
polymorphism in high intensity circuit training has been studied [206]. The authors 
concluded that the carriers of T allele seem to exhibit a lower lactate transport 
activity [206], which is consistent with our finding. This finding contradicts with 
the result obtained using PolyPhen and SIFT algorithms, which predicted the 1470 
T>A (Asp490Glu) polymorphism to be benign. Nishimura and Balch reported that 
a di-acidic signal (asp-x-glu; where x represents any amino acid) on the 
cytoplasmic tail of vesicular stomatitis virus glycoprotein (VSV-G) and other cargo 
molecules is required for selective release from the endoplasmic reticulum [205]. 
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The glutamate residue at position 490 is located in the signal sequence (asp-x-glu; 
aa 488-490) for release from the endoplasmic reticulum when downstream from a 
tyr-x-x-φ motif [205]. Although glutamic acid and aspartic acid are both amino 
acids with similar physical-chemical properties, it is likely that aspartic acid may 
not be as effective as the preferred glutamate. However, as the MCT1 expression 
level on RBC membrane was not quantified in this study, we could not conclude 
that a substitution from glutamate to aspartate at position 490 of MCT1 protein will 
reduce the MCT1 membrane expression, and resulting in lower lactate transport 
activity.  
 
Linkage disequilibrium analysis revealed a complete disequilibrium between the 
1470 T>A (Asp490Glu) and 2917 C>T polymorphisms. Therefore, the genotype 
distribution of 2917 C>T was screened to study the haplotype-phenotype 
association of SLC16A1 gene. The genotyping data revealed that the “T” allele of 
1470 T>A (Asp490Glu) polymorphism was consistently inherited with the “C” 
allele of 2917 C>T variant. From our observation, the ATC haplotype predicted 
from haplotype analysis of SLC16A1 gene (Table 17) may be associated with the 
lower lactate transport activity in the erythrocyte. Therefore, the apparent higher 
Km for this particular ATC haplotype shows that the T allele may be associated 
with the reduced activity of MCT1, which is supported by previous study [206].  
 
The differences found between TA and AA genetic groups were found to be not 
statistically significant. As only ten subjects were recruited in this study, the lack of 
statistical significance may be due to the small sample size. Besides, all the 
subjects recruited in this study were the carriers of A allele (TA or AA genotype). 
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No homozygous wildtype (TT genotype) subjects were identified. As result of it, 
the gene dose effect of TT genotype cannot be examined in this study. Therefore, 
additional studies involving larger samples will be required to establish the clinical 




The main findings of the present study were that 1) low interindividual variations 
were observed in the total lactate influxes and MCT1-mediated lactate influx across 
RBC membrane in the local Chinese population; 2) human MCT1 system exhibited 
a low affinity but high capacity transport mechanism for the transport of lactate 
into RBC; and 3) the T allele of 1470 T>A (Asp490Glu) polymorphism may have a 





















A RANDOMIZED CROSSOVER STUDY TO EVALUATE THE 
POTENTIAL INFLUENCE OF MCT1 AND ITS INHIBITOR, 
DIFLUNISAL, ON THE DISTRIBUTION OF LACTATE  



















The objective of this study was to clinically examine the effect of monocarboxylate 
transporter 1 inhibitor, diflunisal, on lactate distribution in plasma and erythrocyte. 
This was a single-centre, randomized, 2 period crossover drug interaction study 
conducted in 10 healthy adult male volunteers. In this study, a single dose infusion 
of sodium lactate was given to each eligible subject at infusion rate of  
5.6 mg/kg/min for 30 min. A dose regimen of 500 mg of diflunisal or placebo was 
administered to the subjects twice daily 2 days prior to the day of dosing and in the 
morning on the day of dosing. Blood for L-lactate analyses was sampled at 
predose, 10, 20, 30, 40, 50, and 60 min after sodium lactate infusion. We observed 
small differences between placebo RBC and diflunisal RBC lactate levels. The 
RBC:Plasma [La]Diflunisal ratios were constantly lower than RBC:Plasma [La]Placebo 
ratios after 20 min of the onset of infusion. These differences, however, were not 
statistically significant. In conclusion, the results from this study show that 
therapeutic recommended dose of diflunisal is insufficient to inhibit lactate 












5.1 MATERIALS AND METHODS 
5.1.1 Study Design 
This was a single-center (Investigated Medicine Unit, National University Health 
System, designated IMU), randomized, 2 period crossover drug interaction study 
conducted in 12 healthy male volunteers. The subjects were randomly divided into 
two groups: A and B, with 6 in each group. The 12 subjects underwent the 
following treatments in 2 periods:  
 
Period 1: administered a single dose infusion of sodium lactate  
(5.6 mg/kg/min for 30 min). Diflunisal (Apo-Diflunisal, Apotec Inc. Canada,  
500 mg) or placebo was administered to the subjects twice daily 2 days prior to the 
day of dosing and in the morning on the day of dosing.  
 
Period 2: administered a single dose infusion of sodium lactate  
(5.6 mg/kg/min for 30 min). Diflunisal (Apo-Diflunisal, Apotec Inc Canada,  
500 mg) or placebo was administered to the subjects twice daily 2 days prior to the 
day of dosing and in the morning on the day of dosing.  
 
Subjects were asked to fast from all food and drink (except water) for at least 10 
hours prior to dosing with study medication until 1 hour after dosing. Each oral 
medication was administered with 250mL of water.  Subjects were asked not to 
break, crush, or chew the diflunisal tablet before swallowing. Blood samples were 
collected at regular intervals as indicated in Table 47 and Table 48.  A washout 
period of 7 days was incorporated between the study periods to avoid the influence 
of previously administered drug(s).  
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Table 48. Study Plan- Period 2 
 
  
Subject admission / 
Pretreatment Pharmacokinetic study duration 
Final 
evaluation 
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5.1.2 Subject Selection 
Twelve male healthy volunteers aged 32.5  4.5 years old (mean  s.d.) and 
weighing 78.3  6.8 kg (mean  s.d.) entered the study. One subject was dropped 
from the study due to medical condition (high blood pressure). Another subject was 
excluded from analysis due to blood clotting which affected the actual lactate 
concentration. Hence, a total of 10 subjects were included in the study. All were 
nonsmokers with no history of serious illness. Subjects with a medical history of 
psychiatric disorders or allergy to diflunisal and other NSAIDs were excluded from 
the study. Their health to be judged to be normal following a physical examination 
and routine biochemical tests of hepatic and renal function. No medications were 
permitted for at least 2 weeks immediately before and during each study period. 
The volunteers were also told to abstain from alcohol 48 hours before and 
throughout the study period. The study was approved by the DSRB, National 
Healthcare Group. The written informed consent was obtained from each subject 
prior to the study. For the inclusion/exclusion criteria and other details of the trial, 
please refer to the full clinical study protocol in Appendix II.  
 
5.1.3 Sample Size Calculations 
A total of twelve subjects were recruited in this study. The sample size was 
calculated based on a 80% power analysis estimates that a minimum number of 
N=8 is required to detect a minimum difference of 30% in plasma, whole blood 
and RBCs lactate levels (mean plasma lactate = 16.7 ± 3.81 mmol/l; mean 
erythrocyte lactate = 8.0 ± 2.42 mmol/l; mean whole blood lactate = 12.4 ± 2.42 
mmol/l), at a level of significance of p=0.05. In case of discontinuing, loss to 
277 
 
follow-up, or any other cause for the subjects not to accomplish this study, the 
number of subject was increased to N=12.  
 
5.1.4 Blood Sampling  
Blood for L-lactate analyses was sampled at predose, 10, 20, 30, 40, 50, and 60 min 
after sodium lactate infusion (Table 36 and Table 37). For each pharmacokinetics 
time point, 10 ml of blood was drawn into 3 heparinized tubes. Blood sample were 
immediately submerged in ice-ethanol slurry (-20C) for 60 seconds and then 
placed on ice (Note: The equilibration of L-lactate across the erythrocyte occurred 
quickly at 37C (~10 minutes), but the equilibration is greatly slowed at 0C, 
taking as long as 100 hours). One tube of blood sample was centrifuged at 4000 
rpm for 10 min at 4C. We transferred 100 L of plasma, erythrocyte and whole 
blood to each of the Eppendoft tubes containing 400 L of Lactate Assay Buffer 
(BioVision, Mountain View, CA, USA). The lyzed samples were transferred to a 
10kD spin column (Merck Millipore, Billerica, Massachusetts, USA) and spun at 
4000 rpm for 10 min at 4C. The plasma, whole blood and erythrocyte extracts 
were sent immediately for lactate analysis.  
 
5.1.5 Lactate Analysis 
Lactate concentrations were measured in duplicate using a lactate kit (BioVision, 
Mountain View, CA, USA). The test samples were prepared at 50 L per well with 
Lactate Assay Buffer in a 96-well plate. 10 L of sample was added into each well 
individually and the volume was adjusted to 50 L per well. For each well, 
Reaction Mix (containing 46 L Lactate Assay Buffer, 2 L Lactate Substrate Mix 
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and 2 L Lactate Enzyme Mix) was added and mixed well. The reaction mix was 
incubated for 30 min at room temperature and measured at OD 450 nm wavelength 
using Quant Universal Microplate Spectrophotometer (ITS). The background was 
corrected by subtracting the value derived from the zero lactate control and 
calculated the lactate concentrations of the test sample using the formula:  
C = La/Sv * D (nmol/µL or mM) 
 
Where: La is the lactate amount (nmol) of test sample from standard curve. 
  Sv is the sample volume (µL) added into the well. 
  D is the dilution factor.  
 
5.1.6 Statistical analysis 
Unless otherwise indicated, all data are expressed as mean  SEM. Student’s t-test 
was used to determine the significance of differences between placebo and 













5.2.1 Plasma and Erythrocyte Lactate Levels 
Figure 13 shows the mean concentration of plasma and erythrocyte lactate over 
time in response to exogenous lactate infusion in ten subjects pre-treated with 
diflunisal or placebo. For the plasma and erythrocyte lactate level of individual 
subjects, please refer to Appendix III. An exogenous lactate infusion rate of  
5.6 mg/kg/min was given to each eligible subject for 30 minutes. As shown in          
Fig. 21 the plasma and erythrocyte lactate levels were elevated from the start of 
infusion and reached maximum at 30 minutes, and gradually returned to normal 
resting level at 60 minutes after the start of lactate infusion. The mean lactate level 
was statistically significantly elevated from 1.00 to 2.31 mmol/L H2O-1 in placebo 
plasma, 1.05 to 2.32 mmol/L H2O-1 in diflunisal plasma, 0.80 to 1.65 mmol/LH2O-1 
in placebo RBC and 0.76 to 1.59 mmol/L H2O-1 in diflunisal RBC. No significant 
differences were observed between the plasma lactate levels of placebo- and 
diflunisal-treated groups (Table 49). The difference between the RBC lactate levels 
of placebo- and diflunisal-treated groups is not statistically significant different at 
all time points except at 60 min (Table 49).  
 
The plasma and erythrocyte AUC0-1h values were calculated by trapezoidal rule 
integration (Fig. 22 and Table 50). There were no significant alterations in the 
plasma AUC0-1h values between the placebo and diflunisal groups (111.9 ± 5.04 vs. 
111.4 ± 1.17). The value of RBC AUC0-1 hr  in the placebo-treated group is slightly 
higher than the AUC0-1 hr  of the diflunisal-treated group (85.30 ± 2.92 vs.             
82.20 ± 6.53). This difference, however, is not statistically significant. The mean 
peak plasma and RBC concentration was occurred at 30 min after the onset of 
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lactate infusion for both placebo-treated and diflunisal-treated groups (Table 50). 
The peak plasma concentration was not significantly altered in the diflunisal-
treated group as compared to the placebo-controlled group. Similarly, no difference 
















































Figure 21. The plasma and RBC compartmental profiles (mean ± S.E.M.) of L-lactate  in 
the subjects pretreated with placebo and diflunisal during lactate infusion (0 to 30 min) 
and during recovery (30 to 60 min) The mean plasma and RBC lactate levels were 
significantly increased above the rest value (zero time point) at 30 min in placebo and 
diflunisal groups. The statistical comparison was performance using paired student’s t-test 
(Table 49).The mean plasma lactate concentration values were not significantly different 
between two treatment groups at all time points. The mean RBC lactate concentration 
values were not significantly different between two treatment groups at all time points 
except at 60 min. Values are presented as mean  SEM. 
 
 
Table 49. The paired t tests were performed to test for the effect of diflunisal in L-lactate 
distribution in plasma and RBC. The statistical significance was defined as p<0.05. 
 
  Placebo versus Diflunisal 
Time point (min) 0 10 20 30 40 50 60 
Plasma  0.6370 0.8013 0.5745 0.8996 0.6310 0.4184 0.9023 





































Figure 22. The total area under the curve (AUC) of plasma and RBC lactate levels in the 
subjects pretreated with placebo and diflunisal. The plasma and RBC values were not 
significantly different between two treatment groups. Values are represented as            












Table 50. Pharmacokinetic parameters for L-lactate in placebo- and diflunisal-treated 
groups (mean ± S.E.M) 
 
 Placebo plasma Diflinisal plasma Placebo RBC Diflunisal RBC 
AUC0-1 hr  (mmol/L H2O-1 Hr) 111.9 ± 5.04 111.4 ± 1.17 85.30 ± 2.92 82.20 ± 6.53 
Cmax (mmol/L H2O-1) 
2.300 ± 0.105 2.320 ± 0.114 1.660 ± 0.096 1.580 ± 0.191 





























































5.2.2 Plasma to RBC Lactate Ratio 
Figure 23 shows the ratio of plasma to erythrocyte lactate over time in response to 
exogenous lactate infusion in ten subjects pre-treated with diflunisal or placebo. 
The RBC:Plasma [La]Placebo ratio was relatively constant throughout the infusion 
and recovery period (ranging from 0.72  0.07 to 0.82  0.06 ). The RBC:Plasma 
[La]Diflunisal ratio was lower than the RBC:Plasma [La]Placebo ratio at rest (zero time 
point). However, the RBC:Plasma [La]Diflunisal ratio elevated above the RBC:Plasma 
[La]Placebo ratio at 10 minutes and decreased again and eventually dropped below 
the RBC:Plasma [La]Placebo ratio at 30 minutes. Although the RBC:Plasma 
[La]Diflunisal ratio was constantly lower than the RBC:Plasma [La]Placebo ratio at all 
time points except 10 and 20 min, the differences were not statistically significant 
for all time points (Table 51).                     


























Figure 23. Plasma to RBC lactate ratio during exogenous lactate infusion (0 to 30 min) 
and during recovery period (30 to 60 min). The differences were not statistically 




Table 51. The paired t tests were performed to analyze the differences of plasma to RBC 
lactate ratio between placebo and diflunisal groups. The statistical significance was 
defined as p<0.05. 
 
  Placebo versus Diflunisal 
Time point (min) 0 10 20 30 40 50 60 
p-value 0.0977 0.6522 0.8262 0.3785 0.2717 0.2294 0.2277 
Significant different? 
(P < 0.05) 












The bulk of evidence suggests that lactate is an important intermediary in 
numerous metabolic processes. It was previously considered as the dead-end waste 
product of glycolysis [233], the primary cause of the O2 debt following exercise 
[234], a major cause of muscle fatigue [146], and a key factor in acidosis-induced 
tissue damage. However, the role of lactate has been redefined since the 
introduction of the lactate hypothesis by George Brooks [235]. The bulk of 
evidence suggests that lactate is an important mobile fuel for main organs (such as 
heart, active muscle and brain) and is also involved in the process of wound repair 
and regeneration.  
 
The blood constitutes a key component in the lactate shuttle because of its role in 
distributing lactate throughout the body’s different tissues. During exercise, lactate 
is transported out from the active muscle into the plasma. From plasma, lactate is 
further transported into the red cell compartment and subsequently distributed to 
different tissues in the body. Given that the MCT1-specific carrier system has been 
shown to be the predominant route for lactate transport in human erythrocytes, any 
impairment in MCT1 activity may have far-reaching consequences. The defect in 
MCT1 transport activity could be due to genetic variations or blocking of transport 
function by inhibitors. In fact, the defect in MCT1 has been associated with lactate 
transport deficiency in red cells and muscle tissues by Fishbein back in 1986 [171]. 
Although several potent MCT1 inhibitors have been reported [109, 110, 236], the 
in vivo effects of these inhibitors have not been investigated. Therefore, it will be 
beneficial to clinically examine the physiological effect of MCT1-mediated lactate 
influx from plasma to erythrocyte.  
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5.3.1 The influence of diflunisal on L-lactate distribution in blood 
In this study, the in vitro inhibitory effects of several pharmaceutical and dietary 
compounds were investigated (Table 38 and Fig. 10). Of which, diflunisal 
exhibited potent inhibitory effect and therefore was chosen as the inhibitor to block 
RBC lactate influx. It was hypothesized that diflunisal will block the in vivo          
L-lactate influx into human erythrocytes and therefore confer higher plasma         
L-lactate and lower erythrocyte L-lactate concentrations (Fig. 24 ). The new 
information provided by the present study consists of the lactate concentration of 
the plasma versus RBC fractions of the blood during exogenous L-lactate infusion 
with or without the influence of MCT1 inhibitor, diflunisal.  
 
 
Figure 24. The illustration figure of diflunisal in inhibiting the L-lactate influx into human 
RBC.  It is hypothesized that diflunisal will block the influx of L-lactate into human RBC 





In this study, a single dose infusion of sodium lactate was given to each eligible 
subject at infusion rate of 5.6 mg/kg/min for 30 minutes. The plasma lactate level 
was expected to increase to approximately 3-4 mmol/L H2O-1 based on the 
reference provided for several studies. However, the plasma lactate level was only 
increased by up to approximately 2.3 mmol/L H2O-1 in both groups. This could be 
due to the difference in the infusion period. In the study done by van Hall et al., the 
subjects were given sodium lactate intravenous infusion at infusion rate of           
5.6 mg/kg/min for 20 minutes, followed by infusion of 4.3 mg/kg/min for another 
100 min. However, an infusion rate of 30 instead of 120 minutes was selected in 
this study because we were concerned that the infusion may cause discomfort and 
the amount of sodium lactate infused may increase the blood pressure of the 
subjects. Besides, the previous studies were designed for athletes who are 
physically trained. Therefore, a mild infusion rate was selected for the safety of the 
subjects. Nonetheless, the plasma lactate concentrations were significantly 
increased and reached maximum at the end of infusion (30 minutes) in both 
treatment groups (Fig. 21). 
 
In this study, diflunisal was used to block MCT1 activity. A dose regimen of  
500 mg was selected based on an assumption that the mean diflunisal plasma 
concentration following administration of 500 mg single oral dose is sufficient to 
inhibit MCT1 transport activity. Diflunisal exhibits a strong inhibitory effect on the 
uptake of L-lacate with a Ki value of 29.56 M, which is equivalent to 7.4 g/ml 
(Table 39). A pharmacokinetics study of diflunisal indicated that the peak plasma 
concentration of diflunisal is 87 g/mL following a single 500 mg oral dose. A 
dose regimen of 1000 mg daily in divided doses has been approved for 
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maintenance therapy of rheumatoid and osteoarthritis. Therefore, a 1000 mg daily 
regimen was selected in order to achieve the maximum suppression on MCT1 
activity.  
 
We expected to see a decrease in RBC:Plasma [La] ratio in the diflunisal treatment 
group. As diflunisal blocks MCT1 activity, this will prevent lactate from entering 
RBCs. Consequently, the plasma lactate may increase as the influx into RBCs is 
blocked. In this study, we did not observe a higher plasma lactate level in the 
diflunisal group (Fig. 22). The diflunisal plasma lactate levels were not 
significantly different from the placebo plasma lactate levels at all time points   
(Fig. 21 and Table 49). However, we observed small differences between placebo 
RBC and diflunisal RBC lactate concentrations. The diflunisal RBC lactate levels 
were constantly lower than placebo RBC lactate levels after 20 min of the onset of 
infusion. However, these differences were not statistically significant at all time 
point except at 60 minutes. The RBC:Plasma [La]Diflunisal ratio was lower than the 
RBC:Plasma [La]Placebo ratio at rest (zero time point). But the RBC:Plasma 
[La]Diflunisal ratio elevated above the RBC:Plasma [La]Placebo ratio at 10 minutes and 
decreased again and eventually dropped below the RBC:Plasma [La]Placebo ratio at 
30 minutes (Fig. 23). These differences, however, were not statistically significant 
(Table 51).  
   
Although diflunisal has been reported as a potent MCT1 inhibitor and its inhibitory 
effect is achievable at clinically relevant concentrations, we did not observe a 
significant inhibitory effect in this study. To some extent, this finding is not 
unexpected. As diflunisal is highly protein bound in the plasma, the unbound 
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plasma concentration of diflunisal may be below its Ki value and therefore 
insufficient to inhibit lactate transport on RBC. The main limitation of this study is 
that the plasma diflunisal concentration was not quantified. Therefore, we could not 
conclude that the negative finding is due to insufficient unbound diflunisal 
concentration in the plasma.  
 
The sample size was calculated based on a 80% power analysis estimates that a 
minimum number of N = 8 is required to detect a minimum difference of 30% in 
plasma, whole blood and RBCs lactate levels (mean plasma lactate = 16.7 ± 3.81 
mmol/l; mean erythrocyte lactate = 8.0 ± 2.42 mmol/l; mean whole blood lactate = 
12.4 ± 2.42 mmol/l) [237]. It is possible that this is an overestimation of the actual 
inhibitory effect of diflunisal on the transport activity of human MCT1 in vivo. 
Nonetheless, the 30% change in RBC plasma level may be apparent if the sample 
size is increased. In this study, an infusion period of 30 minutes instead of 120 
minutes was selected because we were concerned of the safety of the subjects. This 
infusion rate might be too short and the extending of the infusion period could have 
caused a positive result. Last but not least, there might be another rescue pathways 
or transporters that mediating L-lactate transport into human erythrocyte when the 
MCT1 pathway is blocked. Therefore, the observed inhibitory effect of diflunisal 
on human MCT1 activity is smaller. 
 
In this study, the PCR amplification of three subjects was unsuccessful despite 
several attempts were made to purify and improve the DNA quality. Therefore, the 
effect of 1470 T>A (Asp490Glu) was not examined in this study because it is 
likely that power may have limited the interpretation of key findings when n = 7.  
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Several potent MCT1 inhibitors have been identified in our lab. These inhibitors, 
namely diclofenac, meclofenamic acid and tolfenamic acid have stronger inhibitory 
effects than diflunisal (Table 38). The peak plasma level of diclofenac achieve 
from multiple doses (oral 50 mg was administered 3 times daily for 7 days) was  
2.3 g/mL [218], while the Ki value of diclofenac is 6.17 M (~1.96 g/mL). 
Although the inhibitory concentration of diclofenac is achievable from the oral 
intake, the peak plasma concentration is only slightly higher than its Ki value. 
Therefore, diclofenac was not selected in this study. Meclofenamate and 
tolfenamate were not selected as study drugs because these inhibitors had only 
been identified a few weeks before the initiation of the trial. However, these two 
inhibitors can be considered as potential MCT1 inhibitors for future studies.   
 
The second objective of the study was to evaluate the impact of the genetic 
variation in SLC16A1 gene on the distribution of lactate and on drug interaction 
with diflunisal. However, the genotyping was unsuccessful in three out of ten 
subjects due to the substandard quality of DNA samples. Therefore, the genotype-












In conclusion, the results from this study show that therapeutic recommended dose 
of diflunisal was insufficient to inhibit lactate transport on RBC. The reason for 
this may due to high protein binding property of diflunisal. The unbound plasma 
concentration of diflunisal may be below its Ki value and therefore insufficient to 
inhibit lactate transport on RBC. However, this assumption cannot be verified 
because the plasma diflunisal level was not measured in this study. Nevertheless, 
we observed small differences between placebo RBC and diflunisal RBC lactate 
levels. The RBC:Plasma [La]Diflunisal ratios were constantly lower than RBC:Plasma 
[La]Placebo ratios after 20 min of the onset of infusion. These differences, however, 













































The monocarboxylate transporter 1 and 4 mediate the transport of metabolically 
important monocarboxylates, such as lactate, pyruvate and butyrate. Given that 
MCT1 and MCT4 have been implicated in lactate shuttle transport, any impairment 
in transport activity may have far reaching consequences. The changes in 
transporter kinetics (e.g. genetic polymorphisms, food/drug-transporter interactions 
and disease-altered expression) may potentially lead to large shifts in the efficacy-
toxicity relationship of a drug. Therefore, the impacts of pharmacogenetics and 
food/drug-transporter interactions on monocarboxylate transports were examined in 
this study. A summary of findings was summarized in Table 52.  
 
For the past decades, no significant progress has been made in the discovery of 
MCT1 and MCT4 polymorphisms and the assessment of allelic frequencies. 
Therefore, the first objective of this project was therefore to describe the genetic 
polymorphism in the promoter, exons, and exon-intron junctions of SLC16A1 and 
SLC16A3 genes that may be present in the ethnic Chinese and Indian groups of 
Singapore population. To our knowledge, this is the first report on the 
comprehensive analysis of SLC16A1 and SLC16A3 genes in any population. 
Although genotyping were carried out on both SLC16A1 and SLC16A3 genes, this 
thesis focuses only on the functional characterization of MCT1.  
 
A total of 21 genetic variations, including 14 novel ones, were found in SLC16A1 
gene. Of the 3 nonsynonymous variants, only 303T>G (Ile101Met) was predicted 
by PolyPhen and SIFT as having a potentially damaging effect on protein function, 
whereas 1282 G>A (Val428Ile) and 1470 T>A (Asp490Glu) were speculated to be 
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benign. Three reported SNPs, namely IVS3-17A>C, 1470T>A (Asp490Glu) and 
2917(1414) C>T are the common polymorphisms found in the coding region of 
SLC16A1 gene in Chinese and Indian populations. Linkage disequilibrium analysis 
revealed strong association between these common variants in both ethnic groups.  
 
A total of 46 genetic variants were detected in SLC16A3 gene, of which 33 are 
novel. Of the 5 nonsynonymous variants, only 44C>T (Ala15Val) was predicted by 
PolyPhen and SIFT as having a potentially damaging effect on protein function, 
whereas 55G>A (Gly19Ser), 574G>A (Val192Met) and 916G>A (Gly306Ser) had 
conflicting results between the SIFT and PolyPhen algorithms. Finally, 641C>T 
(Ser214Phe) was predicted to be tolerated variant. 
 
MCT1 is the only MCT isoform found in the human erythrocyte and contributes up 
to 90% of lactate influx. In this study, we examined the interindividual variation in 
total and MCT1-mediated lactate influx into human erythrocytes in local Chinese 
population. However, low interindividual variability was observed in the total and 
MCT1-mediated lactate influx. In the MCT-1 mediated lactate influx, the apparent 
Km and Vmax were 220.1±35.33 mM and 15877±968.1 nmol/ml of RBC/min, 
respectively. The finding of this study suggests that lactate transport across human 
erythrocyte membrane is low affinity but high capacity transport process. We have 
previously genotyped the MCT1 gene in the ethnic Chinese and Indian groups of 
Singapore population and a common nonsynonymous polymorphism, 1470 T>A 
(Asp490Glu) had been identified in MCT1 gene. With knowledge that MCT1 is 
responsible for up to 90% of lactate influx into RBC, it would be intriguing to 
correlate the in vitro uptake assay with the MCT1 polymorphism. The findings of 
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this study suggest that T allele of 1470 T>A (Asp490Glu) may have a defective 
effect in transport function and appear to have a lower transport activity. However, 
additional studies involving larger samples are required to verify the impact of 
1470 T>A (Asp490Glu) polymorphism in MCT1 transport activity.  
 
The diet-interaction via MCT1 inhibition may affect lactate shuttling and drug 
disposition. Therefore, the effects of various dietary and pharmacological agents on 
MCT1 were evaluated. Of these, diflunisal, diclofenac, mefenamic acid, 
meclofenamic acid, tolfenamic acid, luteolin, etodalac, phloretin and morin were 
the most potent with IC50 values of 40.24  1.10, 1.33  1.17, 11.83  1.24, 9.68  
1.10, 5.95  1.12, 2.71  1.28, 13.30  1.06, 47.98  1.11 and 44.53  1.08M, 
respectively. The inhibitory concentrations of tested NSAIDs (diflunisal, 
mefenamic acid, meclofenamic acid, flufenamic acid and tolfenamic acid) are in 
the range of physiologically relevant concentrations that are achievable from the 
oral intake. However, due to high protein binding of the tested NSAIDs, the actual 
unbound plasma concentrations of tested NSAIDs may be below the Ki values 
reported in this study. The tested NSAIDs may not contribute significantly to the in 
vivo inhibition of MCT1 activity. Therefore, we examined the inhibitory effects of 
NSAID on MCT1 in vivo.  
 
The fourth objective of this study was to clinically examine the effect of MCT1 
inhibitor, diflunisal, on lactate distribution in plasma and erythrocyte. We observed 
small differences between placebo RBC and diflunisal RBC lactate levels. The 
RBC:Plasma [La]Diflunisal ratios were constantly lower than RBC:Plasma [La]Placebo 
ratios after 20 min of the onset of infusion. These differences, however, were not 
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statistically significant. In conclusion, the results from this study show that 
therapeutic recommended dose of diflunisal is insufficient to inhibit lactate 
transport in blood. The reason of this may due to high protein binding property of 
diflunisal, short lactate infusion period and the presence of rescue pathways that 
mediating lactate influx into human erythrocyte when MCT1 pathway is inhibited. 
Nonetheless, the findings of this study will increase our understanding of the 





















Table 52. Summary of data  
PHARMACOGENETICS OF TRANSPORTER 
Objective  Summary of data 
 
Population genetics studies 
in SLC16A1 and SLC16A3 
 
SLC16A1 (MCT1) 
 A total of 21 genetic variations were found, of which 
14 are novel 
 
 Three nonsynonymous variants were found 
 303 T>G (Ile101Met) - predicted as having 
detrimental effect 
 1282 G>A (Val428Ile) - predicted to be benign 
 1470 T>A (Asp490Glu) - predicted to be benign 
 
 Genotyping data was in accordance to HWE for all 
loci, except for -363-100 C>G  
 
 LD analysis revealed strong association between three 
common polymorphism, namely IVS3-17A>C, 
1470T>A (Asp490Glu) and 2917(1414)C>T in both 




 A total of 46 genetic variants were detected, of which 
33 are novel 
 
 Five nonsynonymous variants were found 
 44C>T (Ala15Val) 
 55G>A (Gly19Ser) 
 574G>A (Val192Met) 
 916G>A (Gly306Ser) 
 641C>T (Ser214Phe) 
 
 Genotyping data was in accordance to HWE for all 
loci, except for IVS2-149 G>T 
 
 Three common SNPs, namely -139-1105 C>T, -139-
804 C>T and -139del(-727-795), were detected in the 
promoter region of transcript variant 2 
 
 
 Three common polymorphisms, namely -118-554 A>T, 
-118-130 A>C and -86 A>G were detected in the 






















association of MCT1 
polymorphism, 1470 T>A 
(Asp490Glu)  
 
 Low interindividual variability was observed in the 
total- and MCT1-mediated L-lactate into human 
erythrocytes 
 
 Human MCT1 system exhibited a low affinity but high 
capacity transport mechanism for the transport of L-
lactate into RBC 
 Km = 123.9 ± 24.6 mM 
 Vmax = 12079.0 ± 722.3 nmol/ml of RBCs/min 
 
 
 The total and MCT1-mediated L-lactate influxes are 
lower in TA group as compared to AA group at 2, 5, 10 
and 20 mM of external L-lactate concentrations 
 
 The differences found between TA and AA genetic 
groups are not statistically significant 
 
 The T allele of 1470 T>A (Asp490Glu) variant may 
have a defective effect in MCT1 protein function and 
appear to have a lower transport activity 
 
DRUG/FOOD-TRANSPORTER INTERACTION 
Objective  Summary of data 
 
Biochemical kinetic studies 
of MCT1 
 
 MCT1 is a low affinity high capacity process for the 
transport of L-lactate into human erythrocytes  
 Km = 123.9 ± 24.6 mM 
 Vmax = 12079.0 ± 722.3 nmol/ml of RBCs/min 
 
 Several MCT1 inhibitors have been identified 
 NSAID: diflunisal, diclofenac, mefenamic acid, 
meclofenamic acid, flufenamic acid, tolfenamic 
acid, etodalac 
 Phytochemical: luteolin, phloretin and morin  
 
 Five NSAIDs are in the range of physiologically 
relevant concentrations that are achievable from the 
oral intake 
 diflunisal, diclofenac, mefenamic acid, 





Clinical study of MCT1 
 
 At rest, no significant differences were observerd in the 
RBC:Plasma lactate ratio between placebo and 
diflunisal group  
 Placebo = 0.82±0.09  
 Diflunisal = 0.75±0.09  
 




placebo RBC lactate level after 20 min of the onset of 
infusion. These differences were not statistically 
significant 
 
 The RBC:Plasma [La]Diflunisal ratio was constantly 
lower than the RBC:Plasma [La]Placebo ratio at all 
time points except at 10 and 20 min. The differences 
were not statistically significant for all time points 
 
 The results from this study show that therapeutic 
recommended dose of diflunisal was insufficient to 

















































7.1 FUTURE DIRECTIONS 
We hope that this study has shed some light on the functional implications of the 
pharmacogenetics of monocarboxylate transporter and the role of such transporters 
in drug actions. For future work, it would be intriguing to characterize functional 
effects of MCT1 and MCT4 variants reported in this study.  Although the 
relationship of  a MCT1 variant, 1470 T>A (Asp490Glu), with erythrocyte activity 
has been investigated in this study, additional studies involving larger sample sizes 
will be required to establish the clinical impact of this variant in MCT1 transport 
kinetics. Three reported SNPs, namely IVS3-17 A>C, 1470 T>A (Asp490Glu) and 
2971 (1414) C>T are the common polymorphisms found in the coding region of 
SLC16A1 gene in Chinese and Indian populations. Haplotype estimation shows that 
haplotype ATC was most common in both ethnic groups. Therefore, haplotype-
phenotype analysis can be performed to investigate the relationship of ATC 
haplotype in MCT1 transport activity. 
 
Although population genotyping were performed on both SLC16A1 and SLC16A3 
gene, this thesis focuses only on the functional characterization of MCT1. 
Therefore, more work can be done to clarify the transport kinetics of MCT4 and the 
effects of various potential inhibitors on its transport activity. There are several 
challenges in constructing the MCT4 functional assay model: 1) absence of cell-
lines which have little or no background activity of other MCT isoforms; 2) absence of 
MCT isoform-specific substrates; and 3) absence of MCT isoform-specific inhibitors. 
A suitable model is therefore necessary to characterize the functional consequence of 




The influence of MCT1 inhibitor, diflunisal, on lactate distribution in human 
plasma and erythrocyte has been investigated. Although there were small 
differences in RBC lactate level between placebo- and diflunisal- treated groups, 
these differences were not statistically significant. One of the most probable 
explanations could be the insufficient power of the study. In addition, an infusion 
period of 30 minutes might be too short to detect differences. Therefore, a clinical 
study with larger sample size and longer infusion period can be designed to further 
investigate the clinical impact of diflunisal on MCT1 activity. In the current study, 
two potent inhibitors, meclofenamate and tolfenamate, were recognized. 
Meclofenamate and tolfenamate have more potent inhibitory effect than diflunisal 
(Table 39). These two inhibitors were not selected as the study drug because they 
had only been identified a few weeks before the initiation of the trial. Nonetheless, 
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APPENDIX II.  
ADMINISTRATIVE INFORMATION 
Protocol Title: A Randomized Crossover Study to Evaluate the Potential Influence 
of MCT1 and Its Inhibitor, Diflunisal, on the Distribution of Lactate in Plasma, 
Whole Blood and Erythrocyte in Healthy Male Adults. 
Protocol Number: PGL2009MCT1 
Development Phase: Not Applicable 
Investigational drug name: Sodium Lactate, Diflunisal  
Primary Study Contact: 




















Protocol Synopsis  
Protocol Title: An Randomized Crossover Study to Evaluate the Potential 
Influence of MCT1 and Its Inhibitor, Diflunisal, on the Distribution of Lactate in 
Plasma, Whole Blood and Erythrocyte in Healthy Male Adults. 
Principal Investigator  
Edmund JD Lee 
Professor 
Pharmacology Department / Pharmacogenetics Laboratory  
National University of Singapore, Singapore 
Study centre, type and number of subjects planned 
12 healthy male subjects will be enrolled at a single study centre (Investigational 
Medicine Unit, National University Health System, designated IMU).  
Study period                                                                          
Estimated date of first subject enrolled     Beginning of March 2011           
Estimated date of last subject completed         End of June 2011        
Phase of development  














The primary objectives of the study are to evaluate the potential influence of MCT1 
and its Inhibitor, diflunisal, on the distribution of lactate in plasma, whole blood 
and erythrocyte. The secondary objectives of the study are to evaluate the impact of 
the genetic variation in MCT1 on the distribution of lactate and on the drug 
interaction with diflunisal. 
Study design 
This will be a single-center, randomized, 2 periods crossover drug interaction study 
conducted in 12 healthy adult male volunteers. Twelve subjects will be randomly 
divided into two groups: A and B, with 6 in each group. The 12 subjects will 
undergo the following treatments in 2 periods: in Period 1: Single dose infusion of 
sodium lactate (5.6 mg/kg/min for 30 min) + Diflunisal (500 mg) multiple oral 
doses to group A subjects; Placebo multiple oral does to group B; in Period 2: the 
two groups will be crossed over. Blood samples will be collected at regular interval 
and will be analyzed for the study drug by validated methods. Post hoc 
examination of polymorphisms in SLC16A1 (MCT1) gene and possibly others will 
be conducted. 
Investigational product, dosage and mode of 
administration 
Each subject will undergo the following treatments in 2 periods in the following 
sequence: 
Period 1: be administered a single dose infusion of sodium lactate (5.6 mg/kg/min 
for 30 min). Diflunisal (Apo-Diflunisal, Apotec Inc Canada, 500 mg) or placebo 
will be administered to the subjects twice daily 2 days prior to the day of dosing 
and in the morning on the day of dosing.  
Period 2: be administered a single dose infusion of sodium lactate (5.6 mg/kg/min 
for 30 min). Diflunisal (Apo-Diflunisal, Apotec Inc Canada, 500 mg) or placebo 
will be administered to the subjects twice daily 2 days prior to the day of dosing 
and in the morning on the day of dosing.  
Duration of treatment 
This will be a single-centre, randomized, 2 periods, drug-interaction study. A 
washout period of 7 days is incorporated between the study periods. 
Outcome variables 
- Pharmacokinetic  
The primary endpoint for the study will be the plasma and erythrocyte lactate 
distribution in the absence or presence of diflunisal. 
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- Pharmacogenetics  
Blood samples will be obtained from each subject and will be used to study genetic 
polymorphisms of monocarboxylate transporter 1 (MCT1, SLC16A1). Post hoc 
examination of polymorphisms in this gene will be conducted using DNA extracted 
from all the participants for pharmacokinetic study. 
1. Introduction 
1.1 Background  
Monocarboxylate transporter 1: The monocarboxylate transporter (MCT) family 
currently comprises 14 members, but only the first 4 members (MCT1-MCT4) 
have been experimentally proven to mediate the transportation of metabolically 
important endogenous monocarboxylates such as pyruvate, lactate, acetate and 
ketone bodies (1-2). These monocarboxylate anions are transported across the 
plasma membrane via active or facilitated transporter down their concentration 
gradients due to their highly charged chemical structures. MCT1 is the first 
member of the family and it is found in the great majority of tissue including 
skeletal muscle, brain endothelium (blood-brain barrier (BBB)), intestine, 
erythrocyte and heart (2-3). MCT1 plays a very vital role in the energy metabolism 
and pH regulation of the cells and its impairment might provide an explanation for 
some pathophysiological conditions.  
MCT1, together with other MCTs, are involved in the pH regulation and 
metabolism of the cells. As large amounts of lactic acid are constantly produced in 
anaerobic glycolytic tissues (such as white skeletal muscle, red blood cells and 
tumor cells), the efflux of lactic acid must keep pace with its production to prevent 
a drop in intracellular pH (1-2). In other tissues (such as red skeletal muscle, brain 
and heart), lactic acid is transported into the cell and is utilized as a respiratory fuel 
(1-2). This cell-to-cell lactate shuttle hypothesis has been proposed in at least 4 
tissues- skeletal muscle, brain, retina and testis (4). The overall pattern of lactate 
transport is quite similar in the aforementioned tissues, by which the organ is 
subdivided into glycolytic and oxidative cell types, with the latter cell type utilizing 
the “waste products” produced by the former cell type as energy source. This 
mechanism provides the most efficient energy utilization and therefore is adapted 
by tissues of which energy demand is high. 
It is now clear that lactate is an intermediary in numerous metabolic process, a 
mobile fuel for aerobic metabolism, and perhaps a mediator for redox state among 
various compartments both within and between cells (5). Blood (both plasma and 
RBCs) constitutes a key component in the lactate shuttle because of its role in 
distributing lactate throughout the body’s different tissues. Plasma carries ~70% of 
the lactate released from muscle lactate output and RBCs provides an additional 
space for translocation ~30% of lactate and hydrogen ions from the plasma (6). 
Transport of these metabolites away from the exercising muscle and into the blood 
by the MCT pathway may reduce the potential for muscle acidosis and fatigue. 
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Lactic acid exists predominantly in the form of lactate at physiological pH due to 
its low pKa value. Lactic acid may diffuse across the cell membrane, but, for the 
transport of lactate anion, a transporter is required. In mammalian erythrocytes, 
three parallel pathways of lactate influx are present: 1) noninonic diffusion of the 
undissociated acid; 2) inorganic-anion exhange system; and 3) monocarboxylate-
specific carrier system (7-9). The significance of each of these pathways with 
regard to lactate transport is known to vary among species(9-10). Interestingly, the 
monocarboxylate-specific carrier system has been shown to be the predominant 
route for lactate influx in human erythrocytes and MCT1 has been shown to be the 
only monocarboxylate transporter expressed in human RBC (11-12). Therefore, 
any impairment (due to genetic defects or MCT inhibitors) in the activity of MCT1 
is likely to have far-reaching consequences. In fact, the defect in MCT1 has been 
associated with lactate transport deficiency in red blood cells and muscle tissues by 
Fishbein back in 1986 (13). 
1.2 Rationale 
1.2.1 Lactate as a probe substrate for MCT1: Transport of lactate across 
erythrocyte membrane is mediated by MCT1 via a proton-mediated manner 
(1,2,4,7-12). Exogenous lactate infusion had been used in several studies to raise 
the blood lactate levels in human (15-18). Sodium lactate is administered by 
intravenous route as an electrolyte replenisher and systemic alkalizer. Adverse 
effects of sodium lactate are essentially limited to overdosage of either sodium or 
lactate ions. 
1.2.2 Diflunisal as an inhibitor for MCT1: Various NSAIDs have been shown to 
strongly inhibit the MCT1 uptake of benzoic acid in Caco-2 cells and diflunisal 
was shown to be the most potent inhibitor among the tested NSAIDs (19). 
Therefore, diflunisal will be chosen to investigate the impact of MCT1 inhibition 
on drug distribution. 
1.3 Significance 
MCT1 plays a very significant role in the energy metabolism and pH regulation of 
the cells and blood constitutes a key component in the lactate shuttle because of its 
role in distributing lactate throughout the body’s different tissues. It will therefore 
be beneficial to clinically examine the physiological effect of MCT1-mediated 
lactate influx from plasma to erythrocyte. Hence, the purpose of this study is to 
evaluate the potential influence of MCT1 on the distribution of lactate in plasma 
and erythrocyte and the effects of the MCT1 inhibitor, diflunisal, on lactate 
distribution in blood. The results of this study will increase our understanding of 







2. Study Objectives 
2.1 Primary 
The primary objectives of the study are to evaluate the potential influence of MCT1 
and its Inhibitor, diflunisal, on the distribution of lactate in plasma, whole blood 
and erythrocyte. 
2.2 Secondary  
The secondary objectives of the study are to evaluate the impact of the genetic 
variation in MCT1 on the distribution of lactate in blood and on the drug 
interaction with diflunisal. 
3. Study Endpoint(s) 
3.1 Primary  
- Pharmacokinetics 
The primary endpoint for the study will be the plasma and erythrocyte lactate 
distribution in the absence or presence of diflunisal. 
3.2 Secondary 
- Pharmacogenetics  
Blood samples will be obtained from each subject and will be used to study 
specific genetic polymorphisms of monocarboxylate transporter 1 (MCT1, 
SLC16A1). Post hoc examination of polymorphisms in this gene will be conducted 












4. Study Design 
4.1 Overall study design 
This will be a single-center, randomized, 2 periods crossover drug interaction study 
conducted in 12 healthy adult male volunteers. Twelve subjects will be randomly 
divided into two groups: A and B, with 6 in each group. The 12 subjects will 
undergo the following treatments in 2 periods: in Period 1: Single dose infusion of 
sodium lactate (5.6 mg/kg/min for 30 min) + Diflunisal (500 mg) multiple oral 
doses to group A subjects; Placebo multiple oral does to group B; in Period 2: the 
two groups will be crossed over. 
For Period 1, subjects will be admitted to the unit in the evening prior of the 
dosing day and will stay until 2 hours after dosing for the collection of blood 
samples for measurement of drug content (Table 1). 
For Period 2, subjects will be admitted to the unit in the evening prior of the 
dosing day and will stay until 2 hours after dosing for the collection of blood 
samples for measurement of drug content (Table 2). 
Subjects will fast from all food and drink (except water) for at least 10 hours prior 
to dosing with study medication until 1 hour after dosing. Each oral medication 
will be administered with 250mL of water.  Subjects will be asked not to break, 
crush, or chew the diflunisal tablet before swallowing. Blood samples will be 
collected at regular intervals as indicated in Table 1 and Table 2.  A washout period 
of 7 days is incorporated between the study periods to avoid the influence of 
previously administered drug(s). Post hoc examination of polymorphisms in MCT1 
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Review 
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Table 2. Study Plan- Period 2 
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Healthy male aged 21-40 years inclusive. Informed Consent. 
Medical/drug history; Physical examination; Clinical laboratory tests, etc 
12 healthy male subjects 
Twelve subjects will be randomly divided into two groups: A and B, with 6 in each 
group. 
Period 1 
Subjects will be administered single dose infusion of sodium lactate 
(5.6mg/kg/min for 30 min). Subjects in Group A will be given with a oral dose of 
diflunisal (500mg) twice daily 2 days prior to the day of dosing and in the 
morning on the day of dosing; while subjects in Group B will be given with a 
tablet of placebo twice daily 2 days prior to the day of dosing and in the morning 
on the day of dosing. Venous blood sampling through a cannula will be done 
before dosage and at regular intervals after dosing. 
Period 2 
Subjects will be administered single dose infusion of sodium lactate (5.6mg/kg/min 
for 30 min). Group B will be given with a oral dose of diflunisal (500mg) twice 
daily 2 days prior to the day of dosing and in the morning on the day of dosing; 
while subjects in Group A will be given with a tablet of placebo twice daily 2 days 
prior to the day of dosing and in the morning on the day of dosing. The blood 
sampling will be performed before the administration of sodium lactate infusion and 
at regular intervals after sodium lactate infusion. 
7 days washout period
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5. Selection of Study Population 
5.1 Number of subjects 
This study will screen approximately 30 subjects to get enough 12 healthy 
volunteers.  
5.2 Study selection record 
In order to establish that the subject population was selected without bias, a record 
will be kept of subjects who were considered for enrolment and the reasons why 
they were not enrolled will be recorded in the subject screening log. 
5.3 Eligibility criteria  
5.3.1 Inclusion criteria  
1. The subject is healthy, as judged by a responsible physician, with no clinically 
significant abnormality identified on the laboratory or medical evaluation, 
including 12-lead ECG, at screening. A subject with a clinical laboratory or 
laboratory parameter outside the reference range (adjusted for age, if 
appropriate), may be included only if the Investigator considers that the 
abnormal finding does not pose additional risk and will not interfere with the 
study procedures.  
2. Male aged 21-40 years inclusive. 
3. Body weight  50kg (110 lbs) and body mass index (BMI) of 18.5 to 29.9 
kg/m2 inclusive (BMI will be calculated as weight in kg/[height in m2]). 
4. Have normal renal function as evident by a normal creatinine clearance and 
normal serum creatine levels. 
5. The subject is capable of giving informed consent, which includes compliance 
with the requirements and restrictions listed in the consent form.  
5.3.2 Exclusion criteria  
1. A positive urine test for drugs of abuse or alcohol at screening or prior to 
the start of dosing in treatment period 1.  
2. Subjects with a clinical history or current alcohol or illicit drug use which, 
in the opinion of the investigator, would interfere with the subject’s ability 
to comply with the dosing schedule and protocol-specified evaluations.  A 
history of regular alcohol consumption averaging > 14 drinks/week (1 
drink (12 g alcohol) = 5 ounces (150 mL) of wine or 12 ounces (360 mL) 




3. The subject has received an investigational drug or participated in any 
other research trial within 30 days, 5 half-lives, or twice the duration of the 
biological effect of any drug (whichever is longer) prior to the first dose of 
current study medication. 
4. Use of any prescription or non-prescription drugs, vitamins, herbal and 
dietary supplements within seven days (or 14 days if the drug is a potential 
enzyme inducer, such as St. John’s Wort) or 5 half-lives (whichever is 
longer) prior to the first dose of study mediation, unless in the opinion of 
the Investigator and sponsor the medication will not interfere with the 
study procedures or compromise subject safety. 
5. Has a history of regular use of tobacco- or nicotine-containing products 
within 3 months of the screening visit. 
6. Subjects with a pre-existing condition interfering with normal 
gastrointestinal anatomy or motility, hepatic and/or renal function, that 
could interfere with the absorption, metabolism, and/or excretion of the 
study drugs. Examples of conditions that could interfere with normal 
gastrointestinal anatomy or motility include gastrointestinal bypass 
surgery, partial or total gastrectomy, small bowel resection, vagotomy, 
malabsorption, Crohn's disease, ulcerative colitis, intestinal or urinary 
obstruction, or celiac sprue. 
7. History of hypersensitivity to sodium lactate or diflunisal or other 
NSAIDs; or history of drug or other allergy that, in the opinion of the 
physician responsible, contraindicates their participation. 
8. Subjects with a history of clinically significant hepatic disease or hepatic 
dysfunction. 
9. Subjects with congestive heart failure or recently had or will be having 
bypass heart surgery.  
10. Subjects with severe renal insufficiency (with calculated creatinine 
clearance < 60mL/min) and in clinical states in which there exists edema 
with sodium retention. 
11. Subjects with a history of stomach or bowel problems (e.g., bleeding, 
perforation, ulcers). 
12. Subjects with a history of swelling or fluid buildup, asthma, growths in the 
nose (nasal polyps), or mouth inflammation. 
13. Subjects with a history of psychiatric disorder or panic attack. 
14. Subjects with known pancreatitis.   
15. Subjects with bleeding, low platelet count and coagulation problems.  
16. Anuria or oliguria. 
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17. Subjects with anoxia, beriberi or diabetes 
 
6. Study Assessment and Procedures  
6.1 Enrolment procedures 
The screening will take place approximately 28 days before the start of the study. 
Recruitment of volunteers will be executed by the IMU staff of National University 
Health System in compliance with GCP guidelines. Approximately 30 male 
subjects between 21 and 40 years of age will be recruited after providing informed 
written consent. Candidates that satisfy all inclusion/exclusion criteria, pass a 
routine physical examination and have acceptable screening laboratory results will 
be enrolled into the pharmacokinetic study. A final number of 12 healthy male 
volunteers are expected to participate in the study.  
6.2 Screening visit procedures  
Screening will be conducted after the DSRB-approved informed consent has been 
signed but within the 28 days preceding study drug administration. Each subject 
will undergo enrolment evaluations and procedures during consecutive screening 
periods, according to the Study Plan (Table 1). 
The following activities will occur during this Screening Visit: 
1st Screening  
 Informed consent; 
 Demography, including date of birth, sex, and race/ethnicity; 
 Determination of eligibility based on inclusion/exclusion criteria; 
 Complete Medical/Drug history; 
A complete medical and drug history will be recorded for each subject. Significant 
medical conditions that have occurred within the past 2 years or conditions that are 
ongoing (ie, headache, backache, indigestion) are to be recorded in the CRF.  The 
drug history must identify any known drug allergies (history of hypersensitivity to 
diflunisal or other NSAIDs; or history of drug or other allergy that, in the opinion 
of the physician responsible, contraindicates their participation), presence of 
history of drug abuse and use of chronic medications.  Medications taken within 2 
weeks of Day 1 of the inpatient period are to be recorded in the CRF. 
 Alcohol/Smoking history; 
 Vital signs- blood pressure, heart rate and temperature, taken after resting at a 
sitting position for at least 5 minutes; 
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 Complete physical examination; 
 12-lead ECG; 
 Clinical (safety) laboratory tests; 
6.3 Treatment phase procedures 
6.3.1 Day -2 pre-dose procedures 
Subjects will be asked to make a separate visit to the unit twice daily on Day-2 for 
pre-treatment with diflunisal or placebo; 
 Administration of diflunisal or placebo at 7am (window period: 7 to 9 
am); 
 Administration of diflunisal or placebo at 7pm (window period: 7 to 9 
pm); 
6.3.2 Day -1 pre-dose procedures 
Subjects will be asked to make a separate visit to the unit at 0700 hour in the 
morning for the administration of diflunisal or placebo. At approximately 1700 
hour, subjects will be asked to admit to the unit.  
 Administration of diflunisal or placebo at 7 am (window period: 7 to 9 
am); 
On admission to the Investigational Medicine Unit (IMU)  at 1700 hour on Day -1, 
subjects will be reminded of study restrictions and undergo the following 
assessments: 
 Interim medical history;  
 Interim concomitant medication history;  
 Seated vital signs; 
 Brief physical examination; 
 Administration with diflunisal or placebo at 7 pm (window period: 7 to 9 
pm);  
6.3.3 Day 1 procedures  
Blood pressure, heart rate and temperature, taken after resting at a sitting position 
for at least 5 minutes (Pre-dose); 
 Brief physical examination (Pre-dose); 
 Interim concomitant medications;  
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 AE assessment; 
 Administration of diflunisal or placebo at -2 hour pre-dose; 
 Collection of pre-dose PK blood sample; 
 Collection of blood sample for blood gas analysis.  
 Administration of sodium lactate infusion (subjects should be fasted for at 
least ten hours prior to and one hour following administration of study 
medication) 
 Collection of PK blood samples at 10, 20, 30 minute post-dose; 
 Collection of blood sample for blood gas analysis.  
 Collection of PK blood samples at 40, 50, 60 minute post-dose; 
 Collection of blood sample for blood gas analysis. 
 Subjects may be discharged from the IMU 2 hours after the collection of 
60 minute PK blood sample; 
6.4.3 Day 8 pre-dose procedures 
Subjects will be asked to make a separate visit to the unit twice daily on Day 8 for 
pre-treatment with diflunisal or placebo; 
 Administration of diflunisal or placebo at 7am (window period: 7 to 9 
am); 
 Administration of diflunisal or placebo at 7pm (window period: 7 to 9 
pm); 
6.3.5 Day 9 pre-dose procedures 
Subjects will be asked to make a separate visit to the unit at 0700 hour in the 
morning for the administration of diflunisal or placebo. At approximately 1700 
hour, subjects will be asked to admit to the unit.  
 Administration of diflunisal or placebo at 7 am (window period: 7 to 9 
am); 
On admission to the Investigational Medicine Unit (IMU)  at 1700 hour on Day 9, 
subjects will be reminded of study restrictions and undergo the following 
assessments: 
 Interim medical history;  
 Interim concomitant medication history;  
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 Seated vital signs; 
 Brief physical examination; 
 Administration with diflunisal or placebo at 7 pm (window period: 7 to 9 
pm);  
 
6.3.6 Day 10 procedures  
Blood pressure, heart rate and temperature, taken after resting at a sitting position 
for at least 5 minutes (Pre-dose); 
 Brief physical examination (Pre-dose); 
 Interim concomitant medications;  
 AE assessment; 
 Administration of diflunisal or placebo at -2 hour pre-dose; 
 Collection of pre-dose PK blood sample; 
 Collection of blood sample for blood gas analysis.  
 Administration of sodium lactate infusion (subjects should be fasted for at 
least ten hours prior to and one hour following administration of study 
medication) 
 Collection of PK blood samples at 10, 20, 30 minute post-dose; 
 Collection of blood sample for blood gas analysis.  
 Collection of PK blood samples at 40, 50, 60 minute post-dose; 
 Collection of blood sample for blood gas analysis.  
 Subjects may be discharged from the IMU 2 hours after the collection of 
60 minute PK blood sample; 
6.4 Follow-up visit procedures  
 Interim concomitant medication history;  
 AE assessment; 




6.5 Safety measurements 
Meaurement used to evaluate safety include clinical laboratory tests, vital signs, 
12-lead ECGs, physical examination and monitoring for adverse events.  
6.5.1 Clinical laboratory tests 
Clinical (safety) tests will be performed including clinical chemistry, hematology 
and urinalysis. Blood and urine samples will be taken during the screening at the 
times stated in the Study Plan (Table 1 and Table 2). The date of collection will be 
recorded on the appropriate CRF.  
- Samples will be collected in the following tubes and at the volumes 
specified: 
 
- The following variables will be measured: 
Clinical chemistry  ALP, ALT, AST, albumin, chloride, creatinine, glucose, 
potassium, sodium, total protein, total & direct bilirubin, 
urea nitrogen, uric acid  
Hematology Erythrocyte count, hemoglobin, hematocrit, leukocyte cell 
count, platelet count 
Urinalysis  Bilirubin, RBC count, glucose, ketone bodies, pH, protein, 
specific gravity 








Clinical chemistry 5 ml in a serum separator tube (SST) 
Hematology 3 ml in a tube containing EDTA 
Urinalysis 10 ml midstream sample in a urine specimen tube 
Blood gas analysis 3 ml in tube containing EDTA 
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6.5.2 Vital signs 
Vital signs consist of oral temperature, heart rate and blood pressure. Assessment 
of vital signs should be performed after resting in a sitting position for at least 5 
minutes.  
 
6.5.3 Physical examinations 
- Complete physical examination 
The complete physical examination consists of an assessment of the eyes, ears, 
nose, throat, lymph nodes, heart, abdomen, lungs/thorax, extremities (including 
spines), skin, and neurologic (reflexes).  Physical examination data to be recorded 
on the CRF will include: 1) normal/abnormal/not done, and 2) a description of any 
abnormalities. 
- Brief physical examination 
The brief physical examination includes the assessment of the abdomen, heart, and 
lungs/thorax.  If the subject states changes have occurred related to systems not 
assessed, then these systems should also be examined.  Brief physical examination 
data to be recorded on the CRF will include: 1) normal/abnormal/not done, and 2) a 
description of any abnormalities. 
 
6.5.4 Adverse event assessments 
Possible side effects of sodium lactate: 
 Adverse effects of sodium lactate are essentially limited to overdosage of 
either sodium or lactate ions; 
Possible side effects of diflunisal: 
 Gastrointestinal discomfort (nausea, vomiting, heartburn, gas, dyspepsia, 
gastrointestinal pain, diarrhea, constipation, and flatulence); 
 Any sign of allergic reaction (pruritus, urticaria, rash etc); 
 Dizziness, drowsiness, headache, fatigue/tiredness. 
 Somnolence, insomnia. 
The Product Prescribing Information will be consulted for detailed information on 




6.6 Genetic Sampling, Labelling, Storage, and Shipping 
Post hoc examination of polymorphisms in MCT1 gene will be conducted. Blood 
samples will be obtained from each subject to identify the genotypes of MCT1. 
DNA extracted from the participants for pharmacokinetic study might also be used 
to identify the genetic variants of other drug transporters. The results of genetic 
testing will be kept confidential, but de-identified genetic data may be reviewed 
with research collaborators and published.  Otherwise, no genetic data will be 
provided to the subject, the subject's family, the investigator, or any other physician 
who is treating the subject or who may treat the subject in the future.  Neither the 
subject's insurance company nor the subject's employer will have any access to 
these test results. There will be no direct benefit to the subject in having DNA 
testing performed. 
6.6.1 Collection and Labelling of Genetic Samples 
Approximately 10 ml of blood will be collected from each subject into EDTA-
coated polypropylene tubes on the day of enrollment screening according to the 
Study Plan (Table 1 and 2).  The blood should be mixed by gentle inversion of the 
tube.  Tubes should be labelled with the following information only: "Genotyping 
Sample", date of sample, study number and subject number. 
 
6.7 Volume of Blood Sampling 
The total volume of blood that will be drawn from each subject in this study is as 
follows: 
Table 3 Volume of blood to be drawn from each subject 
Assessment Samples volume (ml) n of samples Total volume (ml)
Pharmacokinetc sampling 
(Lactate assay) 
10 14 140 
Genetic Analysis 10 1 10 
Safety      Clinical chemistry 
                Hematology 
















6.8 Pharmacokinetic samples  
6.8.1 Blood samples for pharmacokinetic measurements 
For timing of individual sample collections refer to the Study Plan (Table 1 and 2).  
The collection and processing of blood samples, and the labelling and storage of 
plasma for bioanalysis are described below. The plasma and whole blood samples 
will be analyzed for study drug by validated methods. Enzymatic method 
(BioVision, Inc) will be used to determine the plasma and whole blood lactate 
levels. All bioanalytical assays will be performed by trained technical personnel in 
compliance with good laboratory practice (GLP) guidelines. 
6.8.2 Collection of blood samples (PK) 
Blood samples (10ml) for the determination of lactate concentrations will be 
collected in EDTA-containing tubes at time specified in the Study Plan (Table 1 
and Table 2) and immediately cooled on ice. Samples will be clearly labelled. The 
date and time of collection will be recorded on the CRF. 
6.8.3 Processing of blood samples (PK) 
The blood sample will be split into 2 tubes. One tube will be centrifuged at 1800g 
for 10 mins at +4C. The resulting plasma and erythrocyte samples will be stored 
separately in below -80C and at +4C, respectively, until assay. The remaining 
tube of whole blood sample will be stored at +4C.  
6.8.4 Labelling of blood samples (PK) 
Labels must be applied to the plasma, erythrocyte and whole blood sample tubes; 



















Analyte: Lactate  
 





Matrix: WHOLE BLOOD 
Analyte: Lactate  
 
6.8.5 Storage of blood samples (PK) 
All frozen samples to be stored in below -20ºC freezer, prior to shipment. 
All erythrocyte and whole blood samples to be stored at +4ºC, prior to shipment. 
All samples should NOT be allowed, at any time, to thaw during storage and 
subsequent delivery to Pharmacogenetics Laboratory of NUS (PGL). 
6.8.6 Shipment of blood samples (PK) 
Plasma samples will be shipped frozen using dry ice in an insulated container while 
erythrocyte samples will be transported on ice in an icebox. 
All blood samples will be delivered to the Pharmacogenetics Laboratory of NUS 





7. Lifestyle and/or Dietary Restrictions 
Subjects will fast from food and drink (except water) for at least ten hours prior to 
dosing until one hour after dosing. 
Standard meals will be served as outlined below.  At all mealtimes, food will be 
served after completion of protocol-specified procedures. 
 An evening snack will be allowed until 10:00 pm. 
 Breakfast will not be provided on the morning of dosing. 
 Standard and identical meals will be provided during PK study. 
7.1 Caffeine, Alcohol and Tobacco Restrictions 
Caffeine 
During each dosing period, subjects will abstain from ingesting caffeine containing 
products for 24 hours prior to the start of dosing until collection of the final 
pharmacokinetic sample during each period. 
Alcohol 
During each dosing period, subjects will abstain from alcohol for 24 hours prior to 
the start of dosing until collection of the final pharmacokinetic sample during each 
period.   
Tobacco 
The use of tobacco or nicotine-containing products is not permitted during this 











8. Investigational products  
8.1 Study Medication/Formulation 
 Sodium Lactate Solution 5.6 mg/kg/min Intravenous Infusion (Hospira Inc. 
USA) 
 Diflunisal 500 mg Regular Release Tablets (Apo-Diflunisal, Apotex Inc. 
Canada) 
 
8.2 Dose Rationale 
A single dose infusion of sodium lactate will be given to each eligible subject at 
infusion rate of 5.6 mg/kg/min for 30 mins. Blood lactate level is expected to 
increase to approximately 3-4 mM based on the references provided for several 
studies (15-18). 
In the study done by van Hall et al., the subjects were given sodium lactate 
intravenous infusion at infusion rate of 5.6 mg/kg/min for 20 mins, followed by 
infusion of 4.3 mg/kg/min for another 100 mins. In the study, no adverse effects 
had been reported (15). Coco M et al. reported that the increase of blood lactate is 
associated with a worsening of attentional processes. However, the effect of blood 
lactate on attentional processes is reversible and attention efficacy will be restored 
upon reversion of blood lactate to normal resting levels (18). This is a transient 
event and blood lactate level will be returned to normal within 20 minutes after the 
lactate infusion (18).  
A dose regiment of 500 mg diflunisal has been selected based on an assumption 
that the mean diflunisal plasma concentration following administration of 500 mg 
single oral dose is sufficient to inhibit MCT1 transport activity. Diflunisal exhibits 
a strong inhibitions effect in the uptake of benzoic acid with an IC50 value of 50 
M, which equivalent to 12.51 g/mL (19). Pharmacokinetics study of diflunisal 
indicated that the mean plasma diflunisal level is approximately 23 g/mL 
following a single does of diflunisal 250 mg in non-fasting state (20). However, 
500 mg dose regimen is selected in order to achieve the maximum suppression on 
MCT1 transport activity. A dose regimen of 1000 mg daily in divided doses has 
been approved for maintenance therapy of rheumatoid arthritis and osteoarthritis. 
Maintenance doses higher than 1500 mg a day are not recommended.  
8.3 Dosage and Administration 
During each treatment period, subjects will receive the following treatments. A 
washout period of 7 days is incorporated between the study periods to avoid the 
influence of previously administered drug(s).  
Period 1: Single dose infusion of sodium lactate (5.6 mg/kg/min for 30 min) + 
Diflunisal (500 mg) multiple oral doses to group A subjects; Placebo multiple oral 
does to group B 
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Period 2: the two groups will be crossed over. 
Subjects will be asked to fast at least ten hours prior to and one hour following 
administration of study medication. Each oral medication will be administered with 
250mL of water.  Subjects will be asked not to break, crush, or chew the diflunisal 
tablet before swallowing. 
8.4 Blinding 
This study is single-blinded study.  
8.5 Packaging and Labeling 
Commercially-available products will be purchased by site for use in this study. 
8.6 Preparation 
No specific preparation of study medication is required prior to administration. 
8.7 Handling and Storage 
Investigational product must be dispensed or administered according to procedures 
described herein.  Only subjects enrolled in the study may receive investigational 
product, in accordance with all applicable regulatory requirements.  Only 
authorized site staff may supply or administer investigational product. All 
investigational products must be stored in a secure area with access limited to the 
investigator and authorized site staff and under physical conditions that are 
consistent with investigational product-specific requirements. 
Investigational products will be stored at a controlled room temperature of 20-25C 
(68-77F); excursions between 15-30C (59-86F) are permissible. 
8.8 Product Accountability 
The medication provided for this study is for use only as directed in the protocol. 
All unused drugs will be accounted for and destroyed appropriately by site 
personnel. The site personnel will account for all drugs dispensed. 
9. Treatment Discontinuation And Subject Withdrawals 
9.1 Treatment Discontinuation 
Subjects may be discontinued early from study treatment and assessments at any 
time, at the discretion of the investigator.  Specific reasons for discontinuing a 
subject from this study are: 
 eligibility criteria not fulfilled, 
 occurrence of SAE or other safety reasons as judged by the investigator, 
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 development of study specific discontinuation criteria, e.g., protocol non-
compliance (any protocol non-compliance will be assessed by the investigator 
to determine if it is severe enough to merit withdrawal), 
 voluntary discontinuation by the subject, who is at any time free to discontinue 
his or her participation in the study without prejudice to further treatment, 
 subject lost to follow-up. 
 
9.2 Subject Withdrawals 
Subjects who withdraw from the study should always be asked about the reason(s) 
for their discontinuation and about the presence of any AEs.  The full assessments 
that are specified at the final follow up visit should also be carried out wherever 
possible.  If possible, they should be seen and assessed by the investigator.  AEs 
should be followed up and any investigational products should be returned by the 
subject. The reason for discontinuation of a subject must be documented into the 
CRF provided. 
Discontinuation of any subject should be communicated to the IMU/PI. All 
withdrawals due to SAE must be reported to the IMU/PI within 24 hours.  
Withdrawals due to the occurrence of non-SAE must be reported to the IMU/PI 
within 15 calendar days. 
Discontinued or withdrawn subjects must be followed up after the last dose of 
investigational product, to the extent possible. All deaths and all SAEs that occur 
during the follow up must be reported to the IMU/PI within 24 hours. All AEs and 
SAEs reported during the subjects’ participation in the study should be followed 
until resolution as far as practicable.   
9.3 Subjects replacement 
In case of dropouts/withdrawals, there will be no replacements during study period 
1 and 2. 
 
10. Adverse Events (Ae) and Serious Adverse Events (Sae) 
The investigator is responsible for the detection and documentation of events 
meeting the criteria and definition of an AE or SAE, as provided in this protocol.  
During the study when there is a safety evaluation, the investigator or site staff will 
be responsible for detecting, documenting and reporting AEs and SAEs, as detailed 




10.1 Definition of an AE 
Any untoward medical occurrence in a patient or clinical investigation subject, 
temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product. 
An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) 
temporally associated with the use of a medicinal product.  For marketed medicinal 
products, this also includes failure to produce expected benefits (i.e. lack of 
efficacy), abuse or misuse. 
Examples of an AE include: 
 Exacerbation of a chronic or intermittent pre-existing condition including either 
an increase in frequency and/or intensity of the condition. 
 New conditions detected or diagnosed after investigational product 
administration even though it may have been present prior to the start of the 
study. 
 Signs, symptoms or the clinical sequelae of a suspected interaction. 
 Signs, symptoms or the clinical sequelae of a suspected overdose of either 
investigational product or a concomitant medication (overdose per se will not 
be reported as an AE/SAE). 
Examples of an AE do not include a/an: 
 Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition 
that leads to the procedure is an AE 
 Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital) 
 Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen 
 The disease/disorder being studied, or expected progression, signs or symptoms 
of the disease/disorder being studied, unless more severe than expected for the 
subject’s condition. 
 





Adverse events will be graded on a three-point scale (mild, moderate, severe) and 
reported in the detail indicated on the Case Report Form. The definitions are as 
follows: 
MILD   Discomfort noticed, but no disruption of normal daily activity 
MODERATE Discomfort sufficient to reduce or affect normal daily activity 




 Causality (Not related, Possibly related, Probably related, Related) 
 
10.3 Definition of a SAE 
A serious adverse event is any untoward medical occurrence that, at any dose: 
 Results in death 
 Is life-threatening 
NOTE:  The term 'life-threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to 
an event, which hypothetically might have caused death, if it were more severe. 
 Requires hospitalization or prolongation of existing hospitalization 
NOTE:  In general, hospitalization signifies that the subject has been detained 
(usually involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or out-patient setting.  Complications that occur during 
hospitalization are AEs.  If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious.  When in doubt as to whether 
“hospitalization” occurred or was necessary, the AE should be considered serious. 
Hospitalization for elective treatment of a pre-existing condition that did not 
worsen from baseline is not considered an AE. 
 Results in disability/incapacity, or 
NOTE:  The term disability means a substantial disruption of a person’s ability to 
conduct normal life functions.  This definition is not intended to include 
experiences of relatively minor medical significance such as uncomplicated 
headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g. 
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sprained ankle) which may interfere or prevent everyday life functions but do not 
constitute a substantial disruption. 
 Is a congenital anomaly/birth defect 
Medical or scientific judgement should be exercised in deciding whether reporting 
is appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may 
jeopardize the subject or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition.  These should also be 
considered serious.  Examples of such events are invasive or malignant cancers, 
intensive treatment in an emergency room or at home for allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospitalization, or 
development of drug dependency or drug abuse. 
 
10.4 Clinical Laboratory Abnormalities and Other Abnormal 
Assessments as AEs and SAEs 
Abnormal laboratory findings (e.g., clinical chemistry, hematology, and urinalysis) 
or other abnormal assessments (e.g., ECGs, X-rays, and vital signs) that are judged 
by the investigator as clinically significant will be recorded as AEs or SAEs if 
they meet the definition of an AE or SAE.  Clinically significant abnormal 
laboratory findings or other abnormal assessments that are detected during the 
study or are present at baseline and significantly worsen following the start of the 
study will be reported as AEs or SAEs.  However, clinically significant abnormal 
laboratory findings or other abnormal assessments that are associated with the 
disease being studied, unless judged by the investigator as more severe than 
expected for the subject’s condition, or that are present or detected at the start of 
the study and do not worsen, will not be reported as AEs or SAEs. 
 
10.5 Time Period, and Frequency of Detecting AEs and SAEs 
Any pre-existing condition or signs and/or symptoms present in a subject prior to 
the start of the study (i.e., before informed consent has been given) should be 
recorded as Medical/ Surgical History. 
From the time a subject consents to participate in the study until he or she has 
completed the study (including any follow-up period), all SAEs assessed as related 
to study participation (e.g., protocol-mandated procedures, invasive tests, or change 
in existing therapy) will be reported. 
All AEs/SAEs occurring after the administration of study medication and on or 
before the Follow-up Visit must be reported as Adverse Events/Serious Adverse 
Events.  All AEs/SAEs must be recorded irrespective of whether they are 
considered drug related.  AEs will be evaluated by the investigator and recorded. 
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Any AEs already documented at a previous assessment and designated as ongoing, 
should be reviewed at subsequent visits as necessary.  If these have resolved, this 
should be documented.  If an AE changes in intensity/frequency then this should be 
recorded as a separate event (i.e., a new record started). 
 
10.6 Reporting of SAEs 
When the investigator becomes aware of an SAE during the course of the study, the 
SAE must be reported to the PI or his representative within one day. 
All SAEs have to be reported, whether or not considered causally related to the 
investigational product. All SAEs will be recorded in the Case Report Form. The 
investigator is responsible for informing the DSRB and/or the HAS 
 
11. Data Analysis and Statistical Considerations 
11.1 Pharmacokinetic Analysis.    
Plasma/whole blood/RBC concentration-time data for lactate will be tabulated and 
graphically displayed for each subject.  Mean plasma/whole blood/RBC 
concentration-time data will also be calculated for study drug. 
Whole-blood and plasma lactate concentrations will be measured in duplicate using 
an enzymatic method (BioVision Research Products, Mountain View, CA, USA). 
Whole-blood and plasma lactate levels will be corrected for water content and 
expressed as mmol.L-1 of water. Intererythrocyte lactate concentrations will be 
calculated from whole-blood and plasma concentrations as follows: 
Cc= [Cb-Cp(1-Hct)]/Hct 
Where Cc is the erythrocyte lactate concentration, Cb is the measured venous blood 
lactate concentration and Cp is the measured plasma lactate concentration, and Hct 
is the measured haematocrit.  
Data will be collected and averaged, and compared by suing paired Student’s t-test. 
Significance will be set at p>0.05 and all data will report as mean ± standard 
deviation.  
 
11.2 Safety Data Analysis  
Safety data, including adverse events and clinical laboratory evaluations, will be 




11.3 Statistical Considerations 
Sample size assumptions. A 80% powered analysis estimates that a minimum 
number of N=8 is required to detect a minimum difference of 30% in plasma, 
whole blood and RBCs lactate levels, at a level of significance of p=0.05 (mean 
plasma lactate = 16.7 ± 3.81 mmol/l; mean erythrocyte lactate = 8.0 ± 2.42 mmol/l; 
mean whole blood lactate = 12.4 ± 2.42 mmol/l). In case of discontinuing, loss of 
follow-up, or any other cause for the subjects not to accomplish this study, the 
number of subject increase to N=12.  
 
12. Study Management 
12.1 Monitoring 
The monitoring of this study will be performed in accordance with the principle of 
Good Clinical Practice (GCP) as laid out in the International Conference on 
Harmonisation (ICH) document "Good Clinical Practice: Consolidated Guideline", 
by staff of the IMU. 
12.2 Training of Staff 
The principal investigator and IMU Manager will maintain a record of all 
individuals involved in the study (medical, nursing and other staff).  He or she will 
ensure that appropriate training relevant to the study is given to all of these staff, 
and that any new information of relevance to the performance of this study is 
forwarded to the staff involved. 
12.3 Changes to the Protocol 
Study procedures will not be changed without the approval of the principal 
investigator. 
If it is necessary for the study protocol to be amended, the amendment and/or a 
new version of the study protocol must be notified to the DSRB and HSA. 
12.4 Study Timetable and Termination 
The first subject is expected to enroll in beginning of 2010 and all subjects are 
expected to complete the study by early March 2010. 
12.5 Data Management 
12.5.1 Case Report Form 
Case report form (CRF) will be used to record all data not captured electronically.  
The actual date and time of each dose and each blood sample will be recorded on a 
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Case Report Form. Data should be recorded legibly onto the CRFs in blue or black 
ball-point pen.  Correction fluid or covering labels must not be used. 
Brief CRFs will be completed for subjects who sign a consent form to participate 
but who are not entered into the study. 
12.5.2 Pharmacogenetic Data 
The samples and data for genetic analysis in this study will be coded.  The samples 
will be labelled with a clinical study subject number that can be traced back to the 
subject only by the investigator.  The samples and data will not carry a personal 
identifier.  Pharmacogenetic data will be managed by the Pharmacogenetics Lab 
NUS. 
12.5.3 Safety Measurements 
Safety will be assessed by adverse events, physical examination, blood pressure, 
heart rate, pulse, clinical chemistry, hematology, and urinalysis in order to assure 
the health and well being of subjects participating in this trial as well as provide 
beginning information regarding the safety profile of the administered drugs. 
13. Ethics 
13.1 Ethics Review 
The final study protocol and the final version of the Written Informed Consent 
Form must be approved or given a favorable opinion in writing by the DSRB as 
appropriate.  The principal investigator is responsible for informing the DSRB of 
any amendment to the protocol in accordance with local requirements.  In addition, 
the DSRB must approve all advertising used to recruit subjects for the study.  The 
protocol must be re-approved by the DSRB annually, as local regulations require. 
The principal investigator must submit progress reports to the DSRB according to 
local regulations and guidelines.  The principal investigator must also provide the 
DSRB with any reports of serious adverse events from the study site. 
13.2 Ethical Conduct of the Study 
The study will be performed in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki and are consistent with Good Clinical 
Practice, applicable regulatory requirements. 
13.3 Subject Information and Consent 
The principal investigator at each centre will ensure that the subject is given full 
and adequate oral and written information about the nature, purpose, possible risk 
and benefit of the study.  Subjects must also be notified that they are free to 
discontinue from the study at any time.  The subject should be given the 




The subject's signed and dated informed consent must be obtained before 
conducting any procedure specifically for the study. 
The principal investigator must store the original, signed Written Informed Consent 
Form.  A copy of the Written Informed Consent Form must be given to the subject. 
 
13.4 Subject Data Protection  
The Written Informed Consent Form will explain that study data will be stored in a 
computer database.  The Written Informed Consent Form will also explain that for 
data verification purposes, authorized representatives of a regulatory authority, 
DSRB may require direct access to parts of the hospital or practice records relevant 
to the study, including subjects' medical history. 
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APPENDIX III.  
Legend:  Green line: Plasma Lactate Concentration 
    Blue line: Whole Blood Lactate Concentration 
    Red line: Erythrocyte Lactate Concentration 
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